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ABSTRACT
The application of magnetic resonance imaging (MRI) to non-invasively assess disease
biomarkers has been hampered by lack of desired contrast agents with high relaxivity, targeting
capability, and optimized pharmacokinetics. We developed a novel MRI probe which targets
HER2, a biomarker for various cancers and a target for anti-cancer therapies. This multimodal
HER2-targeted MRI probe integrates a rationally designed protein contrast agent with a high
affinity HER2 affibody and near IR dye. Our probe can differentially monitor tumors with different HER2 levels in both cells and xenograft mice. In addition to its 10-fold higher dose efficiency
compared to clinically-approved agent DTPA, our developed agent also exhibits advantages in
crossing the endothelial boundary, tissue distribution, and tumor tissue retention as demon-

strated by even distribution of the imaging probe across the entire tumor mass. Additionally, a
second series of protein contrast agents that included affibody against EFGR developed with
the capability to specifically target EGFR. These contrast agents have been utilized to monitor
drug treatments and quantitatively analyze biomarker expression level. Furthermore, we anticipate these agents will provide powerful tools for quantitative assessment of molecular markers, and improved resolution for diagnosis, prognosis and drug discovery.

INDEX WORDS: MRI, Contrast agent, Protein engineering, Gadolinium, Relaxivity, HER2

TARGETED MOLECULAR MR IMAGING OF HER2 AND EGFR USING A DE NOVO DESIGNED
PROTEIN CONTRAST AGENTS

by

JINGJUAN QIAO

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2011

Copyright by
Jingjuan Qiao
2011

TARGETED MOLECULAR MR IMAGING OF HER2 AND EGFR USING A DE NOVO DESIGNED
PROTEIN CONTRAST AGENTS

by

JINGJUAN QIAO

Committee Chair:

Dr. Jenny J. Yang

Committee:

Dr. Aimin Liu
Dr. Zhi-ren Liu
Dr. Lily Yang

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
December 2011

iv

ACKNOWLEDGEMENTS
All the work in this dissertation was carried out under the direction of Dr. Jenny J. Yang;
in collaborate with Dr. Zhi-ren Liu. Dr. Yang’s knowledge guided my research with valuable suggestions.
I am fortunate indeed to have such knowledgeable committee members who helped to
make this a wonderful learning event for me. Throughout my dissertation experience, Dr. Yang
provided immeasurably wise and perceptive counsel. I am especially grateful to her for continuously supporting my experiments and ideas, and helping me to express my research goals in
writing. My sincere thanks to Dr. Lily Yang, Dr. Hui Mao and Dr. Hans Grossniclaus, each of
whom contributed important and unique perspectives throughout the research development
and analysis. Their advice and feedback have been more helpful than they may realize.
I want to express many thanks to my friends Dr. Shunyi Li, Dr. Jie Jiang, Shenghui Xue,
Fan Pu and other members in Dr. Jenny Yang’s lab. I also want to thank Dr. Robert Long, Dr. Liya
Wang, and Dr. Hekmatayar for collecting MRI data.
This work is supported by grants from National Institute of Health and National Cancer
Institute, as well as a Brain and Behavior Fellowship provided by Georgia State University.
Finally, and most importantly, I would like to thank my parents and my husband, Liangwei Li, for their love, encouragement and quiet patience while supporting my research work.

v

TABLE OF CONTENTS
ACKNOWLEDGEMENTS .......................................................................................................iv
LIST OF FIGURES ................................................................................................................ xiv
LIST OF ABBREVIATIONS ................................................................................................... xix
Chapter 1. INTRODUCTION .............................................................................................. 1
1.1

Cancer as human diseases .................................................................................... 1

1.1.1 Biomarkers and its role in diagnosis, prognosis and treatment ...................... 2
1.1.2 Detection of biomarkers .................................................................................. 6
1.2

EGFR family function as biomarkers for diagnosis and therapy ........................... 8

1.2.1 Structure of EGFR family proteins ................................................................... 9
1.2.2 Roles of EGFR family in tumor formation and growth .................................. 11
1.2.3 Distribution of EGFR family members in various cancers and cell lines........ 16
1.3

Targeted reagents for EGFR family ..................................................................... 18

1.3.1 Intra-cellular inhibitor an extra-cellular ligands of EGFR (HER1)................... 19
1.3.2 Engineered antibodies and drugs for HER2 ................................................... 21
1.4

Affibody library and screening ............................................................................ 23

1.4.1 Affibody derived from z-domain of Protein A and screened by phage
display………….. ....................................................................................................................... 23
1.4.2 ZEGFR:1907 binds to EGFR with highest affinity ................................................. 25

vi

1.5

Clinical imaging techniques and the application................................................. 26

1.5.1 Magnetic Resonance Imaging and its application ......................................... 27
1.5.2 Near Infra-red imaging and in vivo application ............................................. 28
1.5.3 Other techniques of molecular imaging ........................................................ 29
1.6

Molecular imaging............................................................................................... 30

1.7

Contrast agents for molecular imaging ............................................................... 33

1.7.1 MRI contrast agents ....................................................................................... 33
1.7.2 Biomarkers targeted contrast agents ............................................................ 36
1.7.3 Criteria of designing ideal contrast agents .................................................... 37
1.8

Objectives of this study, and over view of the dissertation ............................... 38

Chapter 2. MATERIAL AND METHODS ........................................................................... 42
2.1

Molecular cloning of ProCA1-affibody to target HER2 and EGFR ....................... 42

2.2

Plasmid construction and protein generation .................................................... 42

2.2.1 GST-fusion ProCA1-affibody and purification................................................ 43
2.2.2 Sub-cloning of tagless ProCA1-affibody and purification .............................. 43
2.3

PEGylation of ProCA1-affibody ........................................................................... 45

2.4

Conjugation of near infra red (NIR) dye to ProCA1-affibody .............................. 45

2.5

Determining the folding condition of ProCA1-affibody ...................................... 46

2.5.1 Mass spectrometry ........................................................................................ 46

vii

2.5.2 Circular dichroism spectroscopy.................................................................... 46
2.5.3 Fluorescence spectroscopy............................................................................ 47
2.5.4 Nuclear Magnetic Resonance (NMR) spectroscopy ...................................... 47
2.6

Relaxivity measurements and metal binding affinity of ProCA1-affibody.......... 47

2.7

Cell culture and mammalian expression ............................................................. 48

2.8

Cancer cell targeting............................................................................................ 49

2.8.1 Enzyme linked immunosorbent assay (ELISA) ............................................... 49
2.8.2 Western blotting ............................................................................................ 50
2.8.3 Radio-active assay on cancer cells ................................................................. 51
2.8.4 Immunofluorescent staining in cancer cells .................................................. 52
2.8.5 Flow cytometer assay (FACS) ......................................................................... 53
2.8.6 Magnetic Resonance Imaging (MRI) in cancer cells ...................................... 53
2.9

Animal experiments ............................................................................................ 54

2.9.1 Nude mouse xenograft model ....................................................................... 54
2.9.2 Nude mouse othotopic model ....................................................................... 54
2.9.3 Magnetic Resonance Imaging (MRI) of tumor mouse ................................... 55
2.9.4 Near infra-red (NIR) imaging of tumor mouse .............................................. 55
2.9.5 Biodistribution and blood circulation measurements ................................... 56
2.9.6 Biodistribution measurements by ICP-OES ................................................... 56

viii

2.10

Histology analysis ............................................................................................ 57

2.10.1 Preparation of tissue slices .......................................................................... 57
2.10.2 Immunohistology chemistry (IHC) on paraffin embedded slices ................ 58
2.10.3 Immunofluorescent staining on frozen slices.............................................. 58
2.11

Measure immunogenecity of ProCA1-affi ....................................................... 59

2.12

Measurement of Acute toxicity ....................................................................... 59

Chapter 3. DESIGN, PREPARATION AND IN VITRO CHARACTERIZATION OF HER2
TARGETD PROCA1 USING AFFIBODY ............................................................................................ 61
3.1

Introduction......................................................................................................... 61

3.2

Results and Discussion ........................................................................................ 63

3.2.1 Designed HER2 targeted protein based contrast agent with one Gd3+ binding
site……………….. ....................................................................................................................... 63
3.2.2 Generation of targeted ProCA1-affi342 ........................................................ 66
3.2.3 Conformational analysis of ProCA1-affibody ................................................ 71
3.2.4 Modified ProCA1-affibody has been increased both in metal binding affinity
and relaxivity 73
3.2.5 Other improved properties for modified contrast agents ............................ 75
3.2.6 Dual label ProCA1-affibody with NIR dye ...................................................... 77
Chapter 4. CELLULAR TARGETING CAPABILITY ANALYSIS .............................................. 82

ix

4.1

Introduction......................................................................................................... 82

4.2

Results and Discussion ........................................................................................ 83

4.2.1 Selection of cell lines ..................................................................................... 83
4.2.2 Monitoring cell targeting of Affibody variants using western blotting ......... 83
4.2.3 Immunofluorescent staining of cancer cells with ProCA1-affi ...................... 86
4.2.4 Cancer cells treated by different amount of ProCA1-affibody demonstrate
the quantitative monitoring capability of designed MRI contrast agents ............................ 91
4.2.5 Flowcytometry measures the constant binding of ProCA1-affi342 to cancer
cells

93
4.2.6 Generation of antibody against ProCA1-CD2-m ............................................ 97
4.2.7 Quantitative analysis of MRI signals in cancer cells .................................... 100
4.2.8 Cell binding was analyzed by measuring retention of

153

Gd cheleted with

ProCA1-affi342..................................................................................................................... 100
4.2.9 Summary and future work ........................................................................... 102
Chapter 5.

ESTBLISHING TUMOR MODELS AND MOLECULAR IMAGING OF HER2 IN

MOUSE BY MRI AND NIR AND FURTHER ANALYSIS BY HISTOLOGY ASSAYS .............................. 104
5.1

Introduction....................................................................................................... 104

5.2

Results and discussion....................................................................................... 106

5.2.1 Cell preparation for xenograft tumor model ............................................... 106

x

5.2.2 MRI on xenograft model indicates the specific targeting of ProCA1affibody……………… ............................................................................................................... 106
5.2.3 NIR imaging shows relative distribution of ProCA1-affibody in various mouse
organs…………….. .................................................................................................................. 110
5.2.4 Immunofluorescent staining of frozen tissue slides can demonstrate the
tissue penetration of ProCA1-affibody ................................................................................ 112
5.2.5 MRI blocking experiment further confirmed the tumor targeting.............. 114
5.2.6 Advantages of ProCA1-affibody to antibodies in tumor targeting .............. 116
5.3

Conclusion ......................................................................................................... 121

Chapter 6.
AGENTS

BIODISTRIBUTION AND PHARMOKINETIC STUDY OF DEVELOPED CONTRAST
124

6.1

Introduction....................................................................................................... 124

6.2

Results and discussion....................................................................................... 126

6.2.1 Distribution calculation by NIR signals in different mouse organs.............. 126
6.2.2 Bio-distribution and blood retention by 153Gd assay................................... 129
6.2.3 Bio-distribution with ICP-OES ...................................................................... 133
Chapter 7. EFFECTS OF DRUG TREATMENTS DETERMINED BY PROCA1-AFFIBODY .... 136
7.1

Introduction....................................................................................................... 136

7.2

Results and discussion....................................................................................... 137

xi

7.2.1 Both receptor level and cell survival decrease after been treated by
Herceptin……… ..................................................................................................................... 137
7.2.2 Monitoring the receptor change after drug treatment using flow cytometry
………………………………………………………………………………………………………………..138
7.2.3 ProCA1-affibody can monitor the total receptor change in cancer cells by
MRI……………………. ............................................................................................................... 140
Chapter 8.

MONITORING CHANGES IN BIOMARKERS OF DISTRIBUTIONS AND

EXPRESSION LEVELS DURING BREAST CANCER PROGRESSION BY TARGETED PROTEIN BASED
CONTRAST AGENTS………….. ........................................................................................................ 142
8.1

Introduction....................................................................................................... 142

8.2

Results and discussion....................................................................................... 150

8.2.1 Biomarker changes during the prognosis .................................................... 150
8.2.2 Generation of EGFR targeted contrast agent .............................................. 150
8.2.3 MR imaging of orthotopic tumors ............................................................... 154
8.2.4 MRI can monitor distribution of biomarkers ............................................... 157
Chapter 9. OTHER CONTRAST AGENTS WITH MULTIPLE METAL BINDING SITES ........ 160
9.1

Designing HER2 targeted contrast agent by using mutated CaM as host protein

(ProCA22-affi342) .................................................................................................................... 160
9.2

Toxicity of protein based contrast agents......................................................... 161

Chapter 10. CONCLUSIONS AND MAJOR DISCOVERIES ............................................... 165

xii

PUBLICATIONS AND MANUSCRIPT IN REVISION ............................................................ 170
MANUSCRIPTS IN PREPARATION .................................................................................... 171
Appendix I ....................................................................................................................... 172
Establish mammalian expression and purification of HER2-ECD ................................ 172
Appendix II ...................................................................................................................... 175
Vaccine and Monkey virus .............................................................................................. 175
REFERENCES .................................................................................................................... 184

xiii

LIST OF TABLES
Table 1 EGFR overexpression rate in different stages of cancers

14

Table 2 HER2 overexpression rate in different stages of cancers

15

Table 3 HER2 inhibitor in clinical use

19

Table 4. Physicochemical characteristics of commercially-available, extracellular,
predominantly renally excreted gadolinium-based MR contrast agents.

36

Table 5 Contents of all the variants

41

Table 6 HER2 expression level in various cancer cells

84

Table 7 Biodistribution of Radioactive assay in CD1 mice

132

Table 8 Bio-distribution of ProCA1-affi-m was measured by ICP-OES at various time
points

134
Table 9 Bio-distribution of MRI contrast agents was measured by ICP-OES to optimize

the modification condition

135

Table 10 Table of different breast cancer types

143

Table 11 Acute Toxicity of ProCA1-affi342

161

xiv

LIST OF FIGURES
Figure 1.1 Occurrence of different cancers in western countries.

2

Figure 1.2 EGFR family and its targeting molecules

5

Figure 1.3 Algorithm for Herceptin use

7

Figure 1.4 EGF receptor activation.

9

Figure 1.5 Crystal structure of HER2 and HER2-Herceptin complex

11

Figure 1.6 EGFR (A) and HER2(B) are negative prognostic factors in breast cancers

12

Figure 1.7 HER2 expression level of various cancer cells

17

Figure 1.8 Therapeutic effects through antibodies

22

Figure 1.9 Structure and Sequences alignment of affibody

24

Figure 1.10 ZHER2:342 is endocytosed into SKBR-3 cancer cells with HER2 over expression
25
Figure 1.11 Spatial resolution and penetration depth of molecular imaging techniques 32
Figure 1.12 Model structure of ProCA1-CD2

35

Figure 2.1 DNA map of PGEX-2T vector

44

Figure 2.2 DNA map of PET-20b vector

44

Figure 3.1 Model Structure of ProCA1-CD2

64

Figure 3.2Model Structure of ProCA1-affibody.

65

Figure 3.3 Construction of ProCA1-affi342.

66

Figure 3.4 Purification Scheme

67

xv

Figure 3.5 SDS gel of expression and initial purification by GS-4B column

68

Figure 3.6 Purification of PEGylated ProCA1-affi342 with cation exchange column

69

Figure 3.7 SDS gel of purified ProCA1-affi342m from SP column

70

Figure 3.8 Expression of ProCA1-affi342 in PET20b vector

71

Figure 3.9 Tryptophan Fluorescence measurement.

72

Figure 3.10 The secondary structure measured by CD.

73

Figure 3.11 Metal binding affinity measurement.

74

Figure 3.12 Relaxivity of ProCA1-affibody.

75

Figure 3.13 SDS gel to measure the stability of modified contrast agent

76

Figure 3.14 PEGylation substantially reduced the immune responses monitored by polyantibodies.

77

Figure 3.15 Chemical structure of Cy5.5 dye

77

Figure 3.16 Extinction Coefficient of Cy 5.5 was measured

78

Figure 3.17 Conjugation rate measurement

79

Figure 3.18 MS spectra of free protein and conjugated protein

80

Figure 3.19 NMR spectra of free protein and protein-dye complex

81

Figure 4.1 Western blot of ProCA1-affi been retained in the cancer cells

85

Figure 4.2 ELISA of ProCA1-affi342

86

Figure 4.3 Immunostaining of HER2 on cell membrane.

88

Figure 4.4 Cell staining by ProCA1-affi WT

89

Figure 4.5 Immunostaining for endocytosis studies.

90

Figure 4.6 NIR imaging of living cells.

91

xvi

Figure 4.7 Immuno staining of Cancer cells at various time points

92

Figure 4.8 ELISA results to measure the binding to cancer cells

93

Figure 4.9 Binding affinity measurements (A) and Curve fitting of the binding between
ProCA1-affi342m and SKOV-3 cancer cells (B)

95

Figure 4.10 Curve fitted by Hill equation

96

Figure 4.11 Competative assay to measure the cell binding

97

Figure 4.12 Western blotting of anti0serum activity

99

Figure 4.13 Purified antibodies from anti-serum

99

Figure 4.14 The HER2 positive cells SKOV-3 can be imaged under MRI after incubated
with various concentrations of contrast agents.

100

Figure 4.15 Different concentrations of ProCA1-affi342 been retained in the cancer cells
by radioactive assay.

101

Figure 4.16 Radioactive assay to measure the cell binding of ProCA1-affibody.

102

Figure 5.1 NIR imaging on Xenografted mouse.

107

Figure 5.2 MRI of Xenografted mouse with Fast Spin Echo.

108

Figure 5.3 MRI of Xenografted mouse with Gradient Echo.

109

Figure 5.4 NIR imaging of mouse organs.

111

Figure 5.5 IHC staining on mouse tissues for biodistribution studies.

113

Figure 5.6 Magnetic resonance images and image intensities of the mouse tumor preblocked by affibody ZHER2:342.

115

Figure 5.7 Direct staining with SKOV-3 tumors.

118

Figure 5.8 Compare the tissue penetration with HER2 antibody by IHC.

119

xvii

Figure 5.9 The tissue penetration properties of ProCA1 –affi-m were compared with
antibody by IHF staining.

120

Figure 6.1 Biodistribution demostrated by NIR imaging

127

Figure 6.2 Average intensity of each organ by NIR measurement

128

Figure 6.3 Western blotting of quantitative analysis of distribution

128

Figure 6.4 Biodistribution demostrated by IHC

129

Figure 6.5 Western blotting of blood retention

130

Figure 6.6 Bio-distribution of ProCA1-affi by 153Gd radioactive assay.

131

Figure 6.7 Blood circulation of ProCA1 series contrast agents

132

Figure 7.1 ELISA assay to monitor the HER2 receptor level changes after being treated
with Herceptin in SKOV3 cells.

137

Figure 7.2 Western blotting results indicated that the total receptor number decreased
about 35% after five days of treatments with Herceptin
Figure 7.3 Drug treatment measued by flow cytometry

138
139

Figure 7.4 Flow cytometry demostrated the receptor level change after being treated
with Herceptin.

140

Figure 7.5 MR images of SKOV3 cells after various days of treatments by Herceptin 141
Figure 8.1 Histological special breast cancer types

144

Figure 8.2 Progression of DCIS tumors

145

Figure 8.3 EGFR and HER expression levels in a human breast cancer xenograft derived
from a basal type of breast cancer cell ine (MCF-10DCIS)
Figure 8.4 Sequence of ProCA1-affibody-EGFR

149
150

xviii

Figure 8.5 ELISA of cell binding with EGFR high expression

152

Figure 8.6 Immunostaining of cancer cells by ProCA1-affibody-EGFR

153

Figure 8.7 Immuno staining of ProCA1-affi1907 in SKOV-3 cancer cells

154

Figure 8.8 MRI of orthotopic model.

155

Figure 8.9 MRI of orthotopic tumor model with fast spin echo

156

Figure 8.10 MRI of orthotopic tumor model with gradient echo

157

Figure 8.11 MR images can demonstrate the structure difference at the edge and core of
the tumor

158

Figure 8.12 Tumor structure can be measured by MRI and IHC

159

Figure 9.1Measurement of creatinine concentration in mouse blood

162

Figure 9.2 The enzyme in liver of ALT (alanine aminotransferase) and ALP(Alkaline
Phosphatase) activity
Figure 9.3 Metal concentration in blood has been measured

163
164

xix

LIST OF ABBREVIATIONS
AP

Alkaline Phosphatase

CaM

Calmodulin

CD

Circular dichroism

CD2

Cluster of differentiation 2

CT

X-ray computed tomography

DAPI

4'-6-Diamidino-2-phenylindole

DCIS

Ductal Carcinoma in situ

DMEM

Dulbecco’s modified Eagle’s medium

ECD

Extracelluar domain

EGFR

Epidermal Growth Factor Receptor

ELISA

Enzyme-lined Immunosorbent Assays

FACS

Fluorescence Activated Cell Sorting

FITC

Fluorescein Isothiocyanate

FISH

Fluorescent in situ Hybridization

FRET

Fluorescence resonance energy transfer

GFP

Green fluorescent protein

GRPR

Gastrin Releasing Peptide Receptor

GST

Glutathione-S-transferase

HBSS

Hank’s Buffered Salt Solution

HER

Human Epidermal Growth Factor Receptor

xx

HRP

Horseradish Peroxidase

ICP-OES

Inductively Coupled Plasma Optical Emission Spectroscopy

IHC

Immunohistochemistry

IPTG

Isopropyl-β-D-thiogalactopyranoside

Kd

Dissociation constant

MRI

Molecular resonance imaging

NIR

Near infrared

NMR

Nuclear magnetic resonance

OCT

Frozen tissue matrix

OD

Optical density

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

PEG

Polyethylene Glycol

PET

Positron-emission tomography

ProCA

Protein Based MRI contrast agents

PSA

Prostate Specific Antigen

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

SNR

Signal to noise ratio

UV

Ultraviolet

1

Chapter 1.

INTRODUCTION

1.1 Cancer as human diseases
Cancer is caused by cells that grow uncontrolled and do not die. Normally, the cells in
the human body will follow a rule of growth, division, and death. Programmed cell death is
called apoptosis [1]. When this process is broken, cancer will form. Unlike regular cells, cancer
cells do not experience programmatic death and instead continue to grow and divide. This leads
to a mass of abnormal cells that grows out of control. In addition, cancer progression through
different stages causes invasiveness and metastasis [2]
In nowadays, cancer has been one of the most common human diseases, 23% of which
will cause death. More than 30% people in the world will receive cancer diagnosis during their
life time [3]. As shown in Figure 1.1, breast cancer and prostate cancer have highest occurrence
among all the cancers also with relatively high death rate [4]. Cancer diagnosis is mainly
achieved by X-ray or biopsy. For example, breast cancer was also been detected by mammography since 1980s.
Prognosis is a prediction of probable outcome of a disease [5].Since a lot of factors of
individuals will affect the progress of disease, prognosis helps to identify which tumors are
more aggressive than others and the possible progression of the tumor [6].
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Figure 1.1 Occurrence of different cancers in western countries.
Although the death rate of cancer is decreasing due to the development of diagnosis
and therapy, the occurrence of breast and prostate cancers are still increasing. Both of the cancers have highest occurrence in the western countries [7]

1.1.1 Biomarkers and its role in diagnosis, prognosis and treatment
Molecular targets, which are called biomarkers were discovered by researchers [8].
Since cancer is one of the common diseases in the world today, cancer biomarkers are of most
interests for researchers. An early diagnosis of cancers determines the possibility of curing disease[9] because the tumor will always prognoses into invasive tumor or metastasis into other
organs, which makes the therapy even more difficult . Therefore, it is necessary to find a target
molecule as a biomarker. In order to diagnose or prognoses the cancers accurately and facilitate early diagnosis that increases the possibility of curing the cancers,
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Various diagnosis assays have been developed based on the analysis of biomarkers [10].
For example, From 1970s, cervix cancer diagnosis by cell sample analysis has been offered. PSA
(Prostate Specific Antigen) in the urea or blood sample has been used to be widely applied to
diagnosing the prostate cancers [11].
The preferred targets for tumors should be present only in tumor cells and easily recognized by targeting reagents during blood circulation. Therefore, cell surface molecules or structures in extracellular matrix are suitable for functioning as biomarkers [12]. For example, PSMA
(Prostate Specific Membrane Antigen) and HER2 are cell membrane proteins which express in
high level only in specific prostate or breast cancers.
The perfect target structure for use in tumor targeting should be present only in tumor
cells, and be easily accessible for targeting agents located in the blood. This makes cell surface
structures, or structures located in the extracellular matrix, suitable. It is also important that
the target is available during the whole treatment time, so that the cancer cells do not down
regulate its expression during treatment. This can be achieved if the target structure is needed
for the cancer cell to grow and divide.
Biomarkers have provided valuable information in patient selection. By estimating the
highest benefit from the treatment, the treatment population can be enriched by biomarkers
identification. Therefore, biomarkers play important roles in two aspects: first, biomarkers will
define which patients will benefit from the disease treatment by drugs; second, whether the
drugs function properly according to the expected mechanism based on biomarkers [13]. In
nowadays, almost half of the new developed molecular entities are involved in biomarker elements.

4

Although biomarkers have been expected to increase the success rates in cancer diagnosis and treatments, there are still several challenges in clinical application of biomarkers [14].
First, the clearly understanding of biomarkers in the development of cancers is required for the
clinical process [15]. Second, reliable testing assay of biomarkers is needed for the reproducible
results. Although PSA is widely used for prostate cancer patient screening, it is not accurate,
with many false positives that gives wrong information if diagnosis [16]. Third, the detection
boundaries have to be defined by the constant testing. Fourth, the possible function of a novel
biomarker during a planned therapeutic strategy has to be estimated before been applied [17].
In a summary, all these factors have to be well considered before and during the clinical application of biomarkers.
To be a biomarker, the molecule must possess several properties: it exits in tumor cells
rather than normal cells; it can be easily detected by targeting agents either in blood or tissue;
the molecule is available during the treatment period. The cell surface molecules or molecules
located in extracellular matrix have the highest possibility to be a biomarker.
In nowadays, almost half of the new molecular entries are involved in the development
of biomarkers. Targeted prognosis and therapy have increased survival percentage [12]. Designing targeted contrast agents can benefit for the diagnosis and prognosis of diseases. One subject of the biomarkers for cancer is receptor on cell surfaces which are widely studied. The popular receptors like PSA (prostate specific antigen), GRPR (gastrin releasing peptide receptor),
EGFR (epidermal growth factor receptor) family have been applied clinically for cancer determination and therapy [18-19]. These receptors always get over expressed in various cancer
cells. The expression level is also related with the cancer stage [20-21]. Gastrin releasing pep-

5

tide (GRP) is a member of bombesin like family of which pre-protein is cleaved into GRP of 27
amino acids or neuromedin C of 10 amino acids [22]. GRP is widely used to conjugate with nanoparticles, quantum dots or other probes to function as a targeted contrast agent against
GRPR [19]. Similar as GRP, EGF is the ligand for EGFR, which is the first member of EGFR family
(Figure 1.2). There is a high expression level of both EGFR and EGF in various cancer cells, like
breast cancers, ovarian cancers and pancreatic cancers [23].

Figure 1.2 EGFR family and its targeting molecules
All the members in EGFR family have an extracellular domain (ECD), a trans-membrane
domain and an intra-cellular domain. HER2 is the one that does not have a natural ligand for
the ECD which tends to form dimer with other members. HER3 is the one lack of a kinase domain. With some ligand binding in the ECD of either member in the former dimer, the inner kinase pathway may be activated which will promote cell proliferation and agiogenesis.
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1.1.2 Detection of biomarkers
Many techniques have been developed to measure specific biomarkers at protein, DNA
or RNA levels; for example, immunohistochemistry (IHC), enzyme-lined immunosorbent assays
(ELISA), fluorescent in situ hybridization (FISH) and real time polymerase chain reaction (RTPCR), as well as Flowcytometre (Figure 1.3). In order to get reproducible and reliable results
from the assays, Validation of the methods is critical to the assay [24].
Take one of the most famous biomarkers for breast cancer, HER2 (human epidermal
growth factor receptor 2) as an example (Figure 1.2). Since HER2 is involved in signal pathway
by the intracellular kinase domain. The mutation of the kinase gene will result in poor prognosis.
Therefore, RT-PCR of the mutated gene can predict the abnormal function of the biomarkers
[25]. HER2 gene also encodes a trans-membrane protein with the extracellular domain as a target for antibodies. Several antibodies against HER2 have been developed which makes IHC is
widely used to measure the expression level of HER2 protein which is related to the disease
stage.
However, most of these established methods are invasive by biopsy or surgery. Unfortunately, the clinical application of targeted therapy is largely limited by current methods for
assessment of these cancer biomarkers using invasive methods such as biopsy. One of five
HER2/Neu clinical tests, including biopsy and immunostaining (IHC) provides incorrect results,
which severely affect the selection of appropriate patients for personalized treatment using
HER2/EGFR targeted cancer therapies. Limitations of these methods are mainly because of invasiveness. They cannot monitor the tumor in real time.
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As shown in Figure 1.3, current diagnosis of HER2 is first based on IHC results. IHC will
predict the expression level of HER2 which is related to the tumor stages. The expression of
HER2 is generally divided into 4 levels, and only the highest level is suitable for targeted therapy.
The cancers with lower level of HER2 will need further analysis by FISH to determine the HER2
gene. However, IHC needs surgery to get the tissue samples for analysis. FISH also need to use
biopsy to get the tissue sample. These invasive techniques may stimulate the tumor growth and
metastasis [26].

IHC
Positive
3
Herceptin
Th

Positive 2+

Positive 1+
or 0

FISH

Positive
Figure 1.3 Algorithm for Herceptin use
In order to diagnose whether the specific type of breast cancer is suitable for Herceptin
therapy, Cancer tissue samples are required for the diagnostic method of IHC. Only the HER2
level detected by IHC is up to stage 3, this type of cancer is illegible for Herceptin treatment. If
the expression level is in stage 2, further diagnosis with FISH to amplify the HER2 DNA will be
taken to confirm the treatment methods [27].
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1.2 EGFR family function as biomarkers for diagnosis and therapy
The epidermal growth factors (EGF) induce signal transduction by activating the kinase
domain of the epidermal growth factor receptors (EGFR) to promote cellular proliferation and
survival (Figure 1.2). EGFRs are comprised of four family members: EGFR/HER1, HER2/Neu,
HER3 and HER4, respectively. They share similar structures with an extracellular ligand binding
domain, a transmembrane domain, and a functional intracellular tyrosine kinase domain (except for HER3). Different from other three receptor family members, HER2/Neu does not have
a natural ligand and its ECD domain is able to adopt an activated state to dimerize with EGFR or
HER3 (EGFR/HER2, HER2/HER3). HER2 is the preferred dimerization partner in the EGFR family.
HER2/Neu and EGFR are also major prognosis biomarkers over-expressed in various types of
cancer cells [28] and tissue samples from cancer patients [20, 29].
Various carcinomas, like glioma, bladder carcinomas and lung cancers, have overexpression of EGFR proteins [30-31]. The EGFR has many ligands, such as EGF and Transforming
Growth Factor-α(TGF-α). As shown in Figure 1.4, ligand binding cause conformational change
which exposing the dimerization of domain II. Because of the effects of dimerization, the tyrosine kinase sites located in the intracellular domain get phosphorylated. However, Her2 is not
dependent on the ligand activation. HER2 is the preferred dimerization partner for all the other
members in the EGFR family. When overexpressed, HER2 homodimers are often formed [32].
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1.2.1 Structure of EGFR family proteins

Figure 1.4 EGF receptor activation.
I-IV: domains of the extracellular part of the receptor, TM: transmembrane domain, IC:
Intracellular domain. Binding of EGF to the domain one and three of EGFR (HER1) ECD will cause
the form change of domain and lead to homo-dimerization.

Figure 1.2 shows that the epidermal growth factors (EGF) induce signal transduction by
activating the kinase domain of the epidermal growth factor receptors (EGFR) to promote cellular proliferation and survival. EGFRs are comprised of four family members: EGFR/HER1,
HER2/Neu, HER3 and HER4, respectively.
They share similar structures with an extracellular ligand binding domain, a transmembrane domain, and a functional intracellular tyrosine kinase domain (except for HER3). The
EGFR has many ligands, such as EGF and Transforming Growth Factor-α(TGF-α). As shown in
Figure 1.4, ligand binding cause conformational change which exposing the dimerization of domain II. Because of the effects of dimerization, the tyrosine kinase sites located in the intracellular domain get [33] .
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Different from other three receptor family members, HER2/Neu does not have a natural
ligand. HER2 is the preferred dimerization partner for all the other members in the EGFR family.
When overexpressed, HER2 homodimers are often formed [34-35]. Its ECD domain is able to
adopt an activated state to dimerize with EGFR or HER3 (EGFR/HER2, HER2/HER3). Among the
EGFR members, HER2 is the one which is lack of natural ligand for the extracellular domain.
Therefore, HER2 has to form dimer with other family members to activate the downstream signal pathway [36]. Since HER3 is lack of the tyrosine kinase domain, when HER2 and HER3 form
into a heterodimer, binding of the ligand to HER3 will activate the tyrosine kinase function of
HER2. Various antibodies or other peptides have been developed to target to HER2 (Figure1.5).
To date, there are structures of extracellular domains have been determined mainly by X-ray
crystallography [37]. As shown in Figure 1.5, these structures reveal a fixed conformation for
HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB
receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region
of HER2, identifying this site as a target for anticancer therapies [37]. This binding may facilitate
the endocytosis by providing direct interaction of the formed steric barrier to the transmembrane regions [38]. By identify the binding patterns of Herceptin Fab domain and HER2 ECD, a
basis of designing new targets for HER2 has been generated for diagnosis and therapeutic effects.
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Figure 1.5 Crystal structure of HER2 and HER2-Herceptin complex
The Fab domain of antibody Herceptin targets to the domain 4 of HER2 ECD close to the
transmembrane domain. This may facilitate the endocytosis of HER2 after binding with Herceptin. The ADCC (antibody dependent cytoxicity) will be triggered after binding [37].

1.2.2 Roles of EGFR family in tumor formation and growth
As epidermal growth factor receptors, HER family proteins express on the cell membrane. Both of the transmembrane proteins are important in tissue normal growth and development [39]. The expression level of EGFR is relatively low in normal tissues except normal skin
epithelial cells. EGFR is also widely expressed in the tumor epithelial cells [40-41]. The expression level of HER2 is about 103-104 per normal cell; however, the expression is up to 106 per cell
in cancer cells especially in breast cancers.
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A

B
Figure 1.6 EGFR (A) and HER2(B) are negative prognostic factors in breast cancers
Those biomarkers that indicate lower survival rate are called negative prognostic biomarkers. Those cancer cells with higher expression level of EGFR or HER2 will have relatively
lower survival rate and shorter survival time [42-43].

EGFR family members play an important role in various tumor etiology including breast
cancers, ovarian cancers, pancreatic cancers, prostate cancers and lung cancers (Figure 1.6).
The over expression of EGFR proteins as a consequence of amplification of EGFR genes in cancer cells is involved in tumor matastasis and aggressiveness. The reason of the over expression
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of EGFR proteins is due to the character of EGFR as they can cause the loss of tumor suppression gene because EGFR is mutationally activated in half of the cancer cells [41].
Among of the members, HER1 and HER2 are two well established biomarkers for diagnosis and treatments. About 30% of the breast cancers have over expression of HER1 or HER2.
HER1 over-expresses in many solid tumors. By binding with its ligands, a signaling network will
be triggered (Figure 1.2). The tyrosine kinase domain will be activated for the downstream signal path way [1, 44]. Therefore, the cell proliferation and angiogenesis will be promoted and
the cell apoptosis will be inhibited [1]. The HER2 positive breast cancer is correlated with high
matastasis and low survival rate. HER2/Neu and EGFR are also major prognosis biomarkers
over-expressed in various types of cancer cells [28] and tissue samples from cancer patients
[20, 29]. Various carcinomas, like glioma, bladder carcinomas and lung cancers, have overexpression of EGFR proteins [30-31]. Table 1 shows that up to 69% percentage of tumors have
high expression level of EGFR especially in later stage. Table 2 shows HER2 has high expression
level in about 30% tumor cells. However, HER2 expression is also over expressed in the early
stages of these cancers, which will benefit for the early diagnosis [45].

14

Table 1 EGFR overexpression rate in different stages of cancers

N

Definition of
HER1/EGFR
overexpression/EGFR
amplification

Percentage of tumors
overexpressing HER1/EGFR

Onn et al, Clin
Cancer Res,
2004

111

2 or 3 staining by IHC

60%

Rusch et al,
Cancer Res,
1993

44

Increase detection by
Northern analysis

45%

Selvaggi et al,
Ann Oncol, 2004

48

2+ or 3+ staining by IHC

37%

Ohtsuka et al, J
Thorac Oncol,
2006

48

2+ or + by Western
blotting

40%

Dancer et al,
Oncol Rep,
2007

32

Two-fold or greater
amplification of the EGFR
gene by FISH

65%

Bloomston et al,
Dig Surg, 2006

71

1+ or higher staining
by IHC

69%

ThybuschBernhardt et al,
Int J Surg
Investig, 2001

24

Positive staining
by IHC

33%

Source
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Table 2 HER2 overexpression rate in different stages of cancers

Source

N

Slamon et al,
Science, 1987

189

Paik et al,
J Natl Cancer
Inst, 2000
Owens et al,
Clin Breast
Cancer, 2004

2034

Seshadri et al,
J Clin Oncol,
19934
Andrulis et al,
J Clin Oncol,
1998

16,092
(FISH)
116,73
6 (IHC)
1056

580

Definition of HER2
overexpression/HER2
amplification

Percentage of tumors with
HER2 overexpression/HER2
amplification

Two-fold or greater
amplification of HER2 gene
by Southern blot
Definite membrane staining
by IHC in any tumor cell

30%

Two-fold or greater
amplification of HER2 gene
by FISH

23%

29%

20%
2+ or higher result by IHC
Two-fold or greater
amplification of HER2 gene
by slot blot
Two-fold or greater
amplification of HER2 gene
by Southern blot, slot blot,
and/or RT-PCR

21%

20%

The over expression of EGFR and EGFR2 are associated with poor prognosis (Figure 1.6)
[10, 46]. The epidermal growth factors (EGF) induce signal transduction by activating the kinase
domain of the epidermal growth factor receptors (EGFR) to promote cellular proliferation and
survival (Figure 1.2). HER2/Neu and EGFR are over-expressed in various types of cancer cells
[28] and tissue samples from cancer patients. HER2 is a negative prognostic factor [20, 29]. In
numerous clinical studies, it is reported to associate with shorter disease-free and overall survival for breast and ovarian cancers as well as increased risk of death. About 30% of all breast
cancer cases are associated with expression of HER2/Neu. High expression of HER2/Neu closely
correlates with low survival rate [45, 47-48]. The rate of HER2/Neu overexpression was estimated within a wide range of 6-35% in gastric cancer [49], 9-32% in ovarian cancer [50], and in
up to 70% of human pancreatic cancer [51]. EGFR also leads to increased cell proliferation and
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motility and decreased apoptosis [52]. EGFR is also a negative prognostic factor for multiple
tumor types, including non-small cell lung carcinoma (NSCLC) and pancreatic cancer [53].
Co-expression of EGFR and HER2 is found in 10–36% primary human breast carcinomas,
and it is generally associated with a poor prognosis compared with expression of a single receptor [34, 54-56]. To date, the roles of EGFR and HER2/Neu in the progression of pre-invasive ductal carcinoma in situ (DCIS) to potentially lethal invasive breast cancer remain under hot debate.
HER2/Neu is overexpressed in 60 to 70% of DCIS tissues which is much greater than in invasive
breast cancer tissues (~30%). In contrast, overexpression of HER2/neu is not found in normal
ductal cells or in hyperplasic ductal cells [57]. In addition, it has been shown that 14 to 91% of
human breast carcinomas express a high level of the EGFRs [52]. The majority (70%) of DCIS tissues identified by mammographic microcalcification are of high grade comedo type, which is
associated with a high proliferation rate, lack of estrogen receptor, and high expression levels
of EGFR and HER2/neu [53]. The importance of EGFR signaling in the growth of DCIS tissues is
further supported by study results obtained from examination of the effects of an EGFR inhibitor, iressa, on human DCIS tissues xenografted in nude mice [58-59].

1.2.3 Distribution of EGFR family members in various cancers and cell lines
There are more than 20 cell lines which have high expression level of HER2. They mainly
come from breast tumor, ovarian and pancreatic tumors. Among these cell lines, several pairs
of positive and negative HER2 cell lines are widely used in research (Table 3) [9].
SKBR-3 is one of the most traditional human breast cancer cell lines. This cell line was
derived in 1970 from pleural effusion cells. AU-565 was established from the same patient as
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SKBR-3. The AU565 cell line amplifies and overexpresses the HER2 oncogene; it expresses the
HER-3, HER-4 and p53 oncogenes. The expression level of HER2 in AU565 is much higher than in
SKBR-3. These two cell line are usually used to study the effect of drug or protein to HER2 cell
lines. However, their tumorigenicity is very low. As a result of that, they are not proper for a
tumor mouse model.
SKOV-3 cell line is a hypodiploid human cell line which originated from ovarain cancer.
The Her2 expression level is higher than SKBR-3. It can generate tumor in nude mice with well
differentiated adenocarcinoma. Because of its ability to generate well shaped tumors, it is
widely used on nude mouse for Her2 tumor model. Compare with SKOV-3, BT474 is another cell
line which is also commonly been used for generating tumors. BT-474 was isolated by E. Lasfargues and W.G. Coutinho from a solid, invasive ductal carcinoma of the breast. The expression
level of BT474 is similar as AU565. Besides these genital cancers, pancreatic cancer sometime
also has a high expression level of Her2, such as MIAPaca-2.

MDA-MB-361
MDA-MB-231
MCF7
SKOV3
SKBR3
BT474
0.00

1.00

2.00

×106

Figure 1.7 HER2 expression level of various cancer cells
The HER2 expression levels have been measured in different cell lines. The cell line
SKOV-3, SKBR-3 and BT474 with an expression level up to 106 per cell are called HER2 positive
cell lines. The cell lines with expression level less than 104 are called HER2 negative cell lines.
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Based on the choice of positive cell lines, negative cell lines can be decided as a pair. For
example, MCF-7 and MDA-MB-231 come from breast cancer which can be control for SKBR-3
and AU565 (Table 3). By choosing cell lines from similar sources, the species difference can be
minimized.
Mouse EGFR-2 is different from HER2 which are from human. However, mouse EGFR-2
is also related to breast cancer of mouse. Both NT5 and EMT-6 are form mouse mammary cancer; EGFR-2 is overexpressed in NT5.

1.3 Targeted reagents for EGFR family
Besides the endogenous ligands for EGFR members, various targeted reagents, like antibodies and peptides, have been developed against EGFR members. Based on the targeted region of the receptor, the targeted reagents can be generally divided into two types. One type of
reagents targets to the intracellular domain of EGFR; while another type targets to the extracellular domain of EGFR [2, 60]. The intracellular targeting reagents are inhibitors to the tyrosine
kinase domain. The reagents target to the extracellular domain can cause endocytosis, ADCC
(antibody dependent cytoxicity) effects of the cancer cells. The targeted molecules can be antibodies such as, Herceptin, protein domain such as EGF and affibody, peptide, such as Latibnib
and small molecules such as Taxol [61]. The traditional cancer treatment like radiation therapy
and chemotherapy, will affect all normal cells. To use protein as a drug, it will decrease the toxicity and increase the specificity.
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The drugs are summarized in Table 4 [62]. Small molecules like Lapatinib function as the
kinase domain inhibitor can inhibit both EGFR and HER2. The HER2 specific antibody like Trastuzumab (Herceptin) only target to the extracellular domain of HER2 which can inhibitor the HER2
expression specifically.
Table 3 HER2 inhibitor in clinical use [63]
Drug
Type
Monoclonal antibodies

Target

Source

Current clinical status

Pertuzumab

Humanized

HER2

Genenthech/Roche

Phase II trials in breast and ovarian cancer with other reagent

Trastuzumab Humanized

HER2

Genenthech/Roche

Lanched for breast cancer in
combination with chemo therapy

Tyrosine kinase inhibitors
Lapatinib

Thioquinazoline HER1/HER2

GlaxoSmith
Kline

EKB-569

Cyanoquinoline

HER1/HER2

Wyeth

BIBW-2992

Quinazoline

HER1/HER2

Boehringer
Ingelheim

Neratinib

Cyanoquinoline

Pan-HER

Wyeth

AEE-788

Pyrrolopyrimidine

HER1/HER2

Novartis

ARRY-543

Quinazoline

HER1/HER2

BMS-599626 Pyrrolotriazine

Pan-HER

Lanched for second-line breast
cancer treatment in combination
with capecitabine
Phase II trials in colorectal and
non-small cell lung cancers
Phase II trials in breast, nonsmall cell lung and head cancers
Phase II trials in breast and nonsmall cell lung cancers
Phase I/II

Array BioPhase I
phama
BristolMyers
Phase I
Squibb

1.3.1 Intra-cellular inhibitor an extra-cellular ligands of EGFR (HER1)
The epidermal growth factor receptors EGFR and HER2/Neu are highly expressed as
biomarkers in various cancers and play important roles in cancer progression and survival. They
are also the major drug targets. Several targeted drugs such as monoclonal antibodies (Hercep-
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tin or Trastuzumab) and small inhibitors (Erlotinib) against HER2 and EGFR have been shown to
be effective with patients over-expressing those biomarkers. Unfortunately, the clinical application of targeted therapy is largely limited by current methods for assessment of these cancer
biomarkers using invasive methods such as biopsy. One of five HER2/Neu clinical tests, including biopsy and immunostaining (IHC) provides incorrect results, which severely affect the selection of appropriate patients for personalized treatment using HER2/EGFR targeted cancer therapies [34, 64].
The epidermal growth factors (EGF) induce signal transduction by activating the kinase
domain of the epidermal growth factor receptors (EGFR) to promote cellular proliferation and
survival (Figure 1.3). HER2/Neu and EGFR are over-expressed in various types of cancer cells
[28] and tissue samples from cancer patients. HER2 is a negative prognostic factor [20, 29]. In
numerous clinical studies, it is reported to associate with shorter disease-free and overall survival for breast and ovarian cancers as well as increased risk of death. About 30% of all breast
cancer cases are associated with expression of HER2/Neu. High expression of HER2/Neu closely
correlates with low survival rate [45, 47-48]. The rate of HER2/Neu overexpression was estimated within a wide range of 6-35% in gastric cancer [49], 9-32% in ovarian cancer [50], and in
up to 70% of human pancreatic cancer [51]. EGFR also leads to increased cell proliferation and
motility and decreased apoptosis [52]. EGFR is also a negative prognostic factor for multiple
tumor types, including non-small cell lung carcinoma (NSCLC) and pancreatic cancer [53].
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1.3.2 Engineered antibodies and drugs for HER2
Based on the function as biomarkers of HER2 and EGFR, especially HER2 without a natural ligand, a lot of antibodies haven been developed against HER2. Antibodies have therapeutic
function by several pathways. Because HER2 mediates cell signaling pathways such as PI3K and
MAPK (mitogen activated protein kinase) pathways, antibody targeting to HER2 can cause ADCC
effects which make the cancer cells been swallowed by macro cells [65]. At the same time, antibody can inhibit proteolysis of HER2 ECD and inhibition the HER2 DNA repair [35].Regarding
these mechanisms, antibody resistance is also developed by loss of antibody binding, increased
downstream signaling and activation of alternative growth factor pathways.
As shown in Figure 1.3 and Table 3, several targeted drugs such as monoclonal antibodies (Herceptin or Trastuzumab) have been developed to against the ECD domain (which region) of the epidermal growth factor receptors EGFR and HER2/Neu expressed at the cell surfaces of various cancers [66-67]. Based on the function as biomarkers of HER2 and EGFR, especially HER2 without a natural ligand, a lot of antibodies haven been developed against HER2
(Table 4).
Because HER2 mediates cell signaling pathways such as PI3K and MAPK (mitogen activated protein kinase) pathways, antibody targeting to HER2 can cause ADCC effects which make
the cancer cells been swallowed by macro cells [65]. At the same time, antibody can inhibit proteolysis of HER2 ECD and inhibition the HER2 DNA repair [35].Regarding these mechanisms, antibody resistance is also developed by loss of antibody binding, increased downstream signaling
and activation of alternative growth factor pathways.
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Due to antibody resistance, other techniques for curing cancer cell through antibodies
are shown in Figure 1.8. The Fc domains of antibodies have been conjugated with drugs, toxic
proteins, radioisotopes and thermotherapy drugs.

A

B

C

D

E

Figure 1.8 Therapeutic effects through antibodies
For antibodies been used as therapeutic reagents, they may kill the cancer cells or get
cancer cells apoptosis in different mechanisms [68]. (A) ADCC effects will be triggered by antibody that helps the macro cells to swallow cancer cells. (B) The antibody is conjugated with
some predrugs which function as a drug once gets into cytosol by killing the cancer cells. (C)
Some toxic proteins which binds to antibody non-covalently will be released in the cytosol and
inhibit the cell growth. (D) For those radioactive labeled antibody, the radioactive reagents will
break the DNA replication of cancer cells directly. (E) The antibody can also be conjugated with
some clinically available chemotherapy medicine. Antibody will provide the specific targeting
and help the chemotherapy medicine to locate in the cancer area which will eliminate the
harmful effects to normal cells.
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1.4 Affibody library and screening
Affibody was selected as our targeted sequence because the suitable size for molecular
imaging of moderate circulation time [69]. Affibody is originated from the “z” domain of protein A, which contains 58 amino acids (Figure 2.1). A variant of this affibody called ZHER342 can
specifically target to HER2 with the Kd of 22 pM. Because of its small molecular weight (7 KDa),
there are more advantages than antibodies for the affibody to penetrate deeper tissue and target the HER2 positive sites. Affibody is able to penetrate the blood vessel and well distribution
in the tumor mass. Biodistribution in SKOV-3 xenografts indicates that the up-take of reagent in
tumor sites by affibody targeting [70-71].

1.4.1 Affibody derived from z-domain of Protein A and screened by phage display
Affibody is originates from the “z” domain of protein A, which contains 58 amino acids.
Affibody molecules with affinity for HER-2 were selected using phage display. The produced affibody molecules were tested for binding to HER-2 ECD immobilized to a Biacore sensorchip.
Three generations of affibody for HER2 were developed. ZHER2-4 is the first generation of affibody with 13 mutations at domain 1 and 2 (Figure 1-9). It has a Kd for HER2 of 50 nM [72]. A variant of the second generation affibody called ZHER2:342 has 7 mutations at L9M, Q11N, Q17A,
A18L, W24N, T25Q and S26K from previous generation, which has a Kd for HER2 about 22 pM
(Figure 1-9) [73]. EGFR affibody call ZEGFR:1907 was screened from affibody library by extracellular
domain of EGFR which has a Kd of 43.6 nM for EGFR [74].
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Figure 1.9 Structure and Sequences alignment of affibody
Affibody is a phage display library with 13 amino acids in domain 1 and domain 2 to be
random. Different affibody variants are screened by specific antigen like HER2 or EGFR. ZHER2:4 is
the first generation of affibody against HER2 and ZHER2:342 is the secondary generation which increase the binding affinity by changing the Kd from 50 nM to 22 pM. ZEGFR:1907 is a variant specific targets to EGFR.
There are several advantages for the affibody than antibodies as a Her2 targeting moiety. First, it can be quickly diffused in vivo and then target to the biomarkers. Second, the optimized size enables affibody to penetrate cell membrane for endocytosis. The endocytosis allows enough affibody molecules concentrate at the cancer cells, which fulfills the molecular imaging of biomarkers. Third, affibody can also be secreted out of the body in shorter time than
antibodies, which will minimize the toxicity. The radioactively labeled affibody was injected into nude mice with SKOV-3 tumor model. Affibody can specifically target to the tumor in 24 hr
[75]. Figure 1.10 shows that HER2 affibody ZHER2:342 can bind to cells with high expression level
of HER2 and has the endocytosis effects [69]. As a targeting moiety, affibody has several advantages. First, it is relatively stable in vivo compared with peptide fragments. Second, HER2 affi-
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body is able to penetrate deeper tissue. Third, Biodistribution in SKOV-3 xenografts indicates
the up-take of reagent in tumor sites by affibody targeting.

Figure 1.10 ZHER2:342 is endocytosed into SKBR-3 cancer cells with HER2 over expression.
HER2 is a protein on the cell membrane. The cells were stained with fluorescent
(Fluo555 with excitation wavelength at 555 nm) conjugated affibody ZHER2:342. Staining in the
cell plasma indicates that the ZHER2:342 gets inside of the cancer cells.

1.4.2 ZEGFR:1907 binds to EGFR with highest affinity
Affibody molecules specific for the epidermal growth factor receptor (EGFR) have also
been selected by phage display technology from a combinatorial protein library based on the
58-residue, protein A-derived Z domain. Three selected Affibody variants were shown to selec-
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tively bind to the extracellular domain of EGFR (EGFR-ECD). Kinetic biosensor analysis revealed
that the three monomeric Affibody molecules bound with similar affinity, ranging from 130 to
185 nM. Head-to-tail dimers of the Affibody molecules were compared for their binding to recombinant EGFR-ECD in biosensor analysis and in human epithelial cancer A431 cells. Although
the dimeric Affibody variants were found to bind in a range of 25–50 nM affinities in biosensor
analysis, they were found to be low nanomolar binders in the cellular assays. Competition assays using radiolabeled Affibody dimmers confirmed specific EGFR-binding and demonstrated
that the three Affibody molecules competed for the same epitope. Immunofluorescence microscopy demonstrated that the selected Affibody dimers were initially binding to EGFR at the cell
surface of A431, and confocal microscopy analysis showed that the Affibody dimmers could
thereafter be internalized.

1.5 Clinical imaging techniques and the application
Visualization techniques are widely used to determine the exact location of the tumors
before surgery, and also to determine if metastasis is present and to monitor the tumor burden
during therapy. The most widely used imaging techniques include: MRI (Magnetic Resonance
Image), PET (Positron emission tomography), Ultra sound, GFP (Green Fluorescent Proteins),
NIR (Near infra-red) in animals and other radioactive methods.
Based on the function and mechanism, these imaging methods can be classified as two
categories [76]. One is an optical image to detect inner but lower imaging, like NIR and fluorescence, has relatively high sensitivity but low resolution. The penetration depth also limits the
application of optical images [77]. The other one is spectrum image, like MRI and PET. Most of
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the optical image techniques have the limitation in depth. The imaging signal varies due to the
depth change in vivo. Spectrum image techniques are able to show much deeper penetration
(Figure 1-10). However, the spectrum technique like PET using radio isotopes to create radioactive signals, have disadvantages in harmful components.
1.5.1 Magnetic Resonance Imaging and its application
Magnetic resonance imaging (MRI) is one of the most powerful imaging techniques in
preclinical and clinical diagnosis due to its significant advantages in non-invasiveness and no
restrictive limitations [78]. MRI measures the water hydrogen properties and interactions in an
external magnetic field. MRI is able to detect signals in tissues from 1 mm to 1 m in thickness.
The high resolution to distinguish various organs also makes MRI a possible technique in clinical
application [79]. Since the MRI signals are from water molecules, the soft tissue such as brain
tissue, which contains high amount of water, will demonstrate strong MRI signals called functional MRI (fMRI). Functional MRI is based on the increase in blood flow to the local vasculature
that accompanies neural activity in the brain. The hemodynamic response from fMRI is related
to neural activities, so fMRI is widely used in neuroimaging [80-81]. For example, the brain tumor is easier to be identified by identifying the change of brain structure using fMRI. For other
organs especially tumors, their detections are hindered by the low sensitivity and signal to
noise ratio of MRI. Due to the lower proton density, regular tissues demonstrate relatively lower signals in the magnetic field comparing with soft tissues. In order to make MRI suitable for
various diseases, contrast agent is required for MRI to image different organs except for the
brain tissue. About 1/3 of MRI scanning requires the use of MRI contrast agents [82].
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1.5.2 Near Infra-red imaging and in vivo application
Near Infra-red (NIR) imaging is one type of the optical imaging, which detects the
transmission protons, penetrates through the tissue since short wavelength of the red color
enables it transparent of tissues [83]. The emission wavelength of NIR is between 700-1000 nm
[76]. Like all the other optical imaging, the photon transmission from tissue is largely affected
by tissue absorption and scattering. NIR dye can be used for in vivo imaging mainly because of
three advantages. First, NIR imaging has a high sensitivity even in nano molar level of molecules
[84], which benefits a molecular imaging for biomarkers. Second, animal body has relatively low
background fluorescence in near infrared region. Third, compared to other fluorescent dyes like
green fluorescence, NIR imaging has better penetration capability. This enables non-invasive
imaging by NIR dyes.
However, several limitations still hinder the application of NIR imaging in animals. First,
most NIR dyes are organic compounds with a molecular weight less than 1.2 KDa [85]. Since
these small molecules have relatively short circulation time in animal bodies, they are conjugated to large molecules like nano-particles and proteins for in vivo imaging [86-87]. The distribution and pharmacokinetics of NIR dyes have been perturbed by the conjugated molecules.
Second, in order to increase the signal to noise ratio (SNR), a filtration wavelength needs to be
appropriately selected to minimize the auto-fluorescence [76]. Besides, low toxicity and molecular stability are also required for the NIR dyes. This problem has been solved by molecular
modification and conjugation [88].
Although NIR dye has high sensitivity and the intensity is linear to the dye concentration,
which is important for the quantitative analysis in the research, the low resolution makes it dif-
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ficult to distinguish different organs. In a summary, NIR imaging performs is very efficient in
probing the drugs or biomarkers; however, due to low resolution it is not suitable for further
studying tissue structure as well as prognosis.

1.5.3 Other techniques of molecular imaging
The X-ray technique, a 3 dimensional X-ray imaging tool, is used in mammography for
solid organs like bones and CT; however it uses gamma-camera which is radioactive and invasive.
Positron-emission tomography (PET) technology is also commonly used for the clinical
diagnosis. PET is an image generated from radionuclides (tracer). This trace can emit pairs of
gamma rays which will be detected by the PET system and generated as a three dimensional
image [89]. In modern scanners, the PET and CT are combined to demonstrate a comprehensive
image of a whole living body. PET can image the soft tissue, while the CT scans the solid organ
as bones by X-ray. Both PET and CT have been used for many years in clinical diagnosis because of their high sensitivity and availability [75]. However, the PET imaging is based on the
decay of radioisotopes, which is harmful. Those isotopes with shorter half life times were selected, including: 11C, 13N, 18F, 64Cu, 68Ga, and so on [90]. Short half life time requires a sensitive
detector in the PET system or high amount of the tracers to generate an image with enough
resolution.
A tumor tracing molecule, coupled to a suitable radionuclide (gamma-emitting for use in
the gammacamera or positron-emitting for use in PET) is administrated, and when the tracer
has reached the tumor, images are taken. The most used PET-tracer is FDG - a 18F labeled glu-
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cose molecule that visualizes areas with high metabolism, such as tumor and inflammation
areas.
Molecular imaging assists the research, diagnosis or therapy of diseases on a molecular
level. This requires a series of biomarkers for various diseases and a necessary carrier to facilitate imaging reagents recognizing the biomarkers. Quantum dot is one of the best carriers for
the molecular imaging. Quantum dot was first introduced to the fluorescent imaging area; because it solves several problems for the organic fluorophores [88]. The inorganic core and shell
will narrow the emission range of the fluorophores within 25-35 nm. The background will dramatically decrease in such a narrow range [88].

1.6 Molecular imaging
Molecular imaging differs from traditional imaging in that probes known as biomarkers
are used to help image particular targets or pathways. Molecular imaging is a prospective technique in various areas like life science, physical science and neurology. Most diseases involve a
molecular basis; therefore, molecular imaging will facilitate the prognosis and diagnosis. It is
also expected to be applied in monitoring drug treatment via imaging biomarkers [56, 76, 91].
The most widely used imaging techniques include: MRI (Magnetic Resonance Image), PET (Positron emission tomography), Ultra sound, GFP (Green Fluorescent Proteins), NIR (Near infra-red)
in animals and other radioactive methods. They can be classified as two categories [76]. One is
optical image to detect inner but lower imaging, like NIR and fluorescence. Optical image has
relatively high sensitivity but low resolution. The penetration depth also limits the application
of optical images [77]. The other one is spectrum image, like MRI and PET. Most of the optical
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image techniques have the limitation in depth. The imaging signal varies due to the depth
change in vivo. Spectrum image techniques are able to show much deeper penetrations (Figure
1.11). However, the spectrum technique like PET using radio isotopes to create radioactive signal, have disadvantages either in harmful components.
Since nowadays, molecular imaging is not only used for studying basic biological
process, but also used for understanding the mechanism of disease development in molecular
level, it is expected that the molecular imaging will provide better differentiations in prognosis,
diagnosis and monitoring therapies by using various biomarkers [92].
Molecular imaging assists the research, diagnosis or therapy of diseases on a molecular
level. This requires a series of biomarkers for various diseases and a necessary carrier to facilitate imaging reagents recognizing the biomarkers.
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A

B

Figure 1.11 Spatial resolution and penetration depth of molecular imaging techniques
The x-axis indicates the spatial resolution of different imaging techniques. The y-axis
shows the sensitivity in (A) and penetration depth in (B). MRI has the largest spatial resolution
comparing with other techniques; however, its sensitivity is very low.
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1.7 Contrast agents for molecular imaging
Contrast agents in molecular imaging are those reagents which can enhance the signal
of imaging or distinguish the disease organs and non-disease organs [93].
In NIR imaging, NIR dye itself function as a contrast agent. Quantum dot is one of the
popular carriers for the molecular imaging. Quantum dot was first introduced to the fluorescent
imaging area; because it solves several problems for the organic fluorophores [88]. The inorganic core and shell will narrow the emission range of the fluorophores within 25-35 nm. The background will dramatically decrease in such a narrow range [88].
Contrast agents in MRI field are more widely used because MRI has high resolution but
low sensitivity. To enhance the sensitivity of imaging, 35% of MRI scans utilize the injection of
MRI contrast agents with paramagnetic, ferromagnetic or super paramagnetic metal ions. In
this dissertation study, we will focus on developing MRI contrast agents.

1.7.1 MRI contrast agents
MRI contrast agents are used to shorten the relaxation time (T1 and T2) of the protons
in the tissue area [82]. Based on the mechanisms, MRI contrast agents can be divided into two
categories: contrast agents which enhance the same level of longitudinal and transverse relaxation are called T1-weighted contrast agents. Contrast agents with much longer transverse relaxation than longitudinal relaxation is called T2-weighted contrast agents [94]. The most common T1 weighted contrast agents are gadolinium (Gd3+) based, since Gd3+ is a lanthanide metal
with seven unpaired electrons, high magnetic moment, and long electron spin relaxation time
[95]. Most iron based contrast agents are T2 weighted. For Gadolinium based contrast agents,
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Gd3+ perturbs the surrounded proton relaxivity. In order to increase the exchanged water numbers with Gd3+ and prevent the toxicity of Gd3+, an encapsulated chelator is required, such as
Gd-DTPA and Gd-DOTA [96].
Gadolinium, Gd3+, a lanthanide metal with seven unpaired electrons, high magnetic
moment, and long electron spin relaxation time, is one of the most widely used ions in T1weighted MRI contrast agents [97]. Since free Gd3+ is highly toxic with LD50=0.2 mmol/kg in
mice [96], it must be encapsulated by chelators. Current FDA approved MRI contrast agents are
based on small chelators (Table 4). Unfortunately, these clinical contrast agents only have a relaxivity of about 5 mM-1 s-1. For example, Gd-DTPA, has a r1 relaxivity of 3.8 mM-1 s-1 at 20
MHz.[94, 98] In order to detect contrast changes due to the difference of proton relaxation
time in organs clinically, a relaxation rate change of 0.5 s-1 is required [82]. Thus, a local concentration of 100 μM of contrast agent is required [82, 99]. In general, about 0.1-0.3 mM/ kg injection dose is needed to obtain high contrast in human and small animal tissues.
The high concentration of contrast agent required for contrast is indicative of low efficiency and results in increased risk for certain disorders. Nephrogenic systemic fibrosis (NSF), a
disease found in patients with kidney disease, has been correlated with the use of a gadolinium-based MRI contrast agents and is reported to be related to the release of free Gd3+[100103]. Further, small molecular contrast agents have a very short half life time (half-life around
0.5-3 min in the blood vessels of mice and elimination half-life about 1.5 hours in patients [104105]) that limits the time window for MRI data collection and often requires repeated dose injections. Moreover, such local concentration and detection limits (~30 µM in mouse skeletal
muscle for the contrast agent [Gd(HP-DO3A)(H2O)][106]) further hinder the number of poten-
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tial biological targets for molecular imaging. Therefore, there is an urgent need to develop contrast agents with significantly improved relaxivity, optimal retention time, and potential targeting capabilities.

Figure 1.12 Model structure of ProCA1-CD2
Protein based contrast agents are designed by grafting a metal binding site in the stable
protein like CD2. For MRI contrast agents, Gd3+ binding site was designed.
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Table 4. Physicochemical characteristics of commercially-available, extracellular, predominantly renally excreted gadolinium-based MR contrast agents.
Brand name

Magnevist

Dotarem

ProHance

Omniscan

MultiHance

Gadovist

OptiMARK

Primovist
(Eovist)

Vasovist

Generic name

Gd-DTPA

Gd-DOTA

Gd-HPDO3A

Gd-DTPABMA

Gd-BOBTA

Gadobutrol

Gadoversetamide

Gd-EOB-DTPA

gadofosveset
trisodium

company

Bayer Schering
Pharma

Guerbet

Bracco

GE Healthcare

Bracco

Bayer Schering
Pharma

Tyco

Bayer Schering
Pharma

Bayer
Schering
Pharma

Year of first
approval

1988

1994

1992

1993

2004

2000

1999

Molecular
structure
Thermodynamic
Stability constant
(log Keq)

Linear, ionic

Cyclic, ionic

Cyclic, nonionic

Linear, nonionic

Linear, ionic

25.81

Linear,
nonionic
16.91

Linear, ionic

22.11
22.57

Cyclic,
nonionic
23.81

2004 inEurope;
2007 in Japan;
2008 in US
Linear, ionic

22.61

21.81

16.61

23.461

N/A

Conditional
stability constant
at pH 7.4
Acid dissociation
half life in 0.1N
HCl
Osmolality
(Osm/kg)
Viscosity (mPa.s
at 37℃)
T1 relaxivity
(L/mmol.s-1)
1.5T, plasma
T1 relaxivity
(L/mmol.s-1) 3T,
plasma
Metal chelate
(mg/ml)

18.12
18.47

19.02

17.12

14.92

18.42

N/A2

15.02

N/A2
18.77

N/A2

10 min2

> 1 month2

3 hours2

35 second2

N/A2

N/A2

N/A2

N/A2

N/A2

1.961

1.351

0.631

0.651

1.971

1.61

1.111

0.6881

0.7-0.953

Chemical
structure

2.9

1

2.0

1

1.3

1

1.4

1

5.3

1

4.96

1

2.0

1

4.14

3.64

4.14

4.34

8.34

4.74

4.74

3.74

3.54

3.74

4.04

6.24

3.6

4.54

4694

278.34

279.34

2874

3344

6054

330.94

1.7.2 Biomarkers targeted contrast agents
In order to view by MRI, the local concentration of contrast agents should be up to micro molar level [107]. By concentrating the contrast agents in the tumor area is required for imaging the tumor tissue. As discussed in previous chapters, biomarkers are expressed endogenously and can be detected as an indicator of biological status. Normally, a biomarker will have
at least two characteristics: first, the biomarker can be probed by contrast agents for molecular
imaging; second, the biomarker is sensitive to drugs or medicine for targeted therapeutics [14].
To generate imaging on biomarkers has benefitted the selection of drug treatments. Therefore,
designing contrast agents to target to biomarkers is essential for the clinical diagnosis and therapy.
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As discussed in the Chapter 1.1, most of the receptors have their ligands, the ligands
themselves can be used as targeted reagents for contrast agents.

1.7.3 Criteria of designing ideal contrast agents
In the design of ideal contrast agents, several factors must be considered. First, negligible or low toxicity is a prerequisite. The contrast agents should be thermodynamically and kinetically stable, with high binding affinity and metal selectivity to minimize the release of free
Gd3+. A high metal selectivity for paramagnetic metal ions against physiological metal ions such
as Zn2+ and Ca2+ is preferred [108-109]. Second, high relaxivity, especially for T1, is preferred in
order to obtain better images with high contrast-to-noise ratio (CNR) and dose efficiency. Third,
an ideal contrast agent should have proper vascular retention time allowing for imaging of tissue enhancement, gauging tissue blood perfusion, and evaluating changes in capillary integrity.
Different strategies are applied to overcome the drawback of small chelator based MRI contrast
agents. For example, the non-covalent binding of small chelators to plasma proteins, such as
albumin (MS-325), greatly increases the relaxivity and blood retention time. On the other hand,
the applications of this class of contrast agents are limited to the cardiovascular system.
Fourth, it should have proper excretion time from the body to allow imaging and reduced toxicity. Molecules that are greater than 70 KDa do not readily pass through the glomeruli (a pore
size 60-70 nm in diameter)[105]. For example, the blood retention time for MS-325 in rabbit is
increased to over an hour[110]. The slow secretion and perfusion time for macromolecules
such as nanoparticles may be a big concern. Finally, targeting specific molecular entities is
greatly preferred since it will increase the specificity of MRI as a screening method for cancer
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diagnosis with the advantage of nondestructive and spatial resolution. Molecular imaging using
MRI contrast agents is also hampered by the low relaxivity, since in most cases these biomarkers have limited number in the disease area. To achieve molecular imaging, developing contrast
agents with high dose efficacy, low toxicity, optimal pharmacokinetics, and the capability of
targeting and permeabilty are required.

1.8 Objectives of this study, and over view of the dissertation
The Yang laboratory has first demonstrated MRI contrast agents (ProCA) with strong
metal binding affinity, selectivity, and stability, developed by de novo design of Gd3+ binding
site(s) into a stable host protein (Figure 1.12). The protein contrast agents exhibit ~20 fold improved MRI relaxivity compared to that of Gd-DTPA at 1.5- 4.7 T field due to controlled correlation time and exchangeable water numbers in the coordination shell [111]. Our study demonstrated a novel strategy to significantly increase the relaxivity of contrast agents by protein design.
There is an urgent need to develop non-invasive and accurate methods for diagnosis
and to monitor biomarker levels/distribution and their changes upon treatment by targeted
drugs in cancer patients. Based on the advantages of MRI of high resolution and deep tissue
penetration and real time, we propose to further develop MRI contrast agents to extend its capability and application in both clinic and preclinical research.
The goals of this research are to develop a novel class of protein-based MRI contrast
agents (ProCAs) with improved relaxivity, targeting capability and reduced toxicity to enable
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accurate monitoring of the expression level and distribution of the HER2/Neu and EGFR in different types of cancers, and to follow tumor response to treatment using targeted therapeutics.
This dissertation aims to answer several important questions in order to apply this strategy to develop MRI contrast agents for molecular imaging:
Chapter 1 discusses the background and related knowledge of this dissertation.
Chapter 2 describes all the methods and techniques have been used for this dissertation.
Chapter 3 discusses the design of HER2 targeting contrast agents. Methods for expression and purification of designed ProCAs with targeted capability have been optimized. Further
modification of ProCAs to increase the solubility, serum stability and reduce the immunogenenicity will be achieved by PEGylation. Dural modality of contrast agents for both MRI and NIR
have been prepared and characterized. Conformational and metal binding properties have
been examined. Furthermore, the relaxation properties have been measured.
Chapter 4 is aimed to evaluate the targeting capability using several methods such as
ELISA, western blotting and flowcytometry. The cell targeting capability has been evaluated using different cell lines with both NIR florescence and immunofluorescent staining. The adioactive assay is also used to measure the retention of Gd3+ in cancer cells. In addition, EFGR targeted contrast agents are also determined by the cell assays.
Chapter 5 discusses the design of xenograft animal model with the injection of our designed targeted MRI contrast agents. The optimized condition for imaging has been determined
for both MRI and NIR of imaging HER2 under various time points. Further histology analysis for
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primary organs shows biodistribution of HER2 and contrast agents. The advantages of ProCA1affi342 to antibodies are also determined by IHC.
Chapter 6 shows quantitative analysis of the distribution and binding capability of ProCA1-affi342 in cancer cells and animals.
Chapter 7 is aimed to show development of another mouse model by implanting tumor
cells in the mammary sites of mice as orthotopic tumor model, which can mimic the real tumor
situation. ProCA1-affi342 and ProCA1-affi1907 will be applied to this tumor model to monitor
the tumor progression and receptor distribution.
Chapter 8 focuses on drug treatment study by using contrast agents to monitor the tumor changes after treated with specific drugs. Initial results in cell treatments have been
achieved by immunology techniques and MRI in cells.
Chapter 9 summarizes other studies related to this dissertation by using designed contrast agents with multiple metal binding sites in developed xenograft models.
Table 5 summarizes all the variants involved in this dissertation.
The contents related with each variant have been listed in the Table 5:
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Table 5 Contents of all the variants
Description

Variants

Related Chapters

Domain 1 of CD2 with a designed Gd3+
ProCA1-CD2

1, 3
binding site
First generation of affibody ZHER2:4 against

ProCA1-affi4

HER2 fused to the C-terminal of ProCA1-

3, 4

CD2
Second generation of affibody ZHER2:342
ProCA1-affi342

against HER2 fused to the C-terminal of

3-8

ProCA1-CD2
Affibody ZEGFR:1907 against EGFR fused to
ProCA1-affi1907

8
the C-terminal of ProCA1-CD2

ProCA1-affi342m

PEGylated ProCA1-affi342

3-8

ProCA1-affi1907m

PEGylated ProCA1-affi1907

8

Second generation of affibody ZHER2:342
ProCA22-affi342m

against HER2 fused to the ProCA22 which

9

has four metal binding sites
Second generation of affibody ZHER2:342
ProCA32-affi342m

against HER2 fused to the ProCA22 which
has two metal binding sites

9

42

Chapter 2.

MATERIAL AND METHODS

2.1 Molecular cloning of ProCA1-affibody to target HER2 and EGFR
The affibody sequences ZHER2-2:4, ZHER2-342 and ZEGFR-1907 were cloned to the C-terminal of
ProCA1-CD2 in the pGEX-2T plasmid. Their sequence alignments have been carried out by online software Clustal W2 (Figure 1.9). The affibody peptide consists of 58 amino acids and 13
amino acids of them are involved in the targeting moieties, which are located in the helix 1 and
2. The sequences have been divided into three fragments and inserted into the plasmid. The
model structure of ProCA1-CD2 with Gd3+ binding site was been generated by SWISSMODEL
[112-113]. The affibody structure was shown in Figure 1.9 [114]. The model structure of ProCA1-affibody was generated by linking two parts of the structure files with GGSGG linker (Figure
3.1).

2.2 Plasmid construction and protein generation
After the fusion of affibody into the ProCA-CD2 plasmid by PCR, the DNA products were
prepared by Miniprep (Qiagen). All sequences were verified by automated sequencing on an
ABI PRISM-377 DNA sequencer (Applied Biosystems) in the Advanced Biotechnology Core Facilities of Georgia State University. Protein concentration is calculated using extinction coefficient
of UV280 nm.
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2.2.1 GST-fusion ProCA1-affibody and purification
The designed ProCA1-affibody were expressed as GST-tag fusion proteins in Escherichia
coli BL21(DE3) transformed with the plasmid constructs in LB medium with 100 mg/L of ampicillin and were grown at 37 °C overnight. On the second day, 50-60 ml inoculating LB medium
with the E coli Bl21 (DE3) is transfer to the big flask with 1L LB medium. 1ml amplicilin (1:1000)
is added into the LB medium. The optical density (OD) of the cultured medium is measured at
600nm. The big flask is shaking in37 ℃, 220rpm for cell growth. When the OD increases to 0.6-

0.8 (usually growth for 2 hours), the 1.5 mM IPTG is added into the LB medium, and the protein

will be expressed. The cell pellets are collected when OD grows over 2.0 for further purification. For low temperature expression, the temperature is changed to room temperature (25℃)
after induction for 16~18 hours overnight.

2.2.2 Sub-cloning of tagless ProCA1-affibody and purification
The DNA sequence of ProCA1-affibody in PGEX-2T (Figure 2.1) vector was cleaved by
BamH1 and EcoR1 restriction enzymes. The BamH1 site locates between GST tag and ProCA1affi, while EcoR1 site locates at the C-terminal of ProCA1-affibody. Then the DNA sequence of
ProCA1-affibody was attached to the cleaved PET-20b vector (Figure 2.2).
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Figure 2.1 DNA map of PGEX-2T vector

Figure 2.2 DNA map of PET-20b vector
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2.3 PEGylation of ProCA1-affibody
Methyl-PEOn-NHS esters, the deviant of Polyethylene glycol (PEG) with different molecular weights of 0.3, 0.6, 2.4, 5, 12 and 20 KDa were selected to modify the designed proteins.
PEGylation was carried out in phosphate buffered saline buffer with a 1:5 ratio of protein and
PEGs. Modified ProCA1-affibodies were further purified by FPLC and confirmed by the MALDITOF mass spectrometric analysis.

2.4 Conjugation of near infra red (NIR) dye to ProCA1-affibody
A Cys amino acid has been cloned to the C-terminal of ProCA1-affibody by PCR. The
Maleid group in the NIR dye can be linked to the –SH group specifically. The protein has been
dissolved in degassed PBS (pH 7.0-7.5) by dialysis at a concentration around 1 mg/ml. Tris-(2carboxethyl)phosphine (TCEP) was added to reduce the protein in N2 environment. Half an hour
later, the NIR dye Cy5.5 in DMF solvent was added in to the reduced protein solution. The conjugation reaction was kept in N2 to keep reducing environment. The ratio of protein to Cy5.5 is
around 5:1. Shake the mixture and keep the reaction for 2 hr. Then dialysis or cation exchange
column will be used to separate the free dye. The absorbance at 650 nm (Cy5.5) and 280 (protein) will be measured to calculate the conjugation yield (Figure 3.16).
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2.5 Determining the folding condition of ProCA1-affibody
2.5.1 Mass spectrometry
The MALDI mass spectrometry analysis was performed on an Applied Biosystems 4800
plus MALDI TOF/TOF analyzer mass spectrometer (Framingham, MA). The data were acquired
in a linear positive mode with sinapinic acid as matrix. The instrument was equipped with a Diode-pumped Nd:YAG laser at 355-nm. The mass spectra were acquired as an average of 3 shots
with a same laser intensity attenuator setting (4002 arbitrary unit) for all samples. Protein samples were prepared as a 200 μM solution in 10 mM Tris buffer (pH 7.4). Matrix was prepared as
a 10 mg/mL solution of Sinapinic acid in a 1:1 acetonitrile: 0.1% TFA solution. A 10:1 matrix:sample mixture was prepared, applied to the sample plate as 1 μL drops, and allowed to air
dry. The molecular weight been measured indicates the conjugation of NIR dye to the ProCA1affibody proteins. The relative peak intensity ratio of the non-conjugated and conjugated ProCA1-affibody was used for the estimation of the conjugation rate. This work was completed by
Dr.Siming Wang and Yanyi Chen.

2.5.2 Circular dichroism spectroscopy
The CD spectra of samples were recorded in a Jasco-810 spectropolarimeter at 25 ºC.
The far-UV CD spectrum of 20 μM ProCA1-affi342 were measured in a 1-mm pathlength cell in
10 mM Tris-Cl (pH 7.4) and the near-UV CD spectrum of those protein studied with a concentration of 100 μM were collected in the same buffer. All spectra were obtained as the average of
at least ten scans with a scan rate of 100 nm/min. The ellipticity was measured from 190 to 260
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nm (far-UV) and 250 to 340 nm (near-UV) and then converted to mean residue molar ellipticity
after subtracting the spectrum of buffer as the blank.

2.5.3 Fluorescence spectroscopy
Fluorescence emission spectra were recorded on a PTI fluorimeter at 25 ˚C using a 1-cm
path length cell. Intrinsic tryptophan fluorescence emission spectra were recorded from 300 to
400 nm with the excitation wavelength at 282 nm. The slit widths were set as 2 and 4 nm for
excitation and emission, respectively. Tryptophan spectra from 300-400 nm of the different
proteins studied were acquired at a concentration of 2 µM in 10 mM Tris-Cl (pH 7.4).

2.5.4 Nuclear Magnetic Resonance (NMR) spectroscopy
NMR spectra were collected on a 600 MHz NMR spectrometer. 1-D 1H-NMR at 25 °C was
measured to determine the folding of ProCA1-affibody and the conjugation with NIR dye. This
part of work was done by Dr. Hing Wong.

2.6 Relaxivity measurements and metal binding affinity of ProCA1-affibody
Relaxation times, T1 and T2, were determined on the 1.41T Minispec Relaxometer
(mq60 NMR Analyzer, Bruker) at 37 °C. The ProCA1-affi and ProCA1-affi-m (modified by PEG)
were diluted with 10 mM Tris buffer, pH7.0. Proteins prepared with a series of concentrations:
40-120 µM, were applied for the relaxation time measurement. The relaxivities, r1 and r2, were
obtained by fitting the relaxation times as a function of the Gd3+ concentrations. The Gd3+ -
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binding affinities with ProCA1-affi and ProCA1-affi-m were investigated by the competitive assay with the dye Fluo5N (a metal ion indicator, Invitrogen Molecular Probes). The fluorescence
spectra were collected on a fluorescence spectrophotometer (Photon TechnologyInternational,
Inc.) with a 10 mm path length quartz cell at room temperature [111].

2.7 Cell culture and mammalian expression
SKOV-3 cells were cultured in 5% CO2 at 37˚C in 75 cm2 flasks in McCoy-5A medium containing 10% fetal bovine serum (FBS) with 100 μg/ml Penicillin-Streptomycin. The other mammalian cancer cell lines are cultured in the same condition with different medium The AU565
cells were cultured in 1640 medium. The MDA-MB-231 cells were cultured in DMEM medium
with low glucose. The EMT-6 cells were cultured in waymouth medium. All the cells were thaw
at 37 ˚C and transferred into a 25T flask with 8 ml medium. After growing to a confluence over
90%, the cells will be suspended by 2% Trypsin and washed with HBSS buffer by centrifuging.
Finally the cells are passaged into several 50T or bigger flasks. The cells were frozen in commercial frozen medium containing 2% EDTA and 10% DMSO. Normally, about 106 cells will be frozen in 1 ml frozen medium.
For the mammalian expression, the LEC1 HER2 pSGHV0 cell line with stable transfection
of HER2-ECD DNA was obtained from Dr. Leahy’s group in Johns Hopkins University. The cells
were thawed rapidly at 37 ˚C. Spin the cells for 5 minutes at 1000rpm and aspirate freezing media. The cells were re-suspend in 1 ml Alpha MEM, 5%Dialized FBS, 100nM Methotrexate, 0.5
mg/ml geneticin. The cells were then transferred to 4 ml of the same in a T25 flask, 5%CO2, 37
degrees. Once expanded to have enough cells to seed a roller bottle (3-5 confluent T150's
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would do it), they are switched to DMEM / F12, 5%FBS, 100nM MTX. Weekly monitoring of expression medium by ELISA was done to ensure expression has not lost. The DMEM / F12 is
HEPES buffered since our roller apparatus is without CO2. Once the single roller bottle is confluent, we use that to split into 1L flasks. After 3 days in 5% serum to insure attachment, serum
is reduced to 1% for collection of media and further purification. The 1L flasks are generally fed
50 ml /flask, twice a week.

2.8 Cancer cell targeting
2.8.1 Enzyme linked immunosorbent assay (ELISA)
The cell lysate was made for the coating of ELISA. Take one flask of cancer cells and suspend with 2% Trypsin. Wash the cells for three times and count 1×108 of cells into a centrifuge
tube. The 1 ml RAPI buffer and 0.1% protease inhibitor cocktail was added into the cell pellets.
The cells were suspended and keep in 4 ˚C for 1 hr shaking. Centrifuge the cells and get the supernatant as cell lysate. AU565 and EMT-6 cells lysate with various dilutions was coated in a 96well plate (BD bioscience) at 37 °C degree overnight. On the second day, the medium was
changed. Different amounts of ProCA1-affi342 and ProCA1-affi342m were incubated with cells
for 1 hr in room temperature. The plate was washed and the CD2 antibody was used as a primary antibody to detect the binding proteins in the cells. HRP conjugated goat anti-mouse IgG
conjugated was used as the secondary antibody. Substrate (OPD,o-phenylenediamine dihydrochloride) was added into each well. After incubation, the absorbance was measured at 492nm
using a Victor V 1420 multiple counter from PerkinElmer.
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In the sandwich ELISA, the CD2 monoclonal antibody was coated on 96-well microplate
at a concentration of 100ng/well with carbonate/bicarbonate buffer (pH 7.4) and incubated at
4°C overnight. The second day, coating buffer was removed and the plate was washed with Tris
buffer saline (TBS) three times. The remaining protein-binding sites in the coated wells was saturated by adding 200 μl blocking buffer (5% nonfat dry milk/TBS, per well). The plate was covered and incubated for 2 hours at room temperature. Diluted proteins or tissue extracts from
mice experiment were added to each well and incubated at 37°C for 2 hours. Each cell treatment was done in triplicate. TBS was used to wash each well three times after incubation. Diluted polyclonal CD2 antibody was added to each well and incubated at room temperature for 2
hours. The plate was washed with TBS four times. HRP conjugated secondary antibody was
added to the 96-well plate in blocking buffer and incubated at room temperature for 2 hours.
After incubation, the plate was washed four times with TBS. The substrate of HRP was prepared
for detection of protein signals. OPD (ophenylenediamine dihydrochloride) was used as the
substrate. After incubation, the absorbance was measured at 492nm using a Victor V 1420 multiple counter from PerkinElmer.

2.8.2 Western blotting
The AU565, originally from human breast cancer, has an expression level of HER2 at
about 106 per cell. The EMT6 is a HER2 negative cell line from mouse breast cancer. The ProCA1-affi342 and ProCA1-affi342m were incubated with the two kinds of cells at 4 and 37 °C, respectively, for 1 hr. Then the cells were washed 3 times, 5 min each with Tris buffer. After this,
the cells in T25 were lysate with 200 µL RAPI buffer for 3 hr in 4 ˚C. Then the cell lysate was cen-
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trifuged and the supernatant was collected for western blotting. The primary antibody was
generated on rabbit by using ProCA1-CD2-m as antigen. The secondary antibody was AP conjugated (Invitrogen). The ProCA1-affi342 or ProCA1-affi342m retained in the cancer cells will be
detected by antibody and the signal will be shown on the developed film.

2.8.3 Radio-active assay on cancer cells
Cancer cells AU565 and EMT-6 were collected into 1.7 ml tubes by trypsin and centrifuging. After careful washing 3 times with HBSS buffer, the cells were incubated with radioactive
reagent 153Gd-ProCA1-affi342 and 153Gd-ProCA1-affi342m. 153GdCl3 (Novagen) was also used as
negative control. The incubation time is 1 hr by shaking. Then the cells were spin down by keeping both the pellets and supernatant. Wash the cells with HBSS buffer for 5 times, the washing
buffer was also collected. Finally, all the samples including cell pellets and washing buffer were
measured by γ-counter. The amount of 153Gd retained in the cancer cells was calculated based
on the standard curve (Figure 2.3).

52

6 104
y = -1390.3 + 10266x R= 0.99608
5 104

Curi
Curi

4 104

3 104

2 104

1 10

4

0
0

1

2
3
4
5
concentration of Gd
3+
Gd concentration (pmol)

6

Figure 2.3 Standard curve of radioactive GdCl3

2.8.4 Immunofluorescent staining in cancer cells
Three cell lines (AU565, SKOV-3 and MDA-MB-231) were seeded in different chambered
microslides (BD Biosciences) and treated with ProCA1-CD2, ProCA1-affibody, and ProCA1affibody-m at 37°C for one hour. The second day, cells were washed and fixed with 4% paraformadehye for 15 minutes at room temperature. Then cells were permeabilized with 0.1% Triton X-100 in 10 mM HEPES pH7.0. ImageiTTMFX signal enhancer (Molecular Probes) and subsequently incubated with the respective antibodies for 1 hour. After extensive wash, cells were
incubated with Alexa Fluor 488nm goat anti-mouse IgG (Molecular Probes) at a 1:1000 ratio.
Cells were washed three times for 5 minutes with TBST. Finally, microslides were mounted in
ProLong Gold antifade reagent with DAPI (Molecular Probes). Slides were scanned in a confocal
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microscopy lab with the Confocal Microscope (Zeiss. LSM510) using 40x or 63x objectives. Two
lasers were used here, 488nm for FITC and blue for UV. The final images were acquired by adjusting detector gain and amplifier offset to get the best images.

2.8.5 Flow cytometer assay (FACS)
The cancer cells SKOV-3 and MDA-MB-231 were cultured for the flow cytometer study.
The cells were lysated and suspended to transfer into a 5 ml FACS tube. The cells were washed
for 5 times by HBSS buffer. Then the PAb-ProCA1-CD2 (Appendix I) was added into the cells
with 1:500 dilutions. After 1 hr incubation in room temperature, the cells were washed with
HBSS buffer for 3 times. Secondary antibody goat anti rabbit with FITC conjugation was added
and incubate for 40 min. After extensive washing, the cells were counted by the FACS machine
with the number of 2,000. The accumulated fluorescent intensity was measured.

2.8.6 Magnetic Resonance Imaging (MRI) in cancer cells
SKOV-3 and MDA-MB-231 cells were collected and washed with 10 mM HEPES buffer
(pH7.0) three times. Up to 107 cells were incubated with Gd-ProCA1, Gd-ProCA1-affibody and
Gd-ProCA1-affibody-m at 37°C for 1 hour. After incubation, cells were washed with TBS three
times, 5 minutes each time. Cell pellets were collected in eppendorff tubes and measured by
MR imaging. T1 weighted MR images were acquired using an inversion recovery sequence (TR =
4000ms, TE = 12ms, IR=500ms) on a 7T MRI scanner. After cell MR imaging, cells were washed
twice with ice-cold PBS. PBS was removed and cell pellets were lysed with 1×RIPA lysis buffer

54

supplemented with 1mM NaF, 1mM PMSF and 1:1000 dilution of protease inhibitor cocktail.
Whole cell lysates were rotated at 4°C for 60 minutes. To remove cell debris, cell lysates were
centrifuged (15,000×g, 10min at 4°C). Cell lysate supernatant was collected and stored at -80°C
until use. 2× loading dye was added to the supernatant and boiled at 100°C for 5 minutes.
Western blotting was applied to check the contrast agent in cells by using the CD2 antibody
against the contrast agents.

2.9 Animal experiments
2.9.1 Nude mouse xenograft model
The nude mice are two weeks old. In 3-5 days after purchase, the mice are ready for
use. The tumor cells are scratched from flask and washed with HBSS buffer for three times. The
cells are counted and then suspended with saline to get a suspension of 5×106 cells per 100 µl
saline. The suspension is mixed with gel matrix in same volume. This procedure is completed on
ice. Every mouse is subcutaneous injected with 100 µl mixture on each spot. Every mouse has
two or three spots on its back. After two to three weeks, the mice will generate tumor of 0.5-1
cm.

2.9.2 Nude mouse othotopic model
The human breast cancer cell line MCF-10DCIS was used to generate the othotopic
model in nude mice. The tumor cells are scratched from flask and washed with HBSS buffer for
three times. The cells are counted and then suspended with saline to get a suspension of 5×104
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cells per 50 µl saline. Inject the cells into the mammary spot of the mouse. After about one
week, the tumor between 0.5 to 1 cm will be generated.

2.9.3 Magnetic Resonance Imaging (MRI) of tumor mouse
The tumor mouse will be anesthetized with constant isoflurane and located in the MRI
machine for a pre-injection scanning. The tumor mouse will be injected by tail vein injection
with our contrast agents in 10 mM HEPES buffer, pH7.0. The concentrations of our contrast
agents are between 3 to 5 mM. About 100 µL of the contrast agents will be injected into each
mouse. The mouse will be scanned on a 4.7 MRI scanner at various time points after injection:
10 min, 30 min, 2 hr, 24 hr, 48 hr and 72 hr. For every time point, three pulse sequences are
used: Fast spin echo (TR=2 s, TE=0.022 s or 0.066 s) Gradient echo (TR=0.116 s, TE=2.9 s ) Gradient echo DCE (TR=0.050 s, TE=2.9 s ) 3D image of Gradient echo was also scanned.

2.9.4 Near infra-red (NIR) imaging of tumor mouse
Engineered protein contrast agents were PEGylated and labeled with Cy5.5 (ProCA1affibody-Cy5.5). The protein was stored in 10mM HEPES buffer at concentration of roughly
5mM. 100 µL of Cy5.5 PEGylated protein was injected into the mouse tail vein. Fluorescence
imaging was taken at different time points using an IVIS imaging system (Xenogen Corporation).
The mouse was maintained under isoflorane anesthesia during imaging. Images were processed
using the living imaging 3.1 from Xenogen Corporation. The excitation filter wavelength of 650
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nm was used to scan the mouse NIR imaging. Another excitation wavelength of 604 nm was also used to scan the background. The emission wavelength is 740 nm.

2.9.5 Biodistribution and blood circulation measurements
The biodistribution of ProCA1-affi342m has been measured in the regular CD1 mouse
and nude mouse with tumors. The mice will be kept in the metabolism cages for 2 days before
experiments. Then mice were injected with 100 µM

153

Gd-ProCA1-affi342m in 10 mM HEPES

buffer (pH7.0) of 100 µL by tail vein injection. The mice are all kept in the metabolism cages individually under monitoring. The total monitoring time is 8 hours. All the urea and feces will be
collected. The blood will also be collected from thigh vein every 1 hr. At the end of 8th hour, all
the mice will be sacrificed and dissected. All the primary organs, like liver, kidneys, lung, heart,
spleen, tumor and muscle were collected for measurements, as well as the carcass. The radioactivity of all the collected organs and blood samples will be measured by γ-counter. From
the standard curve of Figure 2.3, the amounts of 153Gd in each organ or blood were calculated.
Then the amount of 153Gd will be divided by the total injection amount and bodyweight to get a
normalized percentage of each sample in each organ per kg of body weight.

2.9.6 Biodistribution measurements by ICP-OES
Besides using radioactive assay for the biodistribution study, we also used ICP-OES to
measure the retention of Gd inside the mouse body. After MRI experiments, we collected all
the primary organs, like liver, kidneys, lung, spleen, heart, tumor and muscle. All the organs
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were dissolved in 30% optimal nitric acid in the containers. The containers were heated at 80100 ˚C overnight until all the organs were dissolved. Based on the previous radioactive distribution results, the dissolved organ solution will be diluted by 2% optimal nitric acid to the measurement range of ICP-OES (50-5000 nM). By measuring the intensity of two excitation wavelengths at 368.4 nm and 342.2 nm [115], the concentration will be obtained based on the
commercial GdCl3 samples. The original Gd3+ concentration in all the samples was calculated by
multiplying the measured concentration with dilution times.

2.10 Histology analysis
2.10.1 Preparation of tissue slices
After MRI experiments, all the organs will be frozen in liquid Nitrogen with OCT embedded. Then the frozen tissue will be kept in -80 ˚C. Before section the tissues, the frozen samples
have to be removed from freezer and equilibrate at -20°C for approximately 15 minutes. This
may prevent cracking of the block when sectioning. Section tissue at a range of 6-8 µm and
place on positively charged slides. Allow sections to air dry on bench for a few minutes before
fixing (this helps sections adhere to slides).
After sections have dried on the slide, they will be fixed in optimal fixative (10% Neutral
buffered formalin) for 10 minutes at room temperature. The staining procedure will be proceeding immediately.
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2.10.2 Immunohistology chemistry (IHC) on paraffin embedded slices
The paraffin on the section needs to be removed before staining by Xylen and the staining procedure will be proceeding immediately. First, wash sections in water three times for 5
minutes each. Incubate sections in 3% hydrogen peroxide for 10 minutes. Wash sections in water twice for 5 minutes each. Wash section in HEPES buffer for 5 minutes. Block each section
with 100-400 μl blocking solution for 1 hour at room temperature. Remove blocking solution
and add 100-400 μl primary antibody diluted in recommended antibody diluent to each section.
Incubate overnight at 4°C. Remove antibody solution and wash sections in wash buffer three
times for 5 minutes each. Add 100-400 μl HRP conjugated secondary antibodies, diluted in
HEPES buffer with 1% Triton, to each section. Incubate 30 minutes at room temperature. If using ABC avidin/biotin method, prepare ABC reagent according to the manufacturer’s instructions and incubate solution for 30 minutes at room temperature.
Remove secondary antibody solution and wash sections three times with wash buffer
for 5 minutes each. Add 100-400 μl DAB or suitable substrate to each section and monitor staining closely. As soon as the sections develop, immerse slides in water. If desired, counterstain
sections in hematoxylin. Wash sections in dH2O two times for 5 minutes each.

2.10.3 Immunofluorescent staining on frozen slices
Wash sections in wash buffer twice for 5 minutes. Incubate for 10 minutes at room
temperature in 3% H202 diluted in methanol. Wash sections in wash buffer twice for 5 minutes.
Block each section with blocking solution for one hour at room temperature. Remove blocking
solution and add 100-400 µL diluted primary antibody to each section. (Dilute antibody in
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blocking solution). Incubate overnight at 4°C. Refer to product datasheet to determine the recommended dilution. Remove antibody solution and wash sections three times with wash buffer
for 5 minutes each. Add 100-400 µL secondary antibody with fluorescent dyes labeled, diluted
in blocking solution to each section. Incubate 30 minutes at room temperature. Remove secondary antibody solution and wash sections three times in wash buffer for 5 minutes each. Add
anti-fade reagents with DAPI dye on the section and seal the tissue section with nail polish.

2.11 Measure immunogenecity of ProCA1-affi
PEGylated contrast agents (P40-ProCA1-affi) and non PEGylated ProCA1-affi with or
without adjuvant were injected into rabbits for antibody generation. The first injection was
mixed with Complete Freund’s Adjuvant and the subsequent boosts (every 2 to 3 weeks) were
mixed with Incomplete Freund’s Adjuvant. Rabbit blood was collected at different time points
(every two to three weeks). Each time, 10ml blood was collected and centrifuged. The serum
was collected in clean tubes and stored in -80°C. The immunogenicity of P40-ProCA1 was analyzed by western blotting and ELISA.

2.12 Measurement of Acute toxicity
The 2 mM of ProCA1-affi-m in 100 µL saline was injected into the two regular CD1 mice
in each group for toxicity analysis. The control group was injected with 100 µL saline only. After
2 days, the mice were sacrificed and blood was collected to get the blood serum. The enzymes
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of creatinine and ALT, ALP in the blood serum were measured to analyze the toxicity in kidneys
and liver (Research Animal Diagnostic Laboratory, University of Missouri).
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Chapter 3.

DESIGN, PREPARATION AND IN VITRO CHARACTERIZATION OF HER2 TARGETD

PROCA1 USING AFFIBODY
3.1 Introduction
As one of the most advanced imaging techniques, MRI plays an important role in clinical
diagnosis and treatment [116]. Therefore, in recent decades, the development of MRI contrast
agents has been the hottest topic in radiology because of the unique characteristics of MR images [117-118]. However, there are limitations for MRI application in the clinic due to its low
sensitivity and specificity. As discussed in Chapter 1.6, molecular imaging of MRI requires contrast agents for significantly improved relaxivity since relaxivity determines the sensitivity of the
MRI contrast agents [119]. The relaxivity of about 5mM-1s-1 of current approved MRI contrast
agents such as DTPA could not detect biomarkers with expressed numbers of up to 106 on the
cell surface (Figure 1.7) [18]. Therefore, there is a strong need to develop MRI contrast agents
with a high relaxivity and targeting capability for molecular imaging of disease biomarkers
[120].
Previously developed protein-based MRI contrast agent (ProCA1-CD2) in the Yang laboratoryshowed high relaxivity with 10-20 folds increased compared with DTPA (Figure
3.11)[111].The designed contrast agents were created by designing a metal binding site in domain1 of CD2. By developing protein based MRI contrast agents, there are several advantages:
first, larger water number enables higher relaxivity than small chelators; second, protein is convenient to covalently link with other ligands for targeting to biomarkers; third, humane proteins
can eliminate side effects.
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In order to produce MRI contrast agents with high relaxivity for clinical application,
there are several challenges. First, we need develop a method to express and purify proteins
with high yield and low cost. Current injection dose for mice for DTPA is 50 mmol/kg [121].
Second, we need increase solubility of the protein MRI contrast agent. If our contrast agent has
a 10 fold increase in relaxivity, protein concentration of 1 mM is required. However, the solubility of ProCA1 is less than 0.7 mM. Although conjugated small chelator molecule such as DTPA to
soluble macro molecules may produce large surface exposure to water and some increase the
relaxibity [107, 122], large molecules always have the problem in solubility and tissue penetration. Third, Gd3+ is the most common used metal for MRI contrast agents since this molecule
has seven free electrons [123]. In order to prevent the competitive binding of physiological
metals such as Ca2+, Mg2+ and Cu2+ binding to the contrast agent cheletors, strong metal selectivity should be achieved in designing the MRI contrast agents. In addition, stability of proteinGd complex is important to prevent the release of free Gd3+ that is linked to NSF (nephrogenic
systemic fibrosis). It is important to maintain relaxivity and serum stability under different conditions. Finally, the targeted protein contrast agent against biomarker will provide us with molecular specificity to against the tumor and further reduce the adverse effect.
In this chapter, we will first discuss our rationale in designing a new protein-based MRI
contrast agent called ProCA1-affi342 with the addition of an affibody, which is capable of producing a molecular image of breast cancer by targeting to biomarker HER2. We have developed
a novel multimodal molecular imaging probe to target cancer marker HER2/neu using magnetic
resonance and near infrared imaging (NIR) (Figure 3.3). We employed a protein-based MRI contrast moiety (ProCA1) that was developed by de novo designing the Gd3+ binding site(s) into a
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stable host protein, the domain 1 of rat CD2 (10 KDa). Due to the unique features of the designed metal binding properties, the protein contrast agent exhibited a significant improved T1
relaxivity for MRI contrast enhancement compared to that of commonly used Gd-DTPA (Diethylenetriamine Pentaacetic Acid) at 1.4- 4.7T field strength [111]. A high affinity HER2 affibody
[37, 72] was engineered into the C terminal of the designed Gd3+-binding protein by a flexible
linker. The small molecular size (16 KDa) provides good tissue penetration. We also introduced
an optical imaging capability by conjugating a near-IR dye Cy5.5 to a Cys residue at C-terminal
of the protein to facilitate imaging analyses (Figure 3.3). To increase protein solubility, blood
circulation time, and reduction of immunogenicity, the designed HER2 targeting protein contrast agent was PEGylated using PEG-40, a molecule with tri-branches of 12 units PEG (denoted
as ProCA1-affi343-m) (Figure 3.1) The protein generation method was optimized to obtain a
high production yield. The biophysical characterization of conformational properties, the metal
binding affinity and selectivity, and relaxivity were performed using various spectroscopic methods.

3.2 Results and Discussion
3.2.1 Designed HER2 targeted protein based contrast agent with one Gd3+ binding site
Figure 3.1a [111] shows the model structure of the designed protein-based MRI contrast
agent (ProCA1-CD2). It was designed with following considerations: First, ProCA1 a designing a
metal binding site in domain1 of CD2 was used. Second, a targeting peptide called affibody
ZHER2:342 was cloned to the C terminal of ProCA1-CD2 (Figure 3.2). As discussed in Chapter 1
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(1.4), affibody ZHER2:342 with 58 amino acid has a strong binding affinity to HER2 that is comparible to antibody of 22 pM. The small size of affibody will provide a better tissue and tumor penetration. Third, a flexible five residues GGSGG linker is added between affibody and ProCA1 to
avoid the interference between them. Thus the contrast capability of ProCA1-CD2 and Targeting capability of affibody to the biomarkers, like HER2 and EGFR are expected to be not altered
much.

A

B A

Figure 3.1 Model Structure of ProCA1-CD2 and PEGylated ProCA1-CD2
(A) The model structure indicates the metal binding pocket with four Aspartates (D) and
one Glutamate (E). The PEG chain can be conjugated to the Lysine (K) to produce hydrophilic
surface and increase the exchangeable water number. (B) The PEGylation sites locate in the lysine which has free amine residue.

In order to make the ProCA1-affi342 suitable for in vivo imaging with high solubility, low
immunogenicity and proper blood retention time, we further improved the protein based contrast agents ProCA1-affi342 for in vivo imaging by protein modification with various sizes of polyethylene glycol (PEG) chain (‘PEGylation’). Figure 3.1 shows the modeled structure of the designed contrast agent ProCA1-CD2 with Gd3+ binding site and the cartoon structure of the secondary and outer sphere water molecules associated with PEG chain.

65

Affibody

ProCA1

Figure 3.2 Model Structure of ProCA1-affibody.
The affibody was linked to ProCA1-CD2 by a flexible linker. Both ProCA1-CD2 and affibody keep their original folded structure. The ProCA1-CD2 functions as contrast agent domain,
which will have MRI signal in magnetic field. The affibody provides the targeting domain to bind
the disease biomarkers.

Since MRI technique has relatively low sensitivity, we also created a duel modality for
the ProCA1-affi342 (Figure 3.3) by addition of fluorescence probe with high sensitivity. A Cysteine was added by gene cloning to the C-terminal of ProCA1-affi342. The NIR (Near infra-red) dye
Cy5.5 with maleimide group was conjugated to the Cysteine residue. The NIR image with high
sensitivity can help to probe our MRI contrast agents in achieving molecular imaging.
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HER2

GGSGG
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Gd3+

ProCA1

Affibody

Figure 3.3 Construction of ProCA1-affi342.
The model structure of multimodal HER2 targeted MR imaging probe created by connecting a high affinity HER2 affibody ZHER2-342 at the C-terminal of a de novo designed protein
contrast agent ProCA1.CD2 with a designed Gd3+ binding site. A near IR fluorescence dye Cy5.5
was then conjugated to the added Cys at the C-terminal of the fusion protein. The designed
probe was further modified by a tri-branched polyethylene glycol (PEG) with 40 PEG subunits
(ProCA1-affi342-m).

To compare the specificity of targeting, we have also created a series of ProCA1affibodies, such as ProCA1-affi-WT, ProCA1-affi2-4 and ProCA1-affi342 (Figure 1.9). It is reported that affibody342 has highest binding affinity (Kd=22 pM) with HER2-ECD [72]. Our cell
binding data also indicates that ProCA1-affi342 has strongest binding with HER2 overexpressed
cells. Therefore, affibody342 was selected as our targeting sequence.

3.2.2 Generation of targeted ProCA1-affi342
In order to get high yield of ProCA1-affi342, two methods for expression and purification
such as GST-fusion and Tagless methods have been studied.
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Figure 3.5 shows the expression of GST fusion of ProCA1-affi342 using PGEX-2T vector
with ampicillin antibiotic property. The protein was expressed in LB medium at 37 ˚C for 6
hours. Then the ProCA1-affi342 was purified by GS-4B column with GST fusion at the Nterminal. After the purified protein (Figure 3.4) was eluted by PBS (Phosphate buffer saline), the
protein was PEGylated with PEG-40 directly in PBS, pH 7.4. The reaction needs 1-2 hr in room
temperature, and then the PEGylation was stopped by free amino acids like glycine. The protein
was further purified by cation exchange SP column (Figure 3.6). SDS-gel had been stained by
coomassie blue for protein and Iodine for PEG (Figure 3.7). From the first step, 40-80 mg/L of LB
medium proteins can be obtained. The yield of further purification is 80-90%.
GST fusion
expression

GST
purification

PEGylation

FPLC

Purified
ProCA1affi342
FPLC

Tris buffer
dialysis

Tagless
expression

8 M Urea
dissolving

4 M Urea
dialysis

2M Urea
dialysis

HEPES
dialysis

Figure 3.4 Purification Scheme
The procedure of GST scheme (black line) needs three days of the whole procedure,
while refolding assay takes one week to get a purified protein.
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Figure 3.5 SDS gel of expression and initial purification by GS-4B column
The highest expression level of ProCA1-affi342 reached 3 hours after induction with
IPTG. After cleaved from GST tag by Thrombin, the pure protein was eluted from the GS-4B column.
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Figure 3.6 Purification of PEGylated ProCA1-affi342 with cation exchange column
The ProCA1-affi342m was purified by pH gradient. The protein was eluted out between
pH7.2-7.4. The elution peak is not asymmetry because the PEGylated ProCA1-affi342 is a mixture with different PEGylation number.
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Figure 3.7 SDS gel of purified ProCA1-affi342m from SP column
After purification, the free PEG reagent has been removed. The SDS-PAGE gel has been
stained with Iodine and coomassie blue in consequence. The coomassie blue stains for proteins
and the Iodine stains for PEG residues.

For the tagless method, the DNA of ProCA1-affi342 was sub-cloned to PET20b vector.
The protein expressed was tagless and insoluble in the inclusion body (Figure 3.8). After refolding with Urea, the protein was purified by cation exchange SP column to obtain a pure protein
The refolded protein obtained from inclusion body cause lower stability and the refolding procedure is time consuming (Figure 3.4). Since the purified protein from GST fusion methods are more soluble and folded, we decide to use GST fusion method to purify targeted protein contrast agent.
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Figure 3.8 Expression of ProCA1-affi342 in PET20b vector
The expression of ProCA1-affi342 in different E. coli shows that the expression level in
tuner strain is much high than that in BL21(DE3).

3.2.3 Conformational analysis of ProCA1-affibody
The tryptophan fluorescent spectrum (Figure 3.8) and far UV CD (Figure 3.9) were used
to exam the secondary structure of ProCA1-affi342. The excitation wavelength for the fluorescent scan is 280 nm; the emission range is 260-420 nm. The far UV CD spectrum at the range of
190-260 nm was scanned to compare the secondary structure of ProCA1-affi with its original
protein ProCA1-CD2.
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Figure 3.9 Tryptophan Fluorescence measurement.
The ProCA1-CD2 or ProCA1-affi342 of 5 µM concentration in HEPES buffer (10 mM,
pH7.2) was measured in 10 mm cuvette. The excitation wavelength for the fluorescent scan is
280 nm; the emission range is 260-420 nm. Compare with the host protein ProCA1-CD2, the
emission peak of ProCA1-affi342 is red shifted due to the fusion with affibody.

73

-CD2
342

Figure 3.10 The secondary structure measured by CD.
The ProCA1-CD2 or ProCA1-affi342 of 20 µM concentration in HEPES buffer (10 mM,
pH7.2) was measured in 1 mm cuvette. The far UV CD spectrum at the range of 190-260 nm
was scanned to compare the secondary structure of ProCA1-affi with its original protein ProCA1-CD2.

3.2.4 Modified ProCA1-affibody has been increased both in metal binding affinity and relaxivity
The designed MRI contrast agent was expressed in E. coli and subsequently purified
(Figure 4.2). The binding affinity was measured by competitive assay using dye Fluo5N. The eq-
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uation 1 was used to calculated the Kd. Similar to the parental protein ProCA1-CD2, the designed protein (ProCA1-affi) had a strong metal binding affinity with Kd for Gd3+ at 1.86 x 10-12
M [111] (Figure 3.10). ProCA1-affi also exhibited R1 and R2 relaxivities of 21 and 30 mM-1s-1 at
1.41 T, respectively (Figure 3.11). PEGylaton resulted in about 15% increases in the relaxivity for
both R1 and R2 [124]. The developed protein with conjugated NIR dye exhibited fluorescence
excitation and emission maxima at 640 and 695 nm, respectively, and excitation coefficient
constant of 0.21 µM-1cm-1 (Figure 4-3).
𝑓=

([𝑃]𝑇 +[𝑀]𝑇 +𝐾𝑑 )−�([𝑃]𝑇 +[𝑀]𝑇 +𝐾𝑑 )2 −4[𝑃]𝑇 [𝑀]𝑇
2[𝑃]𝑇

(Equation 1)

Figure 3.11 Metal binding affinity measurement.
The metal binding of ProCA1-affi342m with Gd3+ was measured by competitive method
using Fluo5N [111]. The binding affinity of Kd is 1.86 x 10-12 M.
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Figure 3.12 Relaxivity of ProCA1-affibody.
The relaxivity of ProCA1-affi342 with (gray) and without PEGylation (ProCA1-affi342m,
black) and clinically used Gd-DTPA (white) were measured under the magnetic field of 1.41 T at
37 °C. The developed contrast agent exhibited 5-6 fold greater relaxivity in both r1 and r2.

3.2.5 Other improved properties for modified contrast agents
Modifying the proteins with PEG may have advantages in increasing solubility, which
enables the ProCA1-affi342 to be concentrated to 5 mM for animal experiments. The stability of
ProCA1-affi342 and ProCA1-affi342m was compared by keeping the protein in 37 ˚C overnight.
Figure 3.12 shows that the PEGylated ProCA1-affi342m is much more stable than the original
ProCA1-affi342. PEGylation well protects the protein from degradation and cleaving by protease. The immunogenicity was further studied by western blotting. Antibody generativity
against the protein contrast agent (both PEGylated and native protein) in the rabbits was examined by western blotting. The experiments were carried out by SDS-PAGE of ProCA1-
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PEG2.4k, ProCA1-PEG0.6k and ProCA1 and detected by anti-serum collected from immunoinoculated rabbits. The results showed that addition of adjuvant induced stronger immune responses. PEGylation modifications of the protein dramatically reduced immune responses in the
rabbits. Figure 3.13 suggests that the immunogenecity of the protein contrast agent may not be
very strong, especially without addition of adjuvant.

Protein in 4˚C

Protein in 37˚C
overninght

Figure 3.13 SDS gel to measure the stability of modified contrast agent
The Gel shows that after staying in 37 ˚C for overnight, the original protein without PEGylation had some degradation, however, the PEGylated protein did not have much change.
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Figure 3.14 PEGylation substantially reduced the immune responses monitored by polyantibodies.
The commercial CD2 polyclonal antibody PAb-ProCA1 was used as positive control (D).
The other antiserum was prepared from the blood collected after two times of injection of native protein ProCA1 mixed with adjuvant (A). ProCA1 in the absence of adjuvant (B). ProCA1 PEG2.4k mixed in absence of adjuvant (C).

3.2.6 Dual label ProCA1-affibody with NIR dye
In order to create a dual moiety for contrast agent for both MRI and optical imaging, a
NIR dye Cy5.5 (Figure 3.15) was conjugated to the ProCA1-affibody. Before conjugation, extinction coefficient of the dye in PBS buffer was measured (Figure 3.15). The conjugation efficiency
can be calculated from the UV-VIS absorbance (Figure 3.16) and extinction coefficient of protein (Obtained from Protein Calculator) and dye.

Figure 3.15 Chemical structure of Cy5.5 dye (GE Health care)
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Figure 3.16 Extinction Coefficient of Cy 5.5 was measured
The dye Cy5.5 was dissolved in HEPES buffer at four different concentrations: 10 µM, 25
µM, 45 µM and 90 µM. The absorbance spectra in the vis-NIR range (500-900 nm) were
scanned. The linear curve was fitted by the absorbance at peak of 680 nm and concentration.
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Figure 3.17 Conjugation rate measurement
The conjugation efficiency was calculated by scanning the ProCA1-affi342m-cy5.5 in
HEPES buffer (10 mM, pH7.0) of a whole spectrum between 220-900nm. The protein concentration was calculated by the Abs280. The dye concentration was calculated by Abs675.

MS spectra and NMR were also used to verify the conjugation of NIR dye to the ProCA1affibody (Figure 3.17). Since Cy5.5 is a very sensitive dye and MRI is a relatively low sensitive
technique which requires high amount of contrast agent, we label a small portion of ProCA1affi342 with Cy5.5 to produce non-saturated NIR imaging. 1D-NMR also confirmed that the dye
was successfully conjugated to the ProCA1-affi342 by viewing the peak shifting (Figure 3.18).
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Figure 3.18 MS spectra of free protein and conjugated protein
MALDI-TOF mass spectrometry analyses the mixture after PEGylation with PEG40
(2.4KDa) and fraction purified by ion-exchange FPLC. There were two major peaks in the PEGylation mixture. Peak I was native ProCA1 with measured molecular weight of 11,192 KDa, peak
II was ProCA1-affibody-Cy5.5 with measured molecular weight of 13,527 KDa.
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Figure 3.19 NMR spectra of free protein and protein-dye complex
About 100 µM of ProCA1-affi342 and ProCA1-affi342-cy5.5 complex were dissolved in
10 mM Tris buffer (pH7.0). The NMR spectra at 600 MHz were obtained.
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Chapter 4.

CELLULAR TARGETING CAPABILITY ANALYSIS

4.1 Introduction
As the discussion in Chapter 1.7, in order to achieve molecular imaging, contrast agent
should have very strong affinity to its biomarker. In addition, a strong selectivity over other receptors or non-cancer cells is also very important. Further, quantitative measurement of the
biomarker level by the contrast agents is also important for the diagnosis and prognosis of the
disease states. Moreover, to achieve molecular imaging of biomarkers by MRI, we also need to
have enriched biomarkers. Since endocytosis especially receptor-mediated endocytosis was reported to facilitate the enrichment of MRI contrast agents in the cancer cells [125].
In this dissertation, we selected the suitable protein of peptide for tumor targeting. The
cancer cell lines were also well considered for the ex vivo and in vivo research model. As men-

tioned in Chapter 1.4, affibody is a Phage display library, several generations of affibody proteins were screen out by targeting to the extracellular domain of biomarker HER2 (Figure 4.1).
Two of them with high binding affinity to HER2 were selected in our research. The two affibody
sequences, ZHER2:4 and ZHER2:342 together with wild type affibody were fused to ProCA1-CD2.
These sequences were selected because ZHER2:4 is the commercial available affibody product.
ZHER2:342 is the reported affibody which has highest binding affinity to HER2 [126]. Wild type affibody was also added to be a non-specific control. At the same time, cancer cell selection is also
very important for the research.
In Chapter 3, we reported our design, preparation, and characterization of the conformation, biophysical properties like relaxivity and metal binding affinity of ProCA1-affi342
against HER2 biomarker. In this chapter, we will focus on evaluate the cell targeting capability
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of the designed contrast using various methods such as western blotting, immunofluorescent
staining and ELISA. Tumor cell lines with different HER2 expression levels were selected. The
endocytosis capabilities of ProCA1-affi342 to accumulate in cancer cells were also investigated.
These results comparisons between ProCA1-affi342 and other affibody series or PEGylated
ProCA1-affi342m confirm the designing strategy and modification advantages.

4.2 Results and Discussion
4.2.1 Selection of cell lines
We used three human cancer cell lines, AU565, SKOV-3 and MDA-MB-231. AU565 is a
human breast cancer cell line, with HER2 expression level 1 x 106 HER2/cell. SKOV-3 is an ovarian cancer cell line with estimated 3 x 106 HER2/cell [127]. MBD-MDA-231 is a breast cancer
cell line with modest HER2 levels (~3 x 104 HER2/cell) [128]. EMT-6 is a HER2 negative mouse
breast cancer cell line.

4.2.2 Monitoring cell targeting of Affibody variants using western blotting
In order to select a proper affibody variant for HER2 targeting, three variants were compared by using the western blotting. All the three variants: ProCA1-affi342, ProCA1-affi4 and
ProCA1-affi WT were added into AU565 and EMT-6 cells respectively.
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Table 6 HER2 expression level in various cancer cells
Positive Cell Lines

Negative Cell Lines

Source

Names

HER2 Number

Names

HER2 Number

AU565

1.0Χ106

MCF-7

2.0Χ104

SKBR-3

7.3Χ105

MDA-MB-231

1.8Χ104

BT474

1.06Χ106

SKOV-3

3.0Χ106

MIAPaca-2

1.0Χ106

Panc-1

Under 2.0Χ103

Pancreatic Tumor

NT5

1.0Χ106

EMT-6

Under 2.0Χ103

Mouse Mammary Tumor

Human Breast Tumor

Human Ovarian Tumor

Two different concentrations 3 µM and 10 µM were used. After being treated with the
proteins for 2 hr in 37 ˚C, the cells were lysed and the cell lysis was used for western blotting.
The antibody against ProCA1-CD2 was used to detect the contrast agents. Figure 4.2 shows that
in HER2 positive cell line AU565, the ProCA1-affi342 was retained most in the lysis, which
means this variant binds most to the HER2 positive cell line. The second generation variant ProCA1-affi4 and wild type also shows some non-specific binding. The cells without treatment were
used as negative control. In the HER2 negative cell line EMT-6, all the three variants show some
binding which may due to the non-specific attachment to the cell membrane. ProCA1-CD2
without targeting sequences was also added to the cells for a negative control (Figure 4.1c).
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A

(µM)
AU565

(µM)

B

EMT6

C
(µM)
ProCA1-CD2

Figure 4.1 Western blot of ProCA1-affi been retained in the cancer cells
The cells were treated with different generations of ProCA1-affibody and the retention
of the protein in the cell lysis was measured to calculate the binding capability. The AU565 cell
with HER2 overexpression shows obvious binding to ProCA1-affi342. ProCA1-affi2-4 and ProCA1-affi-WT also have some non-specific binding (A). In the HER2 negative cells EMT6. Only
ProCA1-affi342 shows weaker binding (B). ProCA1-CD2 was used as negative control which also
has some non-specific binding in both cell lines (C).
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ELISA was further used to confirm the specific binding of ProCA1-affi342 to the HER2
positive cell lines (Figure 4.3). ELISA is a method with more accurate quantitative analysis of
protein and protein interactions. Equal number of SKOV-3 and MDA-MB-231 cells were cultured
and treated with ProCA1-affi342 and ProCA1-342m respectively for 2 hr in 37 ˚C. After carefully
washing with HBSS buffer, the cells were lysed and the lysis was used to coat the ELISA plates.
Then the ProCA1-affi342 or ProCA1-affi342m retained in the will be detected by PAb-ProCA1CD2. The final absorbance read from ELISA was substrate from the absorbance of SKOV-3 cells
with the one of MDA-MB-231 cells. The results show that the contrast agents can target to the
HER2 positive cells lines. The PEGylated ProCA1-affi342 keeps the tumor binding capability.
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Figure 4.2 ELISA of ProCA1-affi342
Indirect ELISA was used to measure the ProCA1-affi342 and ProCA1-affi342m binding to
the cancer cells. Cell lysis of AU565 (HER2 positive) and EMT-6(HER2 negative) was used to coat
the ELISA plate. Then the ProCA1-affi342 and ProCA1-342m was added and detected by primary
antibody and secondary antibody with HRP conjugation. Finally, OPD was added to react with
HRP and the Abs450 was read. The x axis is protein concentration. The y axis is the absorbance
of AU565 substrates with EMT6.
4.2.3 Immunofluorescent staining of cancer cells with ProCA1-affi
We next examined whether the designed ProCA1-affi can target to cancer cells by cell
binding analyses. Binding of the Gd-ProCA1-affi to the selected cells was first analyzed by im-

87

muno-fluorescence staining using the polyclonal antibody against PEGylated parental protein
ProCA1 (PAb-ProCA1). A substantial staining intensity of ProCA1-affi bound to AU565 cells was
observed and increased as incubation times increased. In contrast, the EMT-6 cells demonstrated very weak staining (Figure 4.4). It was evident that the Gd3+ ProCA1-affi bound to the cell
surface HER2 with a clear membrane staining pattern in AU565 cells at 4 °C (Figure 4.4). The
wild type affibody variant, ProCA1-affi WT was also used to stain the cancer cells, Figure 4-5
shows that the wild type variant can only non-specifically attach to the cell membrane. However, binding of the Gd3+ proteins to the cells triggered receptor mediated internalization at 37 °C
as demonstrated by the staining of the intracellular ProCA1-affi. The majority of the contrast
agents entered the cells after 120 minutes incubation (Figure 4.6). The Gd3+ ProCA1-affi was
stable after internalization at 120 minutes, indicating that the designed Gd3+ ProCA1-affi withstood protein degradation during and after endocytosis. The immunostaining results were consistent with NIR fluorescence imaging results (Figure 4.7).
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ProCA1-affi

ProCA1-affi-m

AU565

AU565

EMT-6

EMT-6

Staining at 4 °C
Figure 4.3 Immunostaining of HER2 on cell membrane.
At 4 C
̊ , the HER2 positive (AU565) and negative (EMT-6) cancer cells were treated with
ProCA1- affi and ProCA1 -affi-m respectively for 2 hours. The HER2 expressed on the cell membrane of AU565 was revealed by the green color from the goat-anti-rabbit secondary antibody
(Invitrogen) for self-generated rabbit antibody against ProCA1-affi-m. The blue color shows the
nuclear staining. The imaging was taken under 40x objective in Zessis microscope.
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AU-WT

EMT-WT

EMT-Blank

Figure 4.4 Cell staining by ProCA1-affi WT
When the tumor cells were stained by ProCA1-affi WT, both the AU565 with high HER2
expression level and the HER2 negative EMT-6 got staining on the cell membrane. This indicated that the wild type affibody only non-specifically binds to the cell membrane. The EMT-6
cell without adding affibody was used as negative control. The imaging was taken under 40x
objective in Zessis microscope.
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120 min treatment

5 min treatment

ProCA1-affi

ProCA1-affi-m

AU565

AU565

EMT-6

EMT-6

AU565

AU565

EMT-6

EMT-6

Staining at 37 °C
Figure 4.5 Immunostaining for endocytosis studies.
At 37 C
̊ , the cancer cells with HER2 positive (AU565) and negative (EMT-6) were treated
with ProCA1 -affi and ProCA1 -affi-m respectively for 5 min and 2 hours. The immunefluorescence staining studies revealed that ProCA1- affi and ProCA1- affi-m bind to HER2 positive cell
extensively and were largely relocated into the cytosol via endocytosis after 2 hours (green color). The blue color shows the nuclear staining. At both 4 and 37 C
̊ , negative staining was obtained in EMT-6 cells that lack HER2 expression. The imaging was taken under 40x objective in
Zessis microscope.
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AU565

SKOV-3

Figure 4.6 NIR imaging of living cells.
The living cells AU565 and SKOV-3 with overexpression of HER2 can be directly detected
by ProCA1-affi342mCy5.5 which will generate NIR signals.

4.2.4 Cancer cells treated by different amount of ProCA1-affibody demonstrate the quantitative monitoring capability of designed MRI contrast agents
In order to get quantitative results from in vivo data, ProCA1-affi342 has to be constantly retained by cancer cells and get endocytosis. Figure 4.7 shows that in HER2 positive cell line
AU565, ProCA1-affi342 can penetrate the cell membrane which makes the cell plasma been
stained with FITC conjugated antibodies. On the other hand, the modified protein ProCA1affi342m can get endocytosis faster than the original ProCA1-affi342, which means the PEG residues facilitate the binding of proteins to cell membrane. The HER2 negative cell line EMT 6
was stained for negative control. According to Table 3, cancer cell express different levels of
HER2, in this dissertation, four cell lines have been measured by ELISA of the binding with Pro-
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CA1-affi342. The ELISA results (Figure 4.8) show that the retained ProCA1-affi342 will be increased as the incubation concentration increasing. The absorbance is highest in SKOV-3 indicates that SKOV-3 has highest HER2 expression level, while EMT-6 is negative.
AU565-ProCA1-affibody

AU565-ProCA1-affibody-m

5 min
AU565-ProCA1-affibody-m

EMT-6-ProCA1-affibody

EMT-6-ProCA1-affibody-m

60 min

AU565-ProCA1-affibody

60 min

Figure 4.7 Immuno staining of Cancer cells at various time points
The cells were treated with ProCA1-affi342 and ProCA1-affi342m with different time
length. In shorter time (5 min), the binding of ProCA1-affi342m to the HER2 positive cells
AU565 had been observed. At longer incubation time (60 min), both ProCA1-affi342 and ProCA1-affi342m can target to the AU565. Therefore, the modified ProCA1-affi342 with PEGylation
can target to the cancer cells with HER2 overexpression in shorter time. However, the EMT-6
negative cells also had some staining with ProCA1-affi342m treatment, which means ProCA1afi342m has more non-specificity also.

93

3
AU565
EMT6
SKOV-3
MDA-MB-231

Absorbance (490 nm)

2.5

2

1.5

1

0.5

0
1

10

100

1000

Cell numbers (X105)
Figure 4.8 ELISA results to measure the binding to cancer cells
In order to detect the expression level of HER2 in different cancer cells, all the cells were
lysate for the ELISA. The cell lysis was diluted into four different concentrations and detected by
ProCA1-affi342. SKOV-3 has highest expression level. EMT-6 is a HER2 negative cell line.

4.2.5 Flowcytometry measures the constant binding of ProCA1-affi342 to cancer cells
Flowcytometry is also another common way to quantitatively analyze the cell binding
capability (Figure 4.9). The binding constant can be fitted by this assay. In this assay, the cells
were incubated with ProCA1-affi342m for 2 hr to enable enough endocytosis. Then the cells
were washed by HBSS buffer and stained by fluorescent conjugated antibody. After that,
2.0×104 cancer cells were counted by Flowcytometre machine and the fluoresence was
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measured. Figure 4.9 shows the binding constant of ProCA1-affi342. However, the binding
cannot be well fitted by the Hill equation (Equation 2) either (Figure 4.10). This is probably due
to the other molecules in the cell enviroment affecting the binding. In order to get the binding
affinity between ProCA1-affi342 and cancer cells, larger number of cells needs to be measured
to get a more statistc result and the measurement needs to be repeated multiple times.
[𝑀]𝑛

∆𝑆 = 𝐾 𝑛+[𝑀]𝑛
𝑑

(Equation 2)

Besides the directly measurement of binding constant between ProCA1-affi342m, the
binding was also measured by competitative assay. Commercial Affibody ZHER2:4 with FITC
conjugated was incubated with the cells first. After 2 hr, the non-specific binding was washed
and a series of concentration of ProCA1-affi342m was added. The fluoresence was measured 2
hr later. Due to the competition of ProCA1-affi342 to ZHER2:4, the fluoresence value decreased as
the increasing of ProCA1-affi342m concentraion.
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Figure 4.9 Binding affinity measurements (A) and Curve fitting of the binding between
ProCA1-affi342m and SKOV-3 cancer cells (B)
The cells were treated by ProCA1-affi342 with different concentrations for 1 hr in 37 °C.
Then the cells were washed and detected by FITC conjugated antibodies. (A) Shows the initial
flow cytometry curve obtained. X-axis is the fluorescent intensity; y-axis is the counted cell
numbers of been stained. (B) With the peak area and protein concentrations, the curve has
been fitted. However, a binding affinity has not been derived from this curve which may due to
the impurity of cell mixture.
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Figure 4.10 Curve fitted by Hill equation
Normalized data were fitted by Hill equation shown in the figure. M0 is the protein concentration, m1 is the dissociation constant (Kd) and m2 is the cooperate number.
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Figure 4.11 Competative assay to measure the cell binding
The cells were treated by both ProCA1-affi342 and ProCA1-affi4-FITC. The concentration
of ProCA1-affi4-FITC is 2 pmol in stable. The concentration of ProCA1-affi342 range is from 0 to
4 pmol.

4.2.6 Generation of antibody against ProCA1-CD2-m
Although there are commercial antibodies against CD2 protein, we mostly use PEGylated contrast agents for our research. The detection sensitivity of commercial available antibodies will be decreased due to the modification covers epitopes of the antibodies. Therefore, the
polyclonal antibodies against PEGylated protein have been generated in our group. The purified
ProCA1-CD2 with PEGylation was injected to New Zealand white rabbit at the concentration of
5 mg/ml in HEPES buffer once every week for six weeks. The protein was mixed with adjuvants
before injection, since adjuvants can stimulate the immune system to generate as much antibody as possible. The first time injection is called inoculation, which uses the complete adju-
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vant. Complete adjuvant is harmful to animal body which can only be allowed to use once during the whole procedure (ICUCA protocol 7206). The non-complete adjuvant is used for the following injections, which are also called boosts. Rabbit blood starts to be collected after the
third boost. The blood serum containing antibodies will be harvest after centrifuging. The activity of anti-serum was measured by western blotting. The same quantity of PEGylated ProCA1CD2 was loaded to each lane of SDS-PAGE gel. The anti-serum was diluted 2000 times and 5000
times to be used. Pre-bleeding from the rabbit without injection of antigen was used as negative control. Figure A1 shows that the generated antibody has high specificity by identifying the
PEGylated ProCA1-CD2 clearly even by 5000 times dilution.
In order to use the generated anti-serum more sufficiently and keep the generated antibodies for longer time, the antibody was extracted out from the serum and purified. The antibodies were purified by precipitation methods. First, octanoic acid was added slowly with the
amount of 28 µL/mL blood serum [129]. In this step, most of the lipids and other hydrophobic
contents will be removed from the serum. Second, saturated ammonium sulfate was used to
make the antibodies been precipitated. The precipitated antibody will be pure and can be dissolved in PBS buffer for long time storage (Figure 4.13).
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Figure 4.12 Western blotting of anti0serum activity
Lane 1 and 4: detected by pre-bleeding serum Lane2: detected by final bleeding with
5000 times dilution Lane3: detected by final bleeding with 2000 times dilution Lane5: detected
by anti-serum of ProCA1-affi342m.

Purified antibodies

Figure 4.13 Purified antibodies from anti-serum
Lane 1-6: antibodies purified from different anti-serums. The antibodies in non-reduced
gel show a molecular weight of 150 KDa.
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4.2.7 Quantitative analysis of MRI signals in cancer cells
MRI is a technique with high resolution which makes quantitative analysis possible in vivo. Here we measured the retention of Gd-ProCA1-affi342m in cancer cells under 7T MRI machine. The cancer cells were incubated with a series concentration of ProCA1-affi342m. The images were scanned with two pulse sequence. In the gradient echo, we can identify the gradual
changes of MRI intensity as the concentration change of ProCAs. In the spin echo, the difference is not visible (Figure 4.14), which indicates than this pulse sequence is not optimized for
your contrast agents.
Spin Echo

Gradient Echo
CA2-affi-5 µM

CA1-affi-5 µM

CA2-affi-5 µM

CA1-affi-5 µM

CA2-affi-2 µM

CA1-affi-2 µM

CA2-affi-2 µM

CA1-affi-2 µM

CA2-affi-0 µM

CA1-affi-0 µM

CA2-affi-0 µM

CA1-affi-0 µM

Figure 4.14 The HER2 positive cells SKOV-3 can be imaged under MRI after incubated
with various concentrations of contrast agents.
The cells were treated with Gd-ProCA1-affi342 or Gd-ProCA22-affi342 with different
concentrations for 1 hr and then washed. The image indicates the specific binding of contrast
agents to SKOV-3, the HER2 positive cells.

4.2.8 Cell binding was analyzed by measuring retention of

153

Gd cheleted with ProCA1-

affi342
Binding of the Gd3+ ProCA1-affibody to the two testing cell lines was further analyzed by
quantification of cell bound Gd3+ by γ-counting the trace of isotope 153Gd3+ in the Gd3+ ProCA1affibody complexes (Fig. 4.15). The results supported our immuno-analyses that Gd3+ ProCA1affibody was retained 3-4 folds greater in HER2 positive AU565 cells than HER2 negative EMT-6
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cells (Fig. 4.16). Measuring the amount of bound Gd3+ from γ-counting revealed that the Gd3+
ions were bound to cells at ~ 0.1 fmole Gd/cell. Under assumption that 1x107 cells make a volume of 50 – 100 µL, this binding capacity led to the accumulation of Gd3+ at 10 – 20 µM in the
cell pellets. This local concentration is sufficient to produce strong MRI contrast, especially with
the high relaxivity protein contrast agent reported here.
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Figure 4.15 Different concentrations of ProCA1-affi342 been retained in the cancer cells
by radioactive assay.
By treated the cancer cells with various concentrations of 153Gd-ProCA1-affi342, the HER2 positive cell line AU565 shows constant binding of the proteins to cells, however, in the HER2 negative cell line, the binding shows non-specifically.
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Figure 4.16 Radioactive assay to measure the cell binding of ProCA1-affibody.
153
GdCl3, and153Gd loaded ProCA1 -affi and ProCA1-affi-m were incubated with cultured
cancer cells for 2 hours. After careful washing, the radioactive signaling in the cell pellets was
measured using γ-counter. The retention of ProCA1-CD2-affi or ProCA1-CD2-affi-m with Gd3+ in
HER2 positive cells (AU565) was ~3-4 folds greater than that in the HER2 negative cells (EMT-6)
and non-specific uptake in 153GdCl3 treated cells.

4.2.9 Summary and future work
In this chapter, various binding assays have been used to measure the binding of Gd3+
with ProCA1-affi342 and ProCA1-affi342 with cancer cells of high expression HER2. The results
show that the fusion of affibody342 does not affect the metal binding site, which indicates a
similar metal binding affinity (Kd=1.86 nM) as native protein ProCA1-CD2. Cell binding assays
demonstrate that ProCA1-affi342 can specifically target to the cancer cells with high expression
of HER2. We also tried initial quantitative analysis of the cell binding assay to obtain the binding
affinity of ProCA1-affi342 with HER2 in cancer cells. However, the fitting of the affinity is not
reliable (Figure 4.9-10). This may due to the non-homogenous of the cell lysate solution and
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non-stable cell status. Further analysis using Biacore, relaxometer or flow cytometer with higher numbers of cells to eliminate or decrease the affecting parameters will be applied.
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Chapter 5.

ESTBLISHING TUMOR MODELS AND MOLECULAR IMAGING OF HER2 IN MOUSE

BY MRI AND NIR AND FURTHER ANALYSIS BY HISTOLOGY ASSAYS
5.1 Introduction
Molecular imaging specifically probes the molecular abnormalities of diseases to allow
earlier detection, monitoring of disease progression, and molecular assessment of treatments
[130]. Molecular imaging using the modality of magnetic resonance imaging (MRI) has significant advantages in pre-clinical research and clinical diagnosis and prognosis as MRI offers superior spatial resolution without depth limitation, exquisite soft tissue contrast, clinical availability, while avoiding ionizing radiation [131]. However, many applications of MRI rely on the administration of contrast agents to amplify the contrast of the interested regions to obtain both
sensitivity and specificity [132]. Developing contrast agents that can be specifically targeted to
various biomarkers allowing real-time imaging of biological events at the molecular level will
have great clinical importance [133-135]. To achieve molecular imaging by MRI, especially to
quantitatively monitor the expression level of the disease biomarkers, it is essential to develop
contrast agents with high relaxivity, target capability, optimized pharmacokinetics, tissue penetration and low or no toxicity [136].
As discussed in Chapter 1.2, human epidermal growth factor receptor (EGFR) type 2
(HER2/neu) is a cell surface receptor of the EGF family that is overexpressed in breast, ovarian,
urinary bladder and many other carcinomas. In the case of breast cancer, HER2 overexpression
is typically associated with younger patients and generally poor prognoses with substantially
higher probabilities of relapse after treatment [45, 48]. In addition, the HER2 mediated recognition system has been widely employed as a drug target for anti-cancer therapies. Unfortunate-
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ly, current diagnosis of HER-2 positive tumor relies mostly on the use of fine needle biopsies
with subsequent immunohistochemistry (IHC) analysis and/or fluorescent in situ hybridization
(FISH). These methods suffer from several drawbacks including sampling errors, misinterpretation due to lack of quantization, and discordance between primary tumors and metastases.
Thus, assessment of HER2/neu levels by non-invasive MR imaging will provide a tremendous
tool for cancer diagnosis/prognosis, design of treatment strategies, and monitoring the effectiveness of the treatment.
In order to measure the in vivo function of ProCA1-affi342, suitable tumor model was
selected. In this chapter, there are mainly two tumor models being discussed. One is subcutaneous model, which the cancer cells were injected under the surface skin [62]. SKOV-3 and
MDA-MB-231 cell lines were selected because they have moderate tumorigenicity and well differential shape. The moderate means the tumor growing speed of these cell lines in nude mice
is around 4-8 weeks which is easy to control and monitor [137]. Since we inoculate two different cell lines on each flank of the nude mouse, the selected cell lines should have similar tumorigenicity. Therefore, the cell lines of AU565 with rare tumorigenicity and EMT-6 which can
generate tumors within one week were not selected for our research. Another tumor model is
the orthotopic model which can mimic the real tumor situation by injecting tumor cells in the
original sites, for example, the breast cancer cell line MCD-10DCIS will be injected to the mammary sites of the nude mice.
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5.2 Results and discussion
5.2.1 Cell preparation for xenograft tumor model
The SKOV-3 and MDA-MB-231 cells were cultured and passaged in Coy’s 5A and DMEM
medium respectively. Cells were scraped from the flask and suspended in HEPES (10 mM,
pH7.2). Then the cells will be washed with HEPES buffer for three times and counted. Finally the
cells will be diluted in to 5x106 /100 µL medium. The injection medium is 50% HEPES buffer with
50% percent matrix gel (BD bioscience). Each spot on the mouse flank will be injected with 100
µL of the cells.

5.2.2 MRI on xenograft model indicates the specific targeting of ProCA1-affibody
We then tested whether our designed contrast agent would result in MRI contrast enhancement in xenograft models of these two human cancer cell lines. The SKOV-3 tumor with a
high HER2 expression was subcutaneously implanted in the right flank, while the MBD-MDA231 with a low HER2 expression was implanted in the left flank of the same mouse for direct
comparison (Figure 5.1). The contrast agent Gd3+ ProCA1-affi-m at concentration of 3 mM (10
fold lower than clinically-approved contrast agent DTPA) was administrated via the tail vein (80
µL). Pre- and post-contrast MRI were collected at different time points using T1 and T2
weighted fast spin echo or T1 weighted gradient echo sequences. After 3 hr, HER2 positive tumor exhibited significant contrast enhancement. Strong contrast enhancement was observed
in the SKOV-3 tumor 24 hours after injection, while there were no significant changes in contrast in the MBD-MDA-231 tumor (Figure 5.2 and Figure 5.3). Such MRI contrast enhancement
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was decreased after 24 hrs post injection. In parallel, the mice were imaged using an optical
animal imaging system (Figure 5.1). Consistent with MR imaging, we observed a strong NIR
light emission from the SKOV-3 tumor at 24-hour post-administration of the contrast agent,
however, the NIR intensities at the MBD-MDA-231 tumor site were much less than that of the
SKOV-3 tumor (Figure 5.4).

Pre-scan

MDA-MB-231

24 hr

SKOV-3

Figure 5.1 NIR imaging on Xenografted mouse.
NIR fluorescence imaging (Kodak 8000) revealed that ProCA1-Affi is able to target to the
HER2 positive tumor (SKOV-3, right) 24 hr after injection from tail vein. No significant near IR
signal was detected in the HER2 negative tumor (MDA-MB-231, left).
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Figure 5.2 MRI of Xenografted mouse with Fast Spin Echo.
Fast spin echo transversal MR images collected prior to injection and at various time
points post injection of 3.0 mM of ProCA1-affi-m in HEPES saline via tail vein. The MRI signal on
the positive tumor (SKOV-3, right) exhibits significant enhancement at 3 hr post injection and
reaches maximum enhancement at 24 hours post injection. The slight differences in MRI signals
result from the use of different pulse sequences for imaging.
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Figure 5.3 MRI of Xenografted mouse with Gradient Echo.
Gradient echo transversal MR images collected prior to injection and at various time
points post injection of 3.0 mM of ProCA1-affi-m in HEPES saline via tail vein. The MRI signal on
the positive tumor (SKOV-3, right) exhibits significant enhancement at 3 hr post injection and
reaches maximum enhancement at 24 hours post injection. The slight differences in MRI signals
result from the use of different pulse sequences for imaging.
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5.2.3 NIR imaging shows relative distribution of ProCA1-affibody in various mouse organs
To further analyze the HER2 targeting properties of the protein contrast agent, tumors
and organs from the imaged mice were collected 48 hours after administration of the agent
(Figure 5.4). The organs and tumors were imaged using optical animal imaging. It was clear that
there were very high levels of accumulation of Cy5.5 in the liver, kidneys, and the SKOV-3 tumor. There were medium levels of the NIR dye at lung. In comparison, the level of Cy5.5 at the
MBD-MDA-231 tumor was quite low (Figure 5.4). The results strongly suggested that our protein contrast agent led to the HER2 specific MR image enhancement.
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NIR

X-ray
Figure 5.4 NIR imaging of mouse organs.
NIR images of the dissected mouse organs. General bio-distribution was obtained based
on the NIR signal and western blot assay. The ProCA1-affi-m mainly distributed in the positive
tumor, liver and kidney.
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5.2.4 Immunofluorescent staining of frozen tissue slides can demonstrate the tissue penetration of ProCA1-affibody
To further verify the contrast agent targeted to the HER2 positive tumor, we carried out
immunohistochemistry (IHC) staining using the antibody PAbPGCA1 with tissue slides made
from the tumor samples collected from the imaged mice as well as selected organs. The strongest staining was observed with liver and the SKOV-3 tumor tissue slides (Figure 5.5). Close examination of the staining patterns of the tumor slides revealed distribution of the designed protein both inside and outside the cancer cells with substantial stronger staining inside the cancer
cells, indicating internalization of the protein contrast agent. This staining pattern provided a
strong support for the cancer cell targeting by the contrast agent. The kidney slides also gave
strong immunostaining consistent with the NIR imaging finding. Interestingly, the areas near
proximal tubes showed the strongest staining (Figure 5.5), suggesting that the protein contrast
agent may be secreted through the kidney. This is consistent with observations that there were
good levels of both Gd3+ (by γ-counting of 153Gd3+) and the protein (by NIR fluorescence) in the
urine of mice that were injected with the contrast agent. Immunostaining of tissue sections
from MBD-MDA-231 tumor revealed very weak staining (Figure 5.5).
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Red: ProCA1-affi-m or HER2 antibody
Green: CD31
Blue: DAPI

Liver

Kidney

Positive tumor stained
with HER2 antibody

Muscle

Blood Vessel

Blood Vessel

Positive tumor stained
with ProCA1-affi-m

Blood Vessel

Negative tumor stained
with ProCA1-affi-m

Figure 5.5 IHC staining on mouse tissues for biodistribution studies.
Immune histology fluorescent (IHF) staining was applied to various tissue slides stained
by antibody against ProCA1-affi-m (red), Blood vessels biomarker CD31 (green), and nucleus
DAPI (blue). The slides stained without primary antibody were used as blank control.
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5.2.5 MRI blocking experiment further confirmed the tumor targeting
To further verify the HER2 specific MRI contrast enhancement, we carried out a competition assay based on the assumption that if our protein contrast agent targeted HER2 and led
to HER2 specific MRI contrast enhancement, affibody alone would be a strong competitor for
the binding to the cell surface HER2 and consequently block the binding by our designed protein. Nude mice that carried SKOV-3 tumors were pre-injected with buffer saline or 3 mM of
HER2 affibody ZHER2-342 labeled with Cy5.5 twice at 12 hr and 2 hr. Gd3+ ProCA1-affi-m (80 µL) at
a concentration of 3 mM was subsequently administrated to the mice by intravenous injection.
The mice were then scanned at a 4.7 T MRI scanner via the same procedures. Our results demonstrated that the MRI contrast enhancements were not observed at the SKOV-3 tumor site in
the mice that received HER2 affibody labeled with Cy5.5, while the contrast enhancements in
the liver and kidney in the same mouse were not affected by the administration of HER2 affibody (Figure 5.5). NIR imaging did exhibit high intensity in the tumor, which indicates that the affibody binds to the positive tumor and blocks the binding of MRI contrast agents. Conversely,
the administration of the saline prior to injection of the designed protein contrast agent did not
block the MRI contrast enhancement (Figure 5.6). The results with HER2 affibody blocking
strongly support our conclusion that the MRI contrast enhancement from administration of
Gd3+ ProCA1-affi-m is HER2 specific.
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Figure 5.6 Magnetic resonance images and image intensities of the mouse tumor preblocked by affibody ZHER2:342.
In the blocking experiment, the mice were born with SKOV-3 tumor on the right back.
The affibody ZHER342 of 3 mM in HEPES buffer was intravenous injected into the mice for 12 hr
and 4 hr before taking MR images [138]. The mice were also scanned at various time points of 4
hr and 24 hr.
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5.2.6 Advantages of ProCA1-affibody to antibodies in tumor targeting
Since antibodies have been widely used in drug and imaging probe deliveries in molecular marker targeted applications [133, 135] we further compared the immunofluorescence
staining patterns of our designed protein agent and a commercially available HER2 antibody. To
this end, ProCA1-affi-m (10 mg/kg) or the HER2 antibody (10 mg/kg) was administrated in the
SKOV-3 tumor bearing nude mice via tail vein. 24 hours post injection, tissue sections were prepared from the tumor tissue, and the sections were analyzed either by immunofluorescence
staining using the antibody PAbPGCA1 (for analyses of ProCA1-affi) or direct application of the
second antibody against rabbit IgG to detect the bound anti-HER2 antibody. The tissue sections
from both cases were also co-stained with the antibody against CD31. At 24 hours post injection, the anti-HER2 antibody was mainly concentrated around endothelial cells as revealed by
co-localization with anti-CD31 staining. This is in sharp contrast to the even distribution of ProCA1-affi-m in the entire tumor (Figure 5.5). The distributions of the anti-HER2 antibody to the
area distant from endothelial cells were clearly quite reduced as demonstrated by weak immunostaining in the areas where there was no CD31 staining (Figure 5.8). We further examined the
distribution of our protein agent and the anti-HER2 antibody at an early time point. Tissue sections from the SKOV-3 tumors were prepared 4 hours after administration of ProCA1-affi-m or
the anti-HER2 antibody. Interestingly, while the ProCA1-affi-m was largely concentrated with
the CD31 staining in the tumor, the anti-HER2 antibody was not detectable by the immunofluorescence staining analyses. (Figure 5.8). The results strongly suggested that our designed protein agent was able to cross the endothelial and distribute to the deep tumor tissue a few hours
after administration while the large size of antibody (~160 kDa) significantly hindered endo-
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thelial and tissue penetration. Consistent with the 50% reduction of MRI intensity at the tumor
site by affibody blocking shown in Figure 5.6, the fluorescence immunostaining at the same tumor site also exhibited about 60-90 ± 20% decrease in intensity (Figure 5.8). Taken together,
our developed MRI contrast agent exhibits a potential capability for future quantitative analysis
of the biomarker in vivo.
A very crucial requirement for application of an agent for delivery of both drugs and imaging probes to target a disease marker is the capability of the agent to cross the endothelial
barrier and to allow for proper tissue penetration and distribution. In particular, even distribution of an imaging probe throughout the entire cancer site is vitally important for quantitative
or semi-quantitative assessment of a particular cancer marker. HER2 is evenly expressed across
the entire SKOV-3 tumor as revealed by immunostaining using a commercially available antibody (Sigma). Co-staining using an antibody against the endothelial marker CD31 revealed that
the distribution of HER2 is not dependent on the distance to the vessels (Figure 5.9).
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HER2 antibody

ProCA1-affi-m

Figure 5.7 Direct staining with SKOV-3 tumors.
Immunofluorescent histology of tumor tissue (Xenograft SKOV-3 model) stained by
HER2 antibody and ProCA1-affi324-m

Presumably, the proper size of ProCA1-affi-m provides a great advantage to target the
molecular markers. To evaluate the tissue distribution and endothelial penetration of our designed protein contrast agent, we conducted immunofluorescence staining of the designed protein in the tissue sections prepared from various organs after systematic administration of the
protein using the antibody PAbPGCA1. The tissue sections were also co-stained with the antibody against CD31. It was clear that high levels of ProCA1-affi-m were targeted to the SKOV-3
tumor at 24 hours post injection, and the protein was distributed in the entire tumor evenly
since its intensity is not changed significantly upon increasing the distance from vessel staining
CD31 to 40 µm (Figure 5.7). The results from the immunofluorescence staining suggested that
the designed protein contrast agent had excellent endothelial and tumor tissue penetration,
and was not simply trapped in the blood in the micro-vasculature of the tumor tissue.
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Red: ProCA1-affi-m or HER2 antibody
Green: CD31
Blue: DAPI
24 hr

24 hr

Blood Vessel
Blood Vessel

Positive tumor stained
with ProCA1-affi-m
4 hr

Positive tumor stained
with ProCA1-affi-m

Positive tumor stained
with HER2 antibody
4 hr

Positive tumor stained
with HER2 antibody

Figure 5.8 Compare the tissue penetration with HER2 antibody by IHC.
Immune histology fluorescent (IHF) staining was applied to various tissue slides stained
by antibody against ProCA1-affi-m (red), Blood vessels biomarker CD31 (green), and nucleus
DAPI (blue).
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Figure 5.9 The tissue penetration properties of ProCA1 –affi-m were compared with antibody by IHF staining.
The tumor slides are from the mice which were dissected 24 hr and 4 hr after injection
with ProCA1-affi-m or antibody. After 4 hr, ProCA1 –affi-m began to distribute around the blood
vessel. The antibody had not been detected in the tumor tissue. After 24 hr, ProCA1-CD2-affi
was evenly distributed in the tumor tissue and the antibody mainly concentrated around the
blood vessel.

HER2 has been validated as a very important prognosis and treatment marker for cancer
patients expressing HER2, especially in the case of breast cancer. Development of Herceptin
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(trastuzumab) and other HER2 targeting drugs has resulted in significant improvement in patient survival. Unfortunately, current methods for determination of HER2 status rely on invasive
biopsy coupled with IHC using a qualitative scoring system [139]. These methods suffer from
both high false positive and false negative results, and large discordance in detection of HER2
expression in primary tumors and metastases due to heterogeneity in tissue sampling. These
methods also cannot detect HER2 expression levels and patterns in the entire cancer site. According to a recent study by Philips et al., one in five HER2 clinical tests provided incorrect results[140]. Therefore, there is a great need to develop MRI contrast agents with specificity and
sensitivity for HER2 imaging [141].

5.3 Conclusion
In this present study, we demonstrate the success in molecular imaging of HER2 by developing a novel class of multiple modality contrast agent. To our knowledge, there is no previous report of effective imaging of HER2 expression cancer in vivo by noninvasive MRI with desirable tissue penetration and using only a single injection. Our approach in designing proteinbased molecular imaging contrast agent differs greatly from previous reported studies in several aspects and represents a significant advance in molecular imaging by MRI. First, high relaxivity value in both T1 and T2 achieved by designing a Gd3+ binding site into a stable scaffold protein [142] allows for increased sensitivity in the detection of disease markers by MRI. Our
achievement of MR imaging in animal with 100-fold lower dose usage than clinically used nontargeting agent DTPA is also likely due to improved pharmokinetic properties such as retention
time and biodistribution. Such significant improvements in in vivo dosage efficiency will poten-
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tially reduce potential Gd3+ toxicity risks, such as NSF (Nephrogenic Systemic Fibrosis). Second,
the relatively small molecular size of the designed agent provides a unique opportunity to target the imaging probe to the molecular marker in the entire tumor mass. This property is of vital importance, especially for quantitative assessment of the molecular marker based on the
imaging results. Several approaches have been employed to develop targeted MRI contrast
agents [134-135, 143-149]. To increase contrast effects, high pay load contrast molecules were
created by either encapsulating a large number of Gd-DTPA, conjugating multiple contrast
agents such as polylysine-Gd-DTPA (PAMAM) [150], or using supermagnetic iron oxide nanoparticles [107, 151]. The antibody approach was widely utilized as the targeting moiety either directly conjugated with high payload contrast agent or elegantly applied in multiple steps to prelabel the tumor as a biotin-labeled antibody[152]. These pioneering studies demonstrated the
feasibility of the targeting approach; however, the large size of the antibody-conjugated imaging probes is likely to severely limit the endothelial penetration and even-distribution of the
probes in the whole tumor (Figure 5.7). On the other hand, our contrast agent exhibits endothelial penetration capabilities and an excellent distribution in the entire cancer mass as revealed by its adequate distribution near the blood vessel four hour after administration, and
the nearly-uniform distribution observed 24 hours post injection. One potential application of
our developed MRI contrast agent is for quantitatively or semi-quantitatively assessing the
HER2 levels in the entire tumor site using MR imaging, which is impossible with any current methods. Since HER2 is overexpressed in a large percentage of breast, ovarian, gastric, urinary
bladder and a number of other carcinomas, the developed contrast agents may be beneficial
for imaging of HER2 in several types of cancer. In vivo real time monitoring of the changes in
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HER2 expression levels and patterns will provide vital information for evaluation of the efficacy
of drug treatments and for designing further strategies for cancer treatments.
Based on the results on the animal model studies, we can also have the model for dynamic study. Since the protein in the small animals in dynamic circulation relies on different cell
types [153], only the orthotopic tumor model can be applied to fulfill the requirements of dynamic situation [154]. In the future research, we will select the cell lines for orthotopic model
with both breast and ovarian cancers.
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Chapter 6.

BIODISTRIBUTION AND PHARMOKINETIC STUDY OF DEVELOPED CONTRAST

AGENTS
6.1 Introduction
Biodistribution is the process of monitoring where a compound or reagent spread in an
animal body [155]. It also includes the kinetic changes of reagents in bloods which is called
blood retention or circulation [156]. The secretion time is also dependent on biodistribution.
For example, the gadolinium distributing to the bone may have long term retention. The biodistribution of a molecule in vivo is dependent on several factors. Molecular weight first defines
where a molecule will travel to. Small molecules like metals less than 5 KDa tends to distribute
to liver [157]. Macro molecules tend to concentrate in spleen. The structure and surface charge
will also define the distribution of specific molecules.
Several imaging methods such as NIR fluorescence and PET have been applied in molecular imaging for disease biomarkers for expression level determination. Antibodies are commonly used to target to the biomarkers. While these imaging techniques are highly sensitive,
which suffer from two major problems: lack of spatial imaging resolution, and limited tumor
penetration due to the large size of the antibodies (~150 KDa). Thus, there is an urgent need for
the development of a non-invasive imaging method with the capability to quantitatively determine the expression level and spatial distribution of biomarkers [34].
As discussed in Chapter 1.6 for the criteria of MRI contrast agents, in order to achieve
MRI contrast enhancement, as a blood pool contrast agent, it should have long retention time.
For achievement of molecular imaging, enough circulation time for targeting is needed. Howev-
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er, too long time may cause toxicity by heavy metals [158]. Current small molecules do not have
good retention time with a half life time less than 5 minutes [159].
In this chapter, we are going measure the biodistribution and metabolism by radioactive assay and ICP-OES. By comparing with the biodistribution of non-targeted and targeted
reagents, pegylation and non pegylation, the modified protein demonstrate long circulation
time and better distribution.
Current methods for determination of disease state largely rely on invasive biopsy
coupled with a qualitative scoring system such as Immunohistochemistry (IHC) to measure the
biomarker expressions such as PSA and HER2 receptors on the cell surface. Fluorescence in situ
hybridization (FISH) was also used to detect gene amplification by measuring the number of
copies of the HER2 gene in the nuclei of tumor cells[139, 160-161]. These methods cannot
detect biomarker expression levels and patterns in the entire tumor especially in quantitative
level. Therefore, incorrect results on HER2/Neu clinical tests were observed in one of five breast
cancer patients [140].
As one of the leading diagnostic techniques in clinical and preclinical settings,[54, 162163] MRI has the unique advantages of high resolution in capturing the 3-dimensional images
with good body depth and without ionized radiation[164-166]. In this dissertation, we developed a targeted contrast agent to HER2 and established a quantitative analysis method in cell
level. Biodistribution was also studied to calculate the retention of contrast agent in various organs.
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6.2 Results and discussion

6.2.1 Distribution calculation by NIR signals in different mouse organs
Besides quantitative analysis in cell level, we also calculated the biodistribution of our
contrast agents using various methods. Since our dual labeled ProCA1-affi342m is also conjugated with NIR, once the mouse organs were dissected out from mouse body two days after
injection, the NIR signal will be less affected by tissue depth. We can draw some quantitative
conclusions. From Figure 6.1, we can see out contrast agents mainly stays in positive tumor and
kidneys. Liver and negative tumor also had some retention. However, there was not so much
contrast agents remaining in the muscle and lung. Figure 6.2 is a scale bar calculated from the
integral intensity from Figure 6.1. Western blotting (Figure 6.3) of tissue extract and IHC of frozen tissue slides (Figure 6.4) were also measured to see the biodistribution. These results are
consistent with the NIR image data. Based on these results, we can conclude that the ProCA1affi342m can still be detected in primary organs after two days of injection. Since large molecules tends to filtered by kidneys, and NIR monitors the signal from the Cy5.5 dye which linked
to the C-terminal of ProCA-affi342m, kidneys have relatively higher intensity than other organs.
Muscle has little blood circulation which makes it completely dark without contrast agents retention and been referred as negative control.
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Figure 6.1 Biodistribution demostrated by NIR imaging
The contrast agent concentrates in the positive site. The liver, kidneys are also the primary organs to accumulate contrast agents.
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Figure 6.2 Average intensity of each organ by NIR measurement

Figure 6.3 Western blotting of quantitative analysis of distribution
The primary organs after MRI have been dissected and lysate. The lysis was detected by
western blotting to estimate how much protein has been retained by each organ.
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Figure 6.4 Biodistribution demostrated by IHC
Primary organs were also embedded in paraffin and detected by PAb-ProCA1 for IHC to
measure the general distribution of ProCA1-affi342m to each organ.

6.2.2 Bio-distribution and blood retention by 153Gd assay
Before measuring the biodistribution with radioactive assay, the general blood retention
of ProCA1-CD2 had been measured by western blotting (Fgure 6.5). Two different concentrations of ProCA1-CD2 had been injected into the CD1 mice of 100 µL with tail vein injection. After different time points of 5 min to 4 hr, mice blood was taken from tail drop or eye ball bleeding. The blood serum was measure by western blotting of the retention of ProCA1-CD2. Even
after 4 hr, ProCA1-CD2 still had some retention in mouse blood without degradation.
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200 µM ProCA1CD2 injected

20

500 µM ProCA1CD2 injected

Figure 6.5 Western blotting of blood retention
The mice have been injected with 200 µM (up) and 500 µM (bottom) of ProCA1-CD2 respectively. The concentration of ProCA1-CD2 in blood has decreased from 5 min to 4 hr.

The previous measurements are based on the distribution of ProCA1-affi342m, because
the protease cleavage and disassociation always exist in animal blood circulation, the distribution of Gd3+ was also measured by radioactive assay (Figure 6.6) or ICP-OES (Table 8). From Table 7, we can see free Gd circulates mostly to spleen and liver, while Gd-ProCA1-affi342m circulates more to the lung and liver. Figure 6.7 summarizes the distribution of contrast agents with
different modification. Most of the GdCl3 and non-modified proteins stays in the liver. The
modified protein stays more in lung and liver. These results indicate that there are some disas-
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sociation which led the small molecules circulates to liver. Based on the blood circulation diagram (Figure 6.7), the modification of contrast agents largely increased the blood circulation
time.
80
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GdCl3

ProCA1-affi-p40

%Injected dosage

50
40
30
20
10
0

Figure 6.6 Bio-distribution of ProCA1-affi by 153Gd radioactive assay.
Injected GdCl3, 100 µM, 100 µL, via tail vein. The accumulation of 153Gd was measured
after 12 hr injection

132

Table 7 Biodistribution of Radioactive assay in CD1 mice
GdCl3/1

GdCl3/2

CA-1/1

CA-1/2

CA-2/1

CA-2/2

CA1-P40/1

CA1-P40/2

Blood

0.8

0.9

1.5

2.4

2.2

3.0

2.7

2.5

Heart

0.2

0.3

0.1

0.1

0.1

0.1

0.1

0.1

Liver

63.3

64.6

68.4

63.9

75.4

72.2

38.1

27.8

Spleen

8.7

9.4

5.8

7.4

4.1

5.0

2.2

1.3

Lung

1.0

1.1

0.6

2.5

0.6

1.0

26.5

47.0

Kidney

1.6

1.5

1.4

1.8

1.3

1.3

1.9

0.9

Colon

4.6

1.0

3.4

2.0

1.6

1.5

2.0

1.0

Tail

1.6

3.7

1.5

1.7

0.9

1.7

1.6

0.9

Feces

0.9

0.7

0.2

0.2

0.3

0.4

2.3

0.9

Urine

1.5

1.2

0.3

0.3

0.2

0.2

1.6

0.6

16.7

15.5

16.7

17.6

13.3

13.5

20.9

11.4

Carcass
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8 hr
12 hr

20

0
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CA1-P12
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Figure 6.7 Blood circulation of ProCA1 series contrast agents
The mice were injected with 153Gd-ProCA1 series proteins. The radioactivity of the blood
samples collected at different time points were measured. The ProCA1-CD2 with 40 units of
PEGylation size has longest circulation time.
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6.2.3 Bio-distribution with ICP-OES
As described in Chapter 2.0, the radioactive assay is a very sensitive technique to monitor the Gd distribution. ICP-OES which can measure the total metal concentration is another
method to measure the Gd distribution. All the mouse organs were dissolved in concentrated
Nitric Acid overnight. Small liquid drop will be formed after all the organs being dissolved. The
liquid drop was diluted with 2% Nitric Acid based on the original weight of each organ. Then the
total Gd3+ concentration will be measured by the ICP-OES. Table 6 listed the percentage of total
Gd3+ injection in each organ. Since GdCl3 circulates fast in animal body, it may be secreted out
of the body within 5 min. Therefore, the mouse was sacrificed right after being injected with
GdCl3. For the protein contrast agents, different time points have been measured. It shows that
in shorter time, most of the contrast agents stay in the liver and lung, however, after one day,
half of the reagents secreted out of the liver and the tumor accumulate more up to 7.59% of
the total injection. After two days, the lung still retains more than 30% of the contrast agents.
Correlated with our MRI data, the tumor receives highest signal after one day injection of ProCA1-affi342m. Liver and lung are the two organs accumulate most of the ProCA1-affi342m. Further optimized modification may be needed to make more protein contrast agents target to
tumor.
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Table 8 Bio-distribution of ProCA1-affi-m was measured by ICP-OES at various time points

Unit: %total injection
GdCl3

ProCA1-affiP40 (4 hr)

ProCA1-affiP40 (24 hr)

ProCA1-affiP40 (>2 d)

Heart

0.8

0.6

0.4

0.2

Liver

35.5±2.1

36.8±1.7

18.5±2.8

17.9±3.4

Spleen

50.3±4.5

22.9±2.6

5.0±1.9

13.4±3.2

Lung

3.8±0.1

38.7±3.6

39.4±4.5

30.6±5.7

Kidney

2.6±0.1

3.9±1.1

3.1±0.9

4.6±0.7

Muscle

0.2

0.4

0.1

0.6

Tumor

1.1±0.1

2.1±0.1

7.5

3.7±0.8

The distribution of different contrast agents are also compared especially the different
distribution between PEGylated and non-PEGylated ProCA1-affi342. Table 9 shows the percentage of total after one day of injection. Without PEGylation, most of the contrast agent goes to
spleen instead of lung, similar like free GdCl3. We may conclude that PEGylation causes the contrast agents move from spleen to lung.
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Table 9 Bio-distribution of MRI contrast agents was measured by ICP-OES to optimize
the modification condition

Unit: %total injection
GdCl3

ProCA1-CD2

ProCA2-P40

ProCA1-affiP40

Heart

0.8

0.6

0.9

0.4

Liver

35.5±2.1

38.1±3.4

22.6±2.1

18.5±2.8

Spleen

50.3±4.5

45.4±2.6

28.2±3.4

5.0±1.9

Lung

3.8±0.1

7.3±0.8

14.7±1.3

39.4±4.5

Kidney

2.6±0.1

2.5±0.1

2.7±0.1

3.1±0.9

Muscle

0.2

0.3

0.4

0.1

Tumor

1.1±0.1

N/A

N/A

7.5
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Chapter 7.

EFFECTS OF DRUG TREATMENTS DETERMINED BY PROCA1-AFFIBODY

7.1 Introduction
As described in Chapter 1.2, two common anti-cancer drugs, Herceptin, and Erlotinib
which overate via the same HER pathway will be selected [153, 167] (Figure 1-1). Herceptin
(trastuzumab) is a humanized antibody that targets the extra-cellular domain of HER2/Neu
[168]. Herceptin is a clinically approved antibody against HER2 in breast and ovarian cancers.
While the drug is well studied in treating breast cancer clinically, it is important to determine
whether treatment of HER2/Neu positive cancer with Herceptin will lead to any changes in
HER2 levels and distribution in tumors [83]. Erlotinib is a tyrosine kinase inhibitor of EGFR and
can promote tumor regression in various xenograft models [169]; it can also be used to treat
the mammary tumor cells which are EGFR positive [170]. In the treated cancer cells, the EGFR
level will be down regulated [171]. Since the erlotinib is an inhibitor to the kinase site in the
intracellular domain of EGFR family, the trastuzumab is an antibody against the extracellular
domain of HER2. The two drugs can be applied together to cancers [172]. The Herceptin and
ProCA1-affi342m have different epitope on HER2 extracellular domain [173], which enables the
detection of HER2 expression in tumors by ProCA1-affi342m.
In this chapter, drug effects on the HER2 receptor expression levels were examined using cultured cancer cells such as SKOV-3 and MDA-MB-231. The drug of Herceptin was chosen
because it is a targeting drug for HER2. The dosage of 5 µM was used based on the estimated
tumor cell numbers and reported receptor level (Chapter 1.2.3).
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7.2 Results and discussion
7.2.1 Both receptor level and cell survival decrease after been treated by Herceptin
Before measured by MRI, we confirmed the effects of drug treatment in the cell level by
ELISA, western blotting and flowcytometry. For ELISA and western blotting, the cells were
treated with Herceptin for 3 and 5 days. Then the cells were lysed and the cell lysis was detected by antibody against ProCA1-CD2m. Both results (Figure 7.1 and 7.2) indicate that the total receptor decreased up to 35%. The receptor change may due to two factors: first Herceptin
may cause cell death so that the total number of cancer cells will decrease; second the expression level of HER2 will also decrease on treatment.
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
2nd lysate

non-treated

treated

Figure 7.1 ELISA assay to monitor the HER2 receptor level changes after being treated
with Herceptin in SKOV3 cells.
1 day: seed cells to 6 well plates (5000) 2 day: add 4 pmol Herceptin (3 times receptor)
4-6 day: change medium and add another 4 pmol Herceptin Cell lysate was collected at day 4
and day 6.

IB: CA1-affi

GAPDH
IB: HER2 Ab

IB: HER2 antibody
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SKOV3 MDA-MB-231

Figure 7.2 Western blotting results indicated that the total receptor number decreased
about 35% after five days of treatments with Herceptin

7.2.2 Monitoring the receptor change after drug treatment using flow cytometry
In order to detect whether the expression level of HER2 is changed due to drug treatment, flowcytometry is also used to measure the receptor change. In each measurement 2×104
cells of treated and non-treated samples were counted and the total fluorescent intensity was
measured. The receptor was detected by HER2 antibody and ProCA1-affi342 respectively (Figure 7.3). Both detections show the receptor level change up to 10% percentage (Figure 7.4).
However the ProCA1-affi342m detection sensitivity is much lower than antibody detection. This
may due to an extra primary antibody need to be added to detect ProCA1-affi342m during
sample preparation.
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SKOV-3

Treated with Herceptin and
detected by ProCA1-affi342
Treated with Herceptin and
detected by antibody
Non-treated with Herceptin
and detected by ProCA1affi342
Non-treated with Herceptin
and detected by antibody

MDA-MB-231

Treated with Herceptin and
detected by ProCA1-affi342
Treated with Herceptin and
detected by antibody
Non-treated with Herceptin
and detected by ProCA1affi342
Non-treated with Herceptin
and detected by antibody

Figure 7.3 Drug treatment measued by flow cytometry
The cells were seeded in 10 cm dishes, and treated with Herceptin (5 nM) during the 5day period. After 5 days, the cells were harvest and stained. Finally, 2x104 cells were counted
and the fluorescent intensity was measured by flow cytometry. The x-axis is fluorescent intensity. The y-axis is cell numbers been counted with staining.
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Figure 7.4 Flow cytometry demostrated the receptor level change after being treated
with Herceptin.
Both antibody and CA1-affibody can show the difference of cells after drug treatment.
Due to the extra step by adding CA1 antibody, the sensitivity is lower of CA1-affibody than antibody.

7.2.3 ProCA1-affibody can monitor the total receptor change in cancer cells by MRI
Based on previous data, we confirmed that ProCA1-affi342m is able to monitor the receptor change in cell level by immune techniques. Then we further add Gd-ProCA1-affi342 to
the drug treated cells and measured by MRI. Figure 7-5a shows that when cells are treated by
various concentration of Herceptin, the receptor change will be different. We selected the
highest treatment concentration 50 µM of Herceptin to measure the effects on different time
points (Figure7-5b). After 5 days treatment, the MRI intensity of cell samples is lower than nontreated samples and those with 3 days treatment. Since MRI is not a sensitive technique, and
each scanning only counts 1 mm thickness of the sample, this makes the intensity change not
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significant. When repeat this measurement in the future, the detection will be integral of up to
1 cm thickness of the samples.
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0.5

0

µM

Figure 7.5 MR images of SKOV3 cells after various days of treatments by Herceptin
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Chapter 8.

MONITORING CHANGES IN BIOMARKERS OF DISTRIBUTIONS AND EXPRESSION

LEVELS DURING BREAST CANCER PROGRESSION BY TARGETED PROTEIN BASED CONTRAST AGENTS
8.1 Introduction
Breast cancer is one of the diseases with highest occurrence in North America. The
death rate is the second among different cancers [174]. There are several breast cancer types
categorized based on its origination from ducts or lobules [175]. Table 8 lists different types of
the breast cancers and their origination or properties. For example, Infiltrating Ductal Carcinoma (IDC) is the most common type of breast cancer representing 78% of all malignancies[176].
Among these cancer types with different morphologies (Figure 7-1), cancer originated
from Ductal Carcinoma In-Situ (DCIS) is an invasive type of early breast cancer occurs inside of
the ductal system[177]. The development of breast cancer is a multi-step process that initiates
as premalignant atypical hyperplasia, transforms into pre-invasive DCIS, and progresses into
invasive breast cancer[178-179]. With a proportion of 20—30% among all the breast cancers,
DCIS turned to be a common type of breast cancer [180]. Currently, the clinical management of
DCIS patients is still controversial, mainly because the natural development of DCIS is largely
unknown [181]. Molecular basis on why and how often DCIS progresses to potentially lethal invasive breast cancer remains to be determined. Therefore, understanding the key molecular
events in initiation and progression of DCIS should allow the identification of biomarkers for
specific therapy to achieve the maximized efficacy of treatment as well as determining molecular targets for the development of new treatment approaches for DCIS.
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Table 10 Table of different breast cancer types
Breast Cancer Type
Characteristics
Ductal Carcinoma in situ (DCIS)
The cancer cells are inside the ducts but have not spread
through the walls of the ducts into surrounding breast.
Lobular Carcinoma in situ (LCIS)
It begins in the milk producing glands but does not grow
through the wall of the lobules.
Infiltrating Ductal Carcinoma
The cancer cell starts in a milk passage (duct) of the breast,
(IDC)
breaks through the wall of the duct and grows into the
fatty tissue of the breast.
ILC starts in the lobules as LCIS. It can spread to other parts
Infiltrating Lobular Carcinoma
of the body. About 10% of invasive breast cancers are ILC.
(ILC)
Triple-negative breast cancer
This type of breast cancer whose cells lack estrogen
receptors and progesterone receptors, and do not have
overexpression of HER2 on the cell membrane.
Medullary Carcinoma
This special type of infiltrating breast cancer has a rather
well defined boundary between tumor tissue and normal
tissue.
Metaplastic Carcinoma
This is a very rare type of invasive ductal cancer. They
include cells that are normally not found in the breast.
Mucinous Carcinoma
This type of breast cancer is formed by mucus-producing
cancer cells. The prognosis is better than other types of
invasive breast cancers.
Tubular Carcinoma
They are called tubular because of the way the cancer cells
are arranged when seen under microscope. It accounts
about 2% of all the breast cancers.
Papillary Carcinoma
The cells of these cancers tend to be arranged in small,
finger-like projections when viewed under the microscope.
Adenoid cystic Carcinoma
These cancers have both glandular and cylinder-like
features when seen under the microscope.
Phyllodes tumor
This rare breast tumor develops in the stroma of the
breast, which is a connective tissue.
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Figure 8.1 Histological special breast cancer types
(A) Tubular carcinoma, (B) cribriform carcinoma, (C) classic invasive lobular carcinoma,
(D) pleomorphic invasive lobular carcinoma, (E) mucinous carcinoma, (F) neuroendocrine carcinoma, (G) micropapillary carcinoma, (H) papillary carcinoma, (I) low grade invasive ductal carcinoma with osteoclast-like giant cells.
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Figure 8.2 Progression of DCIS tumors
The progression stages of DCIS tumors show morphology changes as the DCIS tumor
proceeds to the invasive tumors [176].
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There are several biomarkers such as HER2, EGFR, estrogen (ER) and progesterone receptor (PR), which have been identified for the diagnostics of breast cancers (Figure 8.1). The
breast carcinoma has been classified into subtypes based on the molecular classification [182].
For example, Infiltrating Lobular Carcinoma (ILC) is often positive for estrogen (ER) and progesterone receptor (PR) [183]. ER has overexpression in about 70% of breast cancers since the
binding of estrogen to ER may cause proliferation of mammary cells [184]. PR also expressed in
most of the breast cancer cells, however, for most ER negative breast cancers are often PR negative [185]. The biomarker of EGFR family has the advantages because they express on the cell
membrane which benefits for the tumor targeting diagnosis and therapy.
The EGFR family also plays an important role in the breast cancers via the signaling
pathway to regulate the cell progression, survival and differentiation [186]. About 70% percent
of the DCIS tissues with high proliferation rate demonstrate a high expression level of EGFR or
HER2 [187]. It has been shown that 14 to 91% of human breast carcinomas express a high level
of the EGF receptors[186]. Most of the DCIS tissues identified is associated with a high proliferation rate, which is negative for estrogen receptor, and expresses high levels of EGFR or
HER2/neu[187]. The importance of EGFR signaling in the growth of DCIS tissues is further supported by study results obtained from examination of the effects of an EGFR inhibitor, erlotinib,
on human DCIS tissues xenografted in nude mice. Inhibition of EGFR induced apoptosis and decreased the growth of human DCIS tissue xenografts by 56% [188-189]. However, only 8% of
non-basal-like breast cancers are EGFR positive [190].
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Figure 8.2 shows that basal type human breast cancer cell line MCF-10 DCIS produces
rapidly growing lesions in nude mice with predominant ductal carcinoma in situ (DCIS) characteristics of human DCIS during the first three weeks of tumor growth and gradually progressing
to invasive tumor in 4 to 8 weeks. HER2/Neu is found in all DCIS lesions, whose expression is
absent or very low in invasive tumor areas. In contrast, EGFR is not found in luminal tumor cells
but only positive in the basal layer of the DCIS lesions. However, microinvasive lesions and invasive tumor areas express a very high level of EGFR, suggesting the role of EGFR signal in developing a basal type invasive breast cancer. To date, the role of EGFR family of proteins, including
EGFR and HER2, in the progression of DCIS is still unclear.
Dr. Fred R. Miller at Wayne State University School of Medicine, Detroit, MI, developed
the MCF10 series of cell lines that were originally derived from benign breast tissues from a
woman with fibrocystic diseases [180, 191-194]. These cell lines exhibit distinct histopathological features of the progression from normal, to atypical hyperplasia, to DCIS and then to invasive breast cancer. MCF10A is a normal immortalized human mammary epithelial cell line with
low levels of EGFR, ER, survivin and a wild type p53 gene. An H-ras–transformed derivative
MCF10AT contains mostly premalignant cells. It has been shown that inoculation of MCF10AT
cells into athymic mice produces sporadic DCIS and invasive cancers (25%) in about a year. A
clonal cell line cultured from a MCF-10AT derived tumor xenograft, MCF10DCIS.com (or MCF-10
DCIS), produces rapidly growing lesions in about three weeks with predominant comedo DCIS
characteristics, such as tightly packed tubular structures with central necrosis, distinct intact
basement membrane surrounding each ductular structure containing luminal tumor cells with
large and vesicular nucleoli, high mitotic figures and moderate foamy cytoplasm (Figure 7-4). In
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this specific xenograft model, tumor progression has been observed by staining several biomarkers, like HER2, EGFR and ER with IHC. Based on these studies and our designed contrast
agents targeting to biomarkers, we used the ProCA1-affi342 to image the xenograft tumor of
MCF10-DCIS model at the early stage. We will also use ProCA1-affi342 and ProCA1-affi1907 to
monitor the biomarker changes in different prognosis stages.
Dr. Lily Yang’s lab has provide the orthotopic tumor model and her work on MCF10A
cancer progression model has been described in Figure 8.3 and with other biomarkers like ER
and PR been analyzed.
We previous have shown that HER2 targeted MRI contrast agents have been developed
(discussed in Chapters 3.7). As discussed in Chapter 1.4 and developed by a Sweden group [195],
affibody, which is a small protein with 58 amino acids, can target to EGFR or HER2 with a high
affinity (nM in Kd) and function as a ligand. In addition, affibody will not activate receptors like
antibody [74]. At the same time affibody does not need post-translational modification, which
makes it easy to express in E. coli.
In this study, we are going to first develop EGFR targeted MRI contrast agents based on
the targeting capability of affibody 1970 to against EGFR. In addition, we will apply MRI based
contrast agents ProCA1-affibody342 against HER2 and ProCA1-affibody1907 against EGFR to
monitor the expression level of HER2 and EGFR respectively in various tumor stages of xenograft mouse model. Furthermore, we will monitor the receptor changes after treated with cancer drugs like Herceptin and Erlotinib by the designed MRI contrast agents.
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Figure 8.3 EGFR and HER expression levels in a human breast cancer xenograft derived
from a basal type of breast cancer cell ine (MCF-10DCIS)
The EGFR and HER2 expression level changes in early and late stages of MCF-10DCIS tumors. The expression level of EGFR increases as the tumor progress to invasive stage. And the
distribution of EGFR extends. The HER2 expression decreased obviously. (Provided by Dr. Lily
Yang)
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8.2 Results and discussion
8.2.1 Biomarker changes during the prognosis
Based on the IHC results from Dr. Lily Yang’s group, we already found that in the xenografted MCF10-DCIS model, the HER2 expressed in the whole tumor area within the the basal
layer of the DCIS lesions in the early pre-invasive stage. The EGFR was found mainly on the basal layers of the DCIS tumors at this stage. After 3-4 weeks, when the tumor turns into invasive
tumors, the expression level of HER2 decrease dramatically; however, the EGFR expression increased in the whole invasive tumor tissue.

8.2.2 Generation of EGFR targeted contrast agent
The ProCA1-affi1907 was created by fusion of affibody ZEGFR1907 which can specifically
target to EGFR [71]. The epitope locates in helix 1 and 2 with 13 amino acids (Figure 8.4). This
three helix protein which consists of 58 amino acids were cloned to the C-terminal of ProCA1CD2 with a GGSGG linker in between. In the fused protein ProCA1-affi1907, there is one Gd3+
binding site in ProCA1-CD2 which can function as an MRI contrast agent [196]. The affibody
ZEGFR1907 keeps the helix structure with the EGFR binding sites exposed.

Figure 8.4 Sequence of ProCA1-affibody-EGFR
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Same as the parental protein ProCA1-CD2, the constructed ProCA1-affi1907 was also
expressed in E.coli and subsequently purified by GS-4B column for GST fusion protein. In order
to apply this fusion protein in cells and animal experiments, PEGylation was also used to modify
this protein, since PEGylation can increase the relaxivity and stability of the fusion protein. An
optimized PEG size of 40 repeated PEG units was used for better tumor penetration and keeping the tumor binding capability.
We next examined whether ProCA1-affi1907 can specifically target to EGFR in cancer
cells with high EGFR expression. Two cancer cell lines were used for immunostaining. One is
breast cancer cell line MDA-MB-231, which overexpresses EGFR but HER2 negative. Another
one is an ovarian cancer cell line SKOV-3, which overexpresses both EGFR and HER2. The parental protein ProCA1-CD2 was used as a negative control. Binding of the Gd-ProCA1-affi1907 to
the selected cells was analyzed by immuno-fluorescence staining using the polyclonal antibody
against PEGylated parental protein ProCA1 (PAbPGCA1) (Figure 4.13). A substantial staining intensity of ProCA1-affi1907 bound to MDA-MB-231 cells was observed and increased as incubation concentration increased. In contrast, the cells stained with ProCA1-CD2 demonstrated very
week binding. In SKOV-3 cells, it showed the same phenomena as MDA-MB-231 (Figure 8.5).
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Figure 8.5 ELISA of cell binding with EGFR high expression
The ProCA1-affi1907 of different concentration was incubated with cancers with different expression level of EGFR. The breast cancer cell line MDA-MB-231 has highest expression
level as indicated. SKOV-3 also shows high expression level of EGFR. MCF-7 is an EGFR negative
cell line.
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ProCA1-affi1907
ProCA1-CD2
5 µM
2 µM
Figure 8.6 Immunostaining of cancer cells by ProCA1-affibody-EGFR
The EGFR positive cell line MDA-MB-231 was used for cell staining. ProCA1-CD2 was
used as control.
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ProCA1-affi1907
5 µM
2 µM
Figure 8.7 Immuno staining of ProCA1-affi1907 in SKOV-3 cancer cells
SKOV-3 cells also have high expression of EGFR

8.2.3 MR imaging of orthotopic tumors
We then tested whether our designed contrast agent would result in MRI contrast enhancement in xenograft orthotopic models of MCF-10DCIS human cancer cell lines. The contrast agent Gd3+ ProCA1-affi342 at concentration of 3 mM (100 fold lower than clinicallyapproved contrast agent DTPA was administrated via the tail vein (80 µl). Pre- and postcontrast MRI were collected at different time points using T1 and T2 weighted fast spin echo or
T1 weighted gradient echo sequences. The mice were imaged using two pulse sequences: the
T1 and T2 weighted fast spin echo sequence (TR=2 s, TE=0.022 or 0.066 s) and the T1 weighted
gradient echo sequence (TR=0.088 s, TE=2 ms and P=0.009 s). The fields of view are 3 cm×3 cm
with matrix of 256 × 256 and slice of 1 mm in thickness. Image J was used to quantitatively analyze the MRI images obtained. The regions of interest (ROI) were selected by circling the tumor
sites. Then the signal intensities of the ROIs were calculated and compared. Six adjacent slides
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were selected to measure signal changes which were averaged to obtain statistical significant
results. At 3 hour time point, the tumor site exhibited significant contrast enhancement. Strong
contrast enhancement was observed in the tumor 24 hours after injection. Such MRI contrast
enhancement was decreased after 24 hrs post injection (Figure 7.4-6). In Figure 7.6, the tumor
showed enhancement in edge area, however, the center of the tumor was still dark as pre-scan.
These results demonstrated the heterogeneous structure of tumor.

Tumor
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50 hr
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74 hr

Figure 8.8 MRI of orthotopic model.
Tissue or organ grafts may be transplanted to their normal situation in the animal.
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Figure 8.9 MRI of orthotopic tumor model with fast spin echo
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Figure 8.10 MRI of orthotopic tumor model with gradient echo

8.2.4 MRI can monitor distribution of biomarkers

The biomarker may not only have expression level change during the progression and
drug treatments, the morphology or the distribution of biomarkers may also change inside the
tumor [13]. IHC can clearly demonstrate the distribution of biomarker in the tumor (Figure
8.11) by staining both the biomarker, like HER2 and nucleus. Since MRI is a technique with high
resolution [197], we expect to use our designed MRI contrast agents to monitor the tumor
structure (Figure 8-10). At the time point of 24 hr, when most contrast agents concentrated in
the tumor area, the heterogeneous structure can be viewed (Figure 8.10). Figure 8-11 shows
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the difference of MRI signal in the edge and core part of the tumor. This MRI results confirms
the biomarkers like HER2 detected by ProCA1-affi342 inside the tumor area is heterogeneous.
The MRI is able to image the structure of the tumor; however, the resolution is not as high as
IHC to give the information of the distribution of HER2. The DCE-MRI (Dynamic Contrast Enhancement) is expected to give more information about the biomarker changes. [198]

Pre

10 min

24 hr

Edge: slide 3

Middle: slide 8

Figure 8.11 MR images can demonstrate the structure difference at the edge and core of
the tumor
The tumor edge with lipids shows brightness after loaded with MRI contrast agents. The
inner heterogeneous structure can also be viewed by MRI with high resolution.
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Figure 8.12 Tumor structure can be measured by MRI and IHC
Slide 3 shows the tumor structure of the edge area. Slide 8 shows the structure in the
core area.
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Chapter 9.

OTHER CONTRAST AGENTS WITH MULTIPLE METAL BINDING SITES

To further increase the contrast capability, protein-based MRI contrast agents with multiple Gd3+ binding sites have been engineered, expressed and characterized. New generation of
protein-based contrasts, named ProCA2 and ProCA3, has two to four Gd3+ binding sites on single protein. Figure 9.3 shows that tail vein injection of 0.02 mmol/kg ProCA32 (~10 folds lower
dosage (0.02 mmol/kg) than that of Gd-DTPA (0.2 mmol/kg) resulted in an enhancement of
blood, liver and kidney 50 min post injection under MRI scanner. The blood circulation time is
much longer than small molecular contrast agents, which indicates that ProCA32 could be potentially used as a blood pool contrast agent. The enhancement of tissue completely disappeared two days after injection, which indicates that our contrast agent could be completely
secreted out after two days.

9.1 Designing HER2 targeted contrast agent by using mutated CaM as host protein
(ProCA22-affi342)
After the first generation of protein contrast agent series with ProCA1-CD2 as host protein, we also linked tumor targeted peptide affibody ZHER2:342 to other designed contrast agents
with multiple metal binding sites. Calmodulin with four metal binding sites has been designed
and grafted to be Gd3+ binding protein. Affibody ZHER2:342 was grafted into the loop region of
CaM and the fusion protein is named ProCA22-affi342. Initial data showed that this designed
contrast agents is able to target to cancer cells with high expression of HER2.
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9.2 Toxicity of protein based contrast agents
The acute toxicity of contrast agent on liver enzymes (ALT, ALP, AST, LDH), urea nitrogen, bilirubin, and total protein from CD1 mice 48 hours post-contrast agent injection were
found to be negligible compared to a control subject (CD-1 mice). No acute toxicity was observed for mice (N > 10) after contrast agent injection, suggesting that our contrast agent is
likely to maintain its metal complex stability and strong affinity for Gd3+ in vivo.
The toxicity of the designed protein was analyzed with CD-1 mice. No acute toxicity was
observed following tail vein injections of 4-fold greater dosages than that currently used in MRI,
evaluated over a 2-day test period. Characterization of serum samples from the test mice receiving the agent detected no apparent damage to kidney, liver, or heart (Table 11).

Table 11 Acute Toxicity of ProCA1-affi342
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Creatinine (mg/dL)
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0

Figure 9.1Measurement of creatinine concentration in mouse blood
Creatine is a nitrogenous organic acid which provide energy mainly for muscle. No obvious change has been observed by measuring the concentration in mouse blood.
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Figure 9.2 The enzyme in liver of ALT (alanine aminotransferase) and ALP(Alkaline Phosphatase) activity
Decreasing of ALP has been observed indicates that the protein based contrast agents
accumulate mainly in liver.
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Figure 9.3 Metal concentration in blood has been measured
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Chapter 10.

CONCLUSIONS AND MAJOR DISCOVERIES

Magnetic Resonance Imaging (MRI) is one of the primary oncological imaging modality
capable of high resolution 3-dimensional imaging, exquisite soft tissue contrast with body
depth without use of ionized radiation [164-166]. In addition, it enables the non-invasive and
repetitive assessment of biological processes of the same living subject at different time points
for monitoring treatment response and disease progression [78-79, 199-201]. Molecular imaging of cancer biomarkers using MRI potentially improves our understanding of the disease and
drug activity during preclinical and clinical drug treatment [202-205]. However, lack of desired
MRI contrast agents capable of enhancing the contrast between normal tissues and tumors
with high relaxivity, tumor targeting, high intratumor distribution and no toxicity is one of the
major barriers for the application of MRI to assess specific biomarkers for diagnosis and monitor drug effect.
Biomarkers such as the epidermal growth factor receptors EGFR and HER2/Neu are
highly expressed in various diseases such as breast and ovarian cancers and play important
roles in disease progression and survival. They are also major drug targets for targeted therapy.
Since the clinical application of targeted therapy is largely limited because current methods for
assessment of these cancer biomarkers involve invasive methods, such as biopsy and the effectiveness of the target therapy largely depends on the pre-selection of patients over-expressing
these biomarkers. To date, one of five HER2/Neu clinical tests, including biopsy and immunostaining (IHC), provides incorrect results, leading to improper selection of appropriate patients
for personalized treatment using biomarker targeted therapies [34, 64]. There is an urgent need
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to develop non-invasive and accurate methods for diagnosis and selection of patients and to
monitor biomarker levels/distribution and their changes upon treatment by targeted drugs.
In this dissertation, we developed novel protein based MRI contrast agents by fusion of
affibody variants to the C-terminal of ProCA1-CD2. The results indicated that ProCA1-affi342
and ProCA1-affi1907 are able to target to HER2 and EGFR respectively. MRI and NIR imaging
have been demonstrated to prove the capability of using the protein based contrast agents to
monitor tumors types, tumor progression and drug treatments.
The targeted protein contrast agents were designed and generated by gene cloning. In
vitro results showed that ProCA1-affi342 is well folded after GST purification. PEGylation of the
ProCA1-affi342 not only increased the stability and decreased the immunogenicity, but also improved the metal binding and relaxivity. The metal binding affinity to Gd3+ is up to 1.86 pM and
the relaxivity with r1 and r2 of 21 and 30 mM-1s-1 exhibited. In order to compensate the shortage of MRI with low sensitivity, a NIR dye Cy5.5 was successfully conjugated to the ProCA1affi342 at the C-terminal. Spectra from UV-absorbance, MS and NMR confirmed the conjugation. All the in vitro measurements and results demonstrate that the ProCA1-affi342 is well designed as an MRI contrast agent, which will be able to generate dual signals of MRI and NIR in
vivo. (Chapter 3)
After measuring the in vitro properties of ProCA1-affi342, the tumor binding capability is
also evaluated in the cell assays. Several immune assays like western blotting, ELISA, immunefluorescent staining and flowcytometry have been used and detected by self generated antibody
against ProCA1-CD2 (PAb-ProCA1-CD2). The results are consistent and show significant binding
of ProCA1-affi342 to the HER2 overexpressed cancer cells. Besides monitoring the ProCA1-
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affi342 by protein and protein interaction, the retention of ProCA1-affi342 in tumor cells was
also measured by monitoring the Gd3+ signals with MRI and radioactive assay. The results
showed that Gd3+ chelated in the ProCA1-affi342 can be retained in the tumor cells compared
with the free Gd3+. This ex vivo studying in the tumor cells provided good knowledge of ProCA1affi342 for further studying in the tumor mouse. (Chapter 4)
In order to apply our contrast agents to tumor mice, the mouse model was carefully estimated and selected. Subcutaneous xenografted model was selected for the initial studying.
Two tumor cell lines SKOV-3 and MDA-MB-231 with different HER2 expression level and moderate tumorigenicity were chosen. The MRI results clearly showed that the ProCA1-affi342 targeted to the HER2 positive SKOV-3 tumor specifically. The tumor got highest MRI intensity after
1 day injection with highest concentration of ProCA1-affi342 concentrated in this tumor site.
Some primary organs like kidney and liver also got enhancements. MRI blocking results also
supported this results that the ProCA1-affi342 accumulated in the positive tumor site specifically by the biomarker HER2 targeting. Further studying of IHC is consistent with the MRI results
which show the ProCA1-affi342m accumulating in the positive tumor sites. The IHC results also
show that ProCA1-affi342m has better tissue penetration and distribution than HER2 antibody.
(Chapter 5)
Since the MRI enhancement has been observed in the positive tumor sites and some
other primary organs like kidneys and liver, further quantitative results of on the distribution of
ProCA1-affi342m are analyzed by NIR intensity, radioactive assay and ICP-OES. The NIR monitors the protein signal since the dye is covalently conjugated to the ProCA1-affi342. The radioactive assay and ICP-OES monitors the Gd3+ signals. By these two methods to monitor the
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biodistribution, we can see that about 20% of ProCA1-affi342m accumulates in the positive site,
however only less than 10% of Gd3+ stays in the tumor site after one day injection. We may
conclude that since some disassociation of Gd3+ from ProCA1-affi342, the free Gd3+ will be secreted out of the body in short time. The pharmokinetics of ProCA1-affi342m needs to be studied in the future. (Chapter 6)
After been proved that the ProCA1-affi342 has the capability to target to HER2 overexpressed tumors both in vitro and in vivo, further application of this contrast agent has started.
First, we tried to use this contrast agent to monitor the effects of drug treatments. In Chapter 7,
the receptor level changes have been detected by ProCA1-affi342 in cancer cells with both immunology techniques and MRI. Further studying of relaxivity changes related to the drug
treatments in cells and the tumor changes in mouse model will be taken to better use ProCA1affi342 with high relaxivity and tumor targeting capability. (Chapter 7) Second, we also try to
use these protein contrast agents to monitor the tumor progression. A new type of contrast
agent ProCA1-affi1907 has been generated to target to EGFR. Since in the specific tumor model
MCD10-DCIS, both the biomarkers HER2 and EGFR will change during the progression, we may
use our contrast agents to view the receptor level change and distribution change. Some initial
work has been done with ProCA1-affi342m. The results showed that ProCA1-affi342m is able to
bind to the orthotopic tumor with MCF10-DCIS in the early stage. We will continue this research by using both ProCA1-affi342m and ProCA1-affi1907 to monitor the tumor in early and
late stage to see the biomarker changes. (Chapter 8)
In this dissertation, targeted protein based contrast agents have been generated and all
the experimental conditions have been optimized, so that we first time successfully got the MRI

169

enhancement in the tumor model by tail vein injection of our contrast agents. This also paved
the way for other contrast agents with multiple metal binding sites (Chapter 9). However, in
order to apply our contrast agents clinically, there is still a long way in front; we are continuing
this project by estimate the lowest dosage needed, the long term toxicity and other physiology
researches. The capability to spatially and temporally visualize as well as quantify HER2 and
EGFR would significantly improve our capability to follow the expression of these biomarkers
during tumor progression and metastasis, monitor treatment efficacy, aid in drug selection for
patients, and further apply and develop novel targeted therapy.
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Appendix I
Establish mammalian expression and purification of HER2-ECD
In this dissertation, we focused a lot on quantitative analysis of biomarkers with various
techniques. In order to get quantitative results, pure biomarker proteins are needed to be a
standard. Dr. Leahy in Johns Hopkins kindly provided stable cell line LEC1 with transfaction of
the HER2-ECD gene in pSGH vector [206]. This HER2-ECD is also His-tag fused. The LEC1 cell was
first thawed and cultured in α-MEM medium with 10% of FBS. After passaged to T250 flasks for
2 days, the medium was changed to DMEM/F12 medium with 1% FBS. This medium was
changed every three days and collected to obtain the secreted HER2-ECD. The expression level
was measured by western blotting (Figure A1). The HER2-ECD was purified from cell culture
medium by His-tag column (Figure A3).
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IB: His tag Ab

IB: HER2 Ab
Figure A 1 Monitoring HER2-ECD expression by western blotting

mg/L
2

2 day

0.728

0.421

4 day

0.993

0.58

1.2

6 day

1.112

0.63

1

9 day

1.235

0.69

12 day

1.387

0.73

15 day

1.376

0.72

18 day

1.385

0.79

1.8

Abs450 nm

1.6
1.4

0.8
0.6
0.4
0.2
0
2 day

4 day

6 day

9 day

12 day

15 day

18 day

Time
Figure A 2 Expression level of HER2-ECD was measured by ELISA
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Figure A 3 Elution curve of HER2-ECD purification

Figure A 4 Purity of HER2-ECD was detected by SDS-PAGE gel
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Appendix II

Vaccine and Monkey virus
Introduction
Vaccinia virus is a member of the Poxviridae family, which is capable of causing severe
systemic human disease [207]. Since the vaccinia virus contains some of the largest, most complex and most challenging viruses, it has been well characterized. It is a classic subject for viral
studies. Other members of this family include variola virus, which is the cause of smallpox,
monkeypox virus, cowpox virus and ectromelia virus. All these viruses are in distinguish in morphology and cross-reactive antigenically. Therefore, any one of them confers some protection
against other members of the family.
In this virus family, both the monkeypox and smallpox can cause infections on human. The
monkeypox was observed when the smallpox had been eradicated [208]. Their signs and symptoms are very similar although the viruses are significantly different. In order to diagnose the
monkeypox, several methods based on protein are used currently [209]. The significance of
protein has provided ways to diagnose post viral infection and tool for epidemic analysis. Furthermore, the development of potential vaccine and new monoclonal antibodies are identified
and characterized. But because of the similarity between monkeypox and smallpox, it is difficult
to diagnose monkeypox or smallpox correctly by clinical presentation alone [210]. So we are
going to find the selectivity of monoclonal antibodies against different virus. Our work will be
based on the structural knowledge of viral fusion proteins.
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A27L is one of the viral fusion proteins. The wide type protein sA27L is a vaccinia virus
envelope protein encoded by the A27L gene. This protein contains 110 amino acids, which can
be divided into four domains. The residues 1-20 form a signal peptide for protein processing;
the second region including residues 21-32 is a lysine/arginine rich region, which is essential for
binding to cell surface GAGs (glycosaminoglycans); the third region contains residues 43-84,
which is coiled-coil structure involving self-assembly; and the last C-terminal sequence has interaction with another viccinia virus protein A17L [210]. A29L is the orthologous gene of A27L
gene, which is also called A27Lo.
As a virus protein, the A27L protein as well as the A27L gene is involved in the immune activities. The A27L gene with other virus genes in same family protects nonhuman primates against lethal monkeypox as a DNA vaccine. The other virus genes include L1R, A33R and
B5R, in which the L1R is specific to IMV, A33R and B5R is specific to the EEV. The previous in vivo experiments demonstrated that the A27L or B5R alone couldn’t protect significantly, while
the combination of these genes made a high level of protection from challenge. Furthermore,
the virus genes also have a combinational activity with the subdomains of the virus proteins.
There are open reading frames of the virus proteins: A27Lo, A33Ro, B5Ro and L1Ro (o refers to
ortholog). These subunits were expressed firstly by deleting the transmembrane region of the
A27L, A33R, B5R and L1R genes respectively. Results showed that both the genes and protein
products alone failed to generate high level antibodies. However, the DNA vaccine boosted by
the subunit of its protein product induces high immune response [208].
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Different antibodies may bind to different epitopes of antigens. The structure of the epitope contains lot information that benefits for preventing, diagnosing and curing diseases [211].
There are mainly two types of epitopes: linear and conformational epitopes. A linear epitope
means the antibodies bind to antigen by recognizing its sequence of amino acids or primary
structure [209]. Site directed mutation, western blotting, immunohisto- chemistry and ELISA
can be applied to study the linear epitope. However, some of these techniques may not be
suitable for conformational epitope research. For example, the protein samples boiled, treated
with beta-mercaptoethanol are denatured; as a result, the samples may fail to keep their original three-dimensional conformation. Therefore, site mutation and western blotting cannot be
applied strictly. In order study the conformational epitope, the three dimensional structure of
the proteins should be studied. The best choice probably is to study the crystal structure of antibody-antigen structure [212]. The complex structure will show the accurate relationship of
antibody and antigen when binding together. NMR is also a powerful technique to study protein structure, while large molecular weight of antibody (150KDa) hinders its application. However, it is possible to study the structure of CDR domain in antibody and small antigen by NMR.
Then special software can be used for docking the structure between antibody and antigen
[213].
The amino acids sequence of protein A29L is highly conserved. The sequences of A27L
and A29L are as following [209]:
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Figure A4 Sequences of monkey virus family proteins
The antibodies against monkeypox virus react with the orthologs of this virus. So
the orthologous gene of A27L was cloned from the monkeypox virus [214]. Because of the high
identity, only specific antibodies can identify A27L and A29L. The monoclonal antibody mAB
126-69-3-7 can recognize A29L with high specificity. The monoclonal antibody VVIV 4B4-2-1 only recognizes A27L. The mAB 126-69-3-7 is supposed to recognize the coil-coiled region of A29L.
It is a conformational epitope. Therefore, we will use site mutation, SPR, Western Blot, CD,
Mass Spectrum, NMR and other techniques to study the structure of A29L and the epitopes of
the antibodies against A29L both in polymer and monomer.

Materials and Methods
Mini-scale expression
Competent cells BL21 were transformed with pET-A29L, pET-A27L-4M and pET-A27L2M; and selected for growth on the Luria broth (LB) ampicillin plates overnight. The individual
clone was used to inoculate in 200ml LB culture containing 100ug/ml ampicillin. The cells were
grown overnight at 37°C to saturation. Then 50ml of the cells were used to inoculate into 1L LB
medium with 100ug/ml ampicillin. The cells were grown at 37°C continuously. When the OD600
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got 0.6, 1mM IPTG was added to induce the expression. Cells were harvest by centrifugation
(7K, 20min). The precipitation was suspended by the lysate buffer (Tris) and sonicated completely. Then the emulsion was centrifuged (14K, 40min) and the supernatant was ready for purification.

Purification of A27L mutants and A29L
The supernatant was harvest and filtered by the 0.45um membrane. Then the supernatant was applied to 2ml Ni2+-chelating affinity column. 20mM, 100mM and 250mM imidazole were added into the washing buffer (PBS) to elute the fusion protein. The fraction obtained
from affinity purification was dialyzed by the buffer of 100mM Tris-HCl, pH7.4 and then loaded
onto Superdex-G75 gel filtration and SP cation exchanging columns in consequence for further
purification. The samples in each step were detected by SDS-PAGE with coomassie blue staining.
After detecting, the parts of interest were collected and dialyzed by the 100mM Tris buffer
again to store the protein.

Binding analysis by surface plasmon resonance
The protein A29L was immobilized on the CM5 sensor chip directly. Then the antibody mAB 126-69-3-7 in different concentrations flows over the chip with A29L. Then the antibody will be immobilized on the chip by covalent bonds. Different concentration of virus proteins flowing through the chip with antibody give different signal changes based on their binding affinity and concentration.
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Site-directed mutagenesis
The A27L gene was cloned to pET-21 vector before. Four mutants called N27A T30A
Y39A and G40A are made from A29L using site-directed mutagenesis. Four pairs of primers
were used: N27A Forward 5-GCTAAAGCTCCAGAGACTAAACGC-3, Reverse 5-AGCCTTTGTAGAAA
AAAATTCAGT-3;

T30A

Forward

5-

CCAGAGGCTAAACGCGAAGCAATT-3,

Reverse

5-

CTTTTTAGCAGCCTTTGTAGAAAA-3; Y39A Forward 5- AAAGCCGCTGGAGACGACAATGAG-3, Reverse 5- AACAATTGCTTCGCGTTTAGTCT-3; G40A Forward 5- AAAGCCTATGCAGACGACAATGAG-3,
Reverse 5-AACAATTGCTTCGCGTTTAGTCT-3. After phosphorylation, the primers were used in
PCR to obtain mutated DNA. The anneal temperature is set to 60 °C. Then the whole PCR products were used in transformation in DH5a cell lines. Two single clones on the ampicillin plate
are picked out and inoculated in 10ml LB medium. Plasmid DNA is extracted by mini preperation and sent to sequence. After getting the correct sequences, the plasmid DNA is transferred
to BL21 competent cells and used to do expression.

Results and Discussions
The SPR binding curves have been showed in figure 1. The protein A29L has specific
binding with the antibody mAb 126-69-3-7. The binding affinity is much higher than A27L (Data
not shown). The binding of the two mutants was tested to check the epitope of the antigen.
The Mass Spectra have been tested on the virus proteins and their mutants. The results indicate
that all of the virus protein exists in trimer. Figure 1 shows the PCR products of A27L mutants.
The mutant M4 contains four amino acids being mutated: K27N A30T D39Y E40G; the mutant
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M2 contains two amino acids being mutated: V61I R74H. The bands are solid and there is no
other non- specific product. After extracting the DNA from agarose gel and mini preparation of
plasmid DNA, the sequences are right after DNA sequencing.

1 2

3

4

5

6 7

8

Figure A5. Mutation of A29L
1,2 N27A 3,4 T30A 5,6 Y39A 7,8 G40A
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Figure A6. SPR spectra of A27L mutations to the antibody mAb 126-69-3-7
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Figure A7 Mass spectra of virus proteins
All the SPR and MS data are provided by Dr. Yiming Ye in CDC
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Summary
Currently, the virus proteins A27L, A29L and the mutants M4, M2 have been expressed
and purified. Some basic characters, like CD and SPR, also have been measured on these proteins. However, we are trying to find the epitope of mAb 126-69-3-7 and whether the epitope
depends on the polymers. Based on the hypothesis, we use Biacore to measure the binding of
mAb 126-69-3-7 with A27L, A29L, M4 and M2 both in polymer and monomer. The current results show that the mutant M4 has specific binding with the antibody, which means the epitope
exists on the region of M4. Therefore, further mutation has been designed to study the exact
epitope. Also fresh samples, which exist in monomer will be prepared to determine the function of trimer in supporting the epitope.
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